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Dissertation supervised by Professor Henk ten Have, MD, PhD 
 Global Governance is the way by which various affairs of human social life at the 
global scale are governed in the absence of a global governance. This field is composed 
of complex networks of role players. Global Health Governance is a branch of Global 
Governance that governs the health-related affairs. An important branch of this huge 
complex of networks that has not been analyzed sufficiently in the scholarly literature yet 
is Global Governance for Health Research. Global health research, although it is a part of 
global health affairs, has its own features and conditions that bring about its specific 
issues and challenges at the global scale. Therefore, Global Governance for Health 
Research, although is generally a part of Global Health Governance, has major 
differences (along with similarities and overlaps) with it in different aspect, including the 
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major role-players, ethical authorities and institutions, and the main issues and 
challenges.  
This dissertation classifies the major role players of Global Governance for Health 
Research into the state and non-state role players. The major state role-players of Global 
Health Governance are intergovernmental organizations such as the World Health 
Organization (WHO), the World Bank, and UNESCO. The non-state organizations 
include the World Medical Association (WMA) and numerous other civil society and 
philanthropic organizations and corporations. The WHO and the World Bank, although 
important in the realm of global research, have not been the most influential role-payers 
in Global Governance for Health Research. Since the Global Governance for Health 
Research has mainly been materialized through internationally recognized frameworks 
and guidelines, the organizations that created, adopted, and promulgated these 
instruments have been the most influential role-players in the realm of Global 
Governance for Health Research, among them being the UNESCO, WMA, and CIOMS. 
Global Governance for Health Research has its own challenges that are discussed in 
chapter 3 and studied through cases in chapter 4 of this dissertation. Challenges such as 
exploitation and helicopter research, double standards, bilateralism, the impact of bio-
politics, ethical imperialism and colonialism, and the problem of data sharing and big 
data. The framework of gaps is also relevant to this field and the knowledge, normative, 
policy, institutional, and compliance gaps show themselves in Global Governance for 
Health Research. The cases discussed in this dissertation include the Zika Pandemic, the 
Research integrity in Iran, HIV/AIDS Research in Africa, Sending Biological Specimens 
Abroad (the problem of Bio-piracy), Research on Pre-Implantation Human Embryo, and 
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Local and International Alternative Medicines. Each of these cases portrays a specific set 
of challenges and gaps in the current situation of Global Governance for Health Research. 
In addition, it has been shown that most of the challenges in this area are of ethical 
nature. Therefore, there is a need to a systematic and comprehensive ethical framework in 
this arena. 
This dissertation suggests an ethical framework for Global Governance for Health 
Research that is composed of three main elements. A virtue-based element/layer that 
encompasses three moral virtues of empathy, compassion, and care. These virtues are the 
most basic moral attributes of physicians/health researchers and underlie their ethical 
behavior and their compliance to the principles. A two-layered principle-based element 
that encompasses a layer of fundamental principles, i.e. Human Dignity, Human Rights, 
and Non-Exploitation and a layer of more specific or practical principles that mostly 
adopted from the UNESCO Declaration of Bioethics and Human Rights to have a 
comprehensive and universal approach and from the NIH framework to have a research-
oriented systematic approach. And the last element of the suggested framework is 
inspired by particularism or situation ethics that demands establishing, empowering, and 
strengthening networks of oversight and review committees/boards to guarantee the 
continual and comprehensive case-by-case ethical review and oversight and monitoring 
all over the gigantic networks involved in global health research enterprise. 
Despite the existing challenging trends such as neoliberalism, isolationism, and 
protectionism in the Western countries and fundamentalism in some developing countries 
it seems that the suggested framework can be helpful in shedding ethical light on the 
challenges of Global Governance for Health Research and in filling its various gaps. This 
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study is a small step in filling the knowledge gap. The suggested framework can fill part 
of the normative gap, this framework can be an ethical basis for policies that may fill the 
policy gap, the situation-ethics element of the framework is concerning the necessity and 
the ethical way for filling the institutional gap and finally, removing or alleviating the 
moral barriers is one of the ways for filling the compliance gap. Filling these gaps is not a 
one-time mission, instead, the process of developing and filling these gaps is continuous 
and will continue as long as the Global Governance for Health research is a reality on the 
global scene.  In the final part of this dissertation, a number of practical and research 
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Chapter One - Definition, Conceptual Analysis, and History 
The first step for understanding and analyzing the situation, challenges, and ethical 
aspects of global governance for health research is understanding its key related concepts. 
These concepts are involved in shaping the main conceptual frameworks within them all 
the discussions and arguments develop and proceed. Therefore, in this beginning chapter 
of this dissertation, providing a comprehensive conceptual analysis of the involved key 
concepts seems to be not only helpful but necessary. Having a clarified set of concepts at 
the beginning of a theoretical endeavor helps the participants to grasp a more vivid 
understanding of the content and the flow of arguments and prevents the unnecessary 
ambiguities and misunderstandings that are just the results of uncertainty and 
disagreement on the exact meaning of the concepts.  
The main concepts that are described in this chapter include Governance, Global 
Governance, Global Health Governance, and Global Governance of Research. These 
main concepts are used in shaping the theoretical frameworks of the discussions and 
arguments throughout this dissertation. Many other concepts are used in other parts of 
this dissertation, such as research integrity, civil society, evidence-based medicine, etc. 
each of them defined in the respective parts. On the other hand, there are other concepts 
that are very important and crucial, but are not defined here or anywhere else in this 
dissertation just because their definitions are considered consensual and a part of 
common knowledge. These “common knowledge” terms and concepts include (but are 
not limited to) research, biomedicine, health, government, state, organization, politics, 
society, etc. Therefore, just four above-mentioned main and essential concepts are 
defined and discussed in this chapter and neither described within the next parts of this 
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dissertation, nor are obvious, consensual, well-defined, and self-evident (or so are 
considered here). 
In addition to the conceptual analysis, a brief history of the theoretical development 
of each one of the above-mentioned concepts has been provided under each respective 
title, along with a conceptual definition. As well, in the last part of this chapter, a brief 
history of the international/global research enterprise and its main developments and 
historical milestones is depicted. A specific part, research integrity, has been explored in 
more details because it provides a more explicit example and has also been separately 
discussed in the next parts of this dissertation (in chapter three as a case study). 
This historical perspective is needed for acquiring a better comprehension of the 
nature and importance of the existing challenges and their ethical nature, dimensions, and 
possible solutions. Exploring the historical perspectives is an integral part of any 
theoretical work (at least in the field of health humanities) since the best way for finding 
a comprehensive and realistic picture of the conceptual challenges is looking at them in 
the mirror of their emergence, developments, variations, and transformations through the 
courses of their histories.  
i. Governance  
Governance, in its traditional sense, can be simply defined as “the process of 
governing.” It is important, however, to notice that this term not only refers to the process 
of governing by governments but also to the process of governance in the absence of a 
specific government. The latter denotes the more dynamic, sophisticated, and sometimes 
subtle processes of governing by various interacting role players in the social/collective 
human life. Therefore, governance can be defined as the sum of a wide variety of means 
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and processes used by various individuals and institutions to manage their various affairs 
in the collective human life.1  
Before proceeding in defining governance, four different notions need to be defined 
in more details: institution, organization, state, and nation. Although the terms institution 
and organization and the terms nation and state can be (and frequently have been) used 
interchangeably, as in some instances in this dissertation they are so, in a closer look they 
have different extent of meanings and connotations: 
 (1) Institutions are “social conventions” or “rules of the game”, therefore, marriage, 
market, church, and democracy are examples of institutions. (2) Organizations, however, 
are “material entities” having physical locations (or seats), and other organs such as 
office, employees, equipment, and budget.” Therefore, entities such as the World Health 
Organization and National Institutes of Health are among the examples of organizations 
(although in the name of National Institutes of Health one can readily see the 
interchangeability of institution and organization). (3) states are “governmental-territorial 
entities”. A governmental-territorial entity means a specific territory defined and 
confined by its borders that is formally under sovereign governance of a government. 
This definition is equal to the formal definition of nation-state (this is the reason behind 
this fact that the terms nation and state are commonly being used interchangeably). The 
examples of states are clear and abundant: The United States of America, the United 
Kingdom, Russia, China, Iran, and other members of the United Nations are among the 
states. (4) Nations, however, can be defined as “communities with share identities”, or in 
other words, “groups of persons professing solidarity based on and around of their 
respective unifying items, such as language, religion, ethnicity, history, or other bonding 
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elements.”2 Although nations and states usually coincide, they are not identical. There are 
nations such as Kurds or Palestinians who are not represented by a single state, and there 
are states, such as Switzerland and former Yugoslavia, that contain (or contained) 
different nations.  In addition, some nations are (or have been) divided between separate 
states, such as former East and West Germany, South and North Korea, and South and 
North Sudan.3 
The role players in governance include (but are not limited to) corporations, 
organizations, professions, religious bodies, media, pressure groups, lobbyists, coalitions, 
civil society actors, activists, and other formal and non-formal role players. In this sense, 
governance encompasses all the processes of social organization and social coordination. 
This function is provided not only by governments (or intergovernmental institutions 
such as organizations, coalitions, treaties, etc.), but also by other social institutions and 
civil arrangements that work in the forms of markets or networks. Therefore, in one 
sense, the forms of governance can be broadly categorized into hierarchies (including 
states), markets, and networks, the last one being the most sophisticated form that shapes 
the main platform of global governance.4 
Governance, in various forms, exists in different fields of collective human life, 
including organizations, activities, and outcomes; and in any level of it, including family, 
team, tribe, community, nation-state, and globe. Therefore, there are countless types of 
governance mentioned and described in the literature, for example, public governance, 
organizational governance, corporate governance, global governance, non-profit 
governance, project governance, environmental governance, health governance, and 
information technology governance.5  
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The origin of the word governance is the Greek word κυβερνάω (kubernáo) that 
means to steer. Governance with the meaning of the process of governing has been used 
in different English texts such as the book titled The Governance of England by Charles 
Plummer that was published in 1885. The meaning of governance had always been linked 
with the functions of governments until the last decades of the twentieth century. In those 
decades, a conceptual shift occurred and this world became a fashionable term in the 
academic and political discourse that equated almost solely with the concept of 
governance without a government or beyond single government(s).6 In other words, the 
term, governance, with its current definition has become popular and viral in political, 
social, economic, and ethical discourses and in the academic literature, since not sooner 
than the early 1990s (see below).  
The newly-emerging ubiquity of the term of governance in the scholarly and 
political literature is an obvious phenomenon at the beginning of the twenty first century. 
This ubiquity is especially noticeable in the field of global affairs. Two main trends have 
led to this abundant reliance on the concept of governance (governing without a 
government) for describing and understanding the current state of global affair: 
First, the ever-increasing complexity of human collective life and emergence of 
new patterns of social interactions and social life that had brought up new challenges and 
problems (e.g. global warming, pandemics, cybersecurity) that cannot be solved or 
managed within the borders of single sovereign states. In other words, in the absence of a 
single government or a single hierarchical order in the global scene, a system of 
governance without government is (or in some cases should be) in place to deal with such 
supranational and transnational challenges and issues. 
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Second, the emergence of numerous non-state and non-governmental and non-
intergovernmental role-players on the scene has changed the scene of global affairs from 
the one once dominated by Intergovernmental Organizations to the current one that is 
mostly governed by other role payers, such as non-governmental organizations, 
transnational enterprises, and civil society organizations (see chapter 2).7 In other words, 
in the absence of a single global government, the sophisticated and intertwined network 
of various role players are in charge of managing different transnational and global 
affairs. This system is best described by “governing without a government” or 
governance. 
The concept of governance, in general, had almost always been accompanied by 
questions about the criteria of good governance, or on the other words, this very question 
that what makes a form of governance a good one. Historically speaking, however, a 
newly-emerged emphasis on the concept of good governance and its theoretical and 
practical components, have arisen over the last decades of the twentieth century through 
the processes originated in the World Bank and International Monetary Fund. They 
developed criteria for good governance to guide the process of financial support for 
developing countries. 
Mark Bevir in his book titled Governance: A Very Short Introduction, holds that 
governance plans deal with issues of efficiency, development, capacity, accountability, 
and legitimacy. They try to combine practical effectiveness with ethical values. This 
obviously shows that the adjective good is a strongly value-ridden one. The values 
overarching these plans have been mainly inspired by liberal democratic theories, that 
means that they aimed to develop representative, accountable, transparent, responsible, 
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and at the same time, stable and sustainable forms of governance,8 although they have 
also been accused of imposing the Western liberal values (or neoliberal values) to other 
countries and lack of respect for cultural diversity and sovereignty of the low and middle 
income societies and countries. Later in this dissertation these accusations are described 
and explored in more details. 
 The collapse of the Soviet Union and many other dictatorships in the developing 
countries in the final years of 1980s and over the 1990s, led to the appearance of 
numerous new democracies on the global sense with a common feature that was their 
desperate need for financial support for reconstructing their infrastructures and for 
developing modern political, social, and economical systems. This need resulted an 
upsurge of new demands for financial support from international organizations such as 
the World Bank and the International Monetary Fund. These financial organizations, in 
turn, needed to make sure that their financial support would produce their 
desired/anticipated developments and changes in the recipient countries.  
The need to ensure the efficiency of their lending activities (compatible with their 
accounts of development), led the international funding bodies to create a set of criteria 
for good governance as the prerequisites of their financial support.9 They clearly 
understood that without a desired governance in place, all the financial supports would 
vanish very fast in a web of corrupted politicians and swamp of ineffective systems. 
Therefore, these intergovernmental financial institutions began to put an emphasis on 
exploring the pitfalls and strengthening the institution of governance in the receiving 
countries. For example, a report published by the world bank in 1989, titled Sub-Saharan 
Africa: From Crisis to Sustainable Growth, argued that the “crisis of governance” is a 
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major obstacle for   development of African countries. Consequently, the World Bank 
started to add the term “good governance” to its technical vocabulary dealing with 
technical issues and civil society and aiming to improve the functions of governance in 
the receiving low and middle income countries.10  
As mentioned above, the criteria set by intergovernmental organizations for good 
governance - because of their inevitable value-ridden nature - have raised concerns on 
and accusations of imposing liberal or neoliberal ideas and ideals to the developing 
countries.11  Although in the historical experience, setting neoliberal prerequisites and 
requirements for financial support has failed in producing sustainable development in the 
developing countries, this question on what entails a good governance still exists. In the 
following chapters of this dissertation, the role of bioethics in dealing with this quest is 
discussed.   
Because of the bioethical nature of many of the supranational and transnational 
problems and their trajectories, trends, implications, and solutions, especially in the 
global health sector (including health-related research enterprise), bioethics is of a special 
relevance to global governance.12 In this sense, two topics of “governance through 
bioethics” and “governance of bioethics” can be separately discussed. The former topic 
covers the discussions about the role of bioethics in global governance for health and the 
latter one covers the governance of theoretical developments of bioethics itself on the 
global scene.13 
As a matter of fact, the current state of global health and global bioethics, and their 
theoretical and practical specifics, developments, and challenges, cannot be 
comprehensively understood and analyzed without taking the concept of global 
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governance into serious theoretical consideration. On the other hand, global bioethics is 
the field or platform in which an ethical framework for setting global criteria for good 
governance is to be sought. 
ii. Global governance 
Global governance can be defined as the way in which different role-players in the 
regional or global spheres exert different sorts of power to manage various affairs at the 
international level.14  In is also defined as: 
 “…the sum of the informal and formal values, norms, procedures, and institutions 
that help all actors – states, intergovernmental organizations […], civil society, 
transnational corporations […], and individuals – to identify, understand, and address 
trans-boundary problems.15”  
This is obvious that power-relation is a central concept in global governance.16 In 
other words, one can say that global governance, as a concept and as a subject of study, 
provides the overall picture of a sophisticated network of different kinds of power 
relations that play role in creating or managing supranational and transnational affairs in 
the contemporary globalized world. 
In a historic perspective, the concept of global governance had two predecessors:  
(1) international relations and (2) the world order. A theoretical and historical 
review of these two preceding concepts can shed light on the current standing and 
characteristics of the concept of global governance. 
1- International Relations: Collaboration among nation-states in the modern world 
has been the subject of international relations studies. The broad range of the forms with 
which the relations among nation-states are being materialized (intergovernmental 
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organizations, bilateral or multilateral coalitions and treaties, international soft or hard 
laws, etc.) has been the subject of this interdisciplinary field of study. The key point has 
been (1) the centrality of sovereign nation states as the supreme role players on the global 
scene and (2) dealing with supranational issues (such as global trade, pandemics, war and 
peace, environmental issues, and humanitarian aids or interventions) through the 
international organizations, treaties, coalitions, or other kinds of collaboration between 
nation states.17 
2- The World Order:  After the end of the cold war, in many of the scholarly works 
on global affairs, the concept of international relations was replaced by the concept of 
world order.18 The central element of this notion has been the centrality of a hierarchical 
order of power and affluence on the global scene that defines the role and influence of 
each role player, at the top being the United States and Western industrialized 
democracies. The theories that relied on this concept tried to provide a realistic portray of 
the realities of the way global affairs were being approached and managed. The concept 
of world order, however, was criticized as being top-down and static. Therefore, the 
concept of world order was soon substituted by the more dynamic and describing concept 
of global governance.19  
The above concepts were gradually replaced by the concept of global governance 
through the last decade of the twentieth century and the first decade of the twenty first 
century. The reasons behind the emergence of the concept of global governance were as 
follow: 
1- The ever-increasing occurrence of some problems with a global nature that 
could not be solved without a globally coordinated operation. For example, the 
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phenomenon of climate change is not limited to any geographic area or national borders 
and cannot be dealt with effectively in the absence of globally coordinated action plans. 
As another instance, pandemics and outbreaks, such as the recent outburst of Ebola virus 
disease in West Africa, demand highly coordinated global reactions. The local 
governments usually are not able to implement effective measures in a timely manner. 
International organizations and foreign aid providers need to be coordinated to act 
effectively and with abidance to a well-planed road map. Coordinating all these resources 
and reactions is done through global governance.20 
2- The above-mentioned increasing appearance of global problems has been 
coupled with the exponential increase of non-state role players who are influential in 
dealing with such problems, in some times, even more than intergovernmental 
organizations who are formally considered in charge of them. In other words, the 
emergence of non-governmental role-players and their influential input in governing 
global affairs, in addition to the relative shortcoming and stumbling of formal 
international organizations in the same areas(see below), led to the emergence of a new 
understanding of the way by which the global affairs are being governed(Also see above, 
under the topic of governance).21   
3- The state role players started to act beyond of and apart from the previously 
established intergovernmental organizations. Instead of originating their actions through 
the programs formulated and conducted within the established intergovernmental 
organizations, they started to launch unilateral or bilateral programs acting in parallel 
with the intergovernmental organizations. The health sector, especially in the cases of 
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pandemics such as HIV/AIDS, is a well-discussed example of such an increased 
emergence of bilateralism instead of multilateral organizations.22 
4- At the same time, at least in some serious world problems, such as the recent 
Ebola outbreak, the formal intergovernmental organizations proved weak and lagged 
behind the other role-players.23 The important role of non-state actors (and the state-
originated interventions beyond the intergovernmental organizations) in managing such 
crises showed that instead of  intergovernmental (international) organizations, there is a 
sophisticated form of global governance in place, with various actors and numerous ways 
of action, that shapes the global approach to such crises and global emergencies.24  
In sum, through the past decades, as a result of (1) the fundamental changes in the 
composition of global role-players in addition of (2) the drastic changes in the nature and 
extend of global issues, and (3) the need for developing and adopting a concept without a 
top-down and unwanted hierarchical nature in the related scholarly and political 
discourse, the concepts of “international relations” and  “world order” have gradually 
been replaced by the concept of “global governance”.25 This new concept achieved 
acceptance and ubiquity in the relevant literature very fast, in a way that nowadays seems 
to be an essential conceptual tool for understanding, describing, analyzing, and discussion  
the issues, problems, and phenomena that have transnational, supranational, or cross-
national nature or element(s). 
As mentioned above, in the emergence of the concept of global governance and 
replacing the previously ruling concepts such as international relations and world order, 
the health sector and the health-related issues have not been the exceptions. The 
transnational and supranational nature, extend, and solutions of many of health issues 
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(e.g. pandemics, health implications of global trends such as climate change, global 
collaborations in the areas of healthcare and health research, etc.) in addition to the 
development of unilateral and bilateral health-related programs beyond the 
intergovernmental organizations, and the abundance of newly-emerged non-state role 
players on the global scene has led to the appearance and prominence of the notion of 
global health governance (also called global governance for health) that is discussed in 
the following part of this chapter. 
iii. Global health governance 
The newly shaped conceptual and practical profile of global governance is 
impeccably mirrored and exemplified in global health governance.  As historically and 
theoretically depicted above, global governance entails collective efforts of various role-
payers and has been practiced in numerous ways.26  The health sector has never been an 
exception. The same scene of numerous role players and numerous ways of role playing 
exist in the health sector. These role players and their actions along with the existing 
problems and challenges, take shape to what we know as the global health governance or 
global governance for health. 
The various means and models of realization of global health governance in the 
contemporary globalized world include (but are not limited to): Promulgating health or 
healthcare ethics-related international instruments, including binding and non-binding 
guidelines, decelerations, resolutions, rules, and regulations; forming bilateral or 
multilateral coalitions and collaborations on heath affairs; establishing and running 
international health-related organizations, including regional and global ones; funding 
health-related program in other countries; conducting international biomedical research; 
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and providing healthcare or emergency interventions in crises in other 
countries/regions.27  
Each of the main categories of actors in global health governance (states, IOs and 
NGOs) encompasses a various array of role players.28  Sometimes, an international 
organization, officially takes the leading role in one of the global affairs, for example, the 
WHO is the organization in charge of global health issues.29  Such international 
organizations, including the WHO, work based on consensus among almost all the 
member states. Although managing everything according to broad consensus seems to be 
the most democratic way of managing global affairs, there are some instances where 
more powerful or wealthy members of such international organizations decide to play 
unilateral roles.30  
When a nation state decides to play a role beyond its borders and intervene in the 
international sphere, that nation state is playing a role in global governance. For instance, 
launching health related initiatives and programs in other countries for fighting outbreaks 
or preventing diseases in an international level is part of global health governance.31  
These efforts raise the problem of bilateralism that sometimes is considered as a threat to 
multilateral global health governance. 
Many countries, mostly in the developing world, cannot afford the healthcare 
needed by their people. In the case of disasters, like outbreaks, famine, or drought, this 
gap becomes wider.32 These countries usually depend on international sources, like the 
helps provided by wealthier countries to provide even basic healthcare for their people. 
According to the WHO’s estimate, 23 countries of the world receive more than 30 
percent of their health budgets from sources outside their borders.33 This monetary aid 
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usually comes with price tags, least of them is the power bestowed to the wealthier 
countries to govern health affairs in developing help-receiving countries. Having 
financial leverage, either in international organizations or in bilateral relations with other 
countries, makes it possible for richer and more powerful countries to play their own role 
in global health governance.34  
Historically speaking, the international coalitions for global health governance, 
however, are dated back to the 19th century. The pandemics and epidemics of various 
infectious diseases, like cholera, yellow fever, smallpox, and typhus, parallel with 
revolutionary scientific discoveries like the germ theory of disease, ended up to some 
international meetings aimed to establish international institutions and guidelines for 
preventing the spread of such diseases35. 
  The first international conference on health was held in Paris in 1851, with 
participation of 12 European countries. Establishing uniform procedures and regulations 
for quarantine and founding an international sanitary board to oversee maritime activities 
were the main subjects of discussions. Although historical in being the first international 
meeting on health, this conference ended up as a failure in the terms of application, 
international cooperation, and implementation. Although the conference produced a 
convention with 11 articles and 137 regulations covering major disease with adverse 
influence on trade, such as cholera, plague, and yellow fever, only three governments 
eventually ratified the convention, two of them, later retracted their ratification. 36 
 Two main reasons for this failure were as follow:   
 First, different participant countries, depending on their geographical locations 
and other factors, had different and conflicting interests in tightening or softening the 
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quarantine measures, for example, while nations with significant trading interests showed 
resistance against tough quarantine measures, countries bordering the Mediterranean Sea 
sought more strict quarantine measures.37  
 Second, there were no consensus on the cause of communicable diseases like 
cholera, plague, and yellow fever. Some delegates (e.g. British officials) attributed 
cholera to environmental factors and bad air, therefore, they insisted on establishing 
sanitary measures instead of quarantine. Others attributed cholera to an infectious agent. 
These countries, like Spain, Greece, and Russia were in favor of quarantine. Although in 
these countries, sometimes the quarantine measures were used to isolate certain social 
groups like Jews or foreigners.  The third theory, for example maintained by Austria, was 
the supernatural theory that attributed such diseases to the displeasure of God and 
considered them as divine punishment, therefore, they insisted on religious measures as 
the only way to contain cholera and other outbreaks.38 
 The next five conferences held between 1859 and 1885 (1- Second Sanitary 
Conference in Paris, 1859; 2- Third Sanitary Conference in Istanbul, 1866; 3-Fourth 
Sanitary conference in Vienna; 4- Fifth Sanitary Conference in Washington, 1881; 5- 
Sixth Sanitary Conference in Rome, 1885). These conferences, also, did not generate any 
substantive agreement.  
 It was after Robert Koch’s work on cholera -which established a scientific 
consensus on the cause and treatment of cholera-that the first international agreement was 
successfully created at 1892’s International Sanitary Conference in Venice.  This 
agreement was titled the International Sanitary Convention (ISC) and allowed for very 
limited quarantine practices for ships passing through the Suez Canal carrying pilgrims to 
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and from Mecca.  Although of limited scope, it was the first successful international 
effort for global health governance.39  
Over the next 58 years and through the next conferences (e.g. Eighth Sanitary 
Conference in Dresden, 1893; Ninth Sanitary Conference in Paris, 1894; Tenth Sanitary 
Conference in Venice, 1897; Liquor Traffic in Africa in Brussels, 1906; Opium in 
Shanghai, 1909; Twelfth Sanitary Conference in Paris, 1911; Opium in The Hague, 1911; 
and (15) Opium in The Hague in 191340), the ISC was revised and expanded in various 
terms including the number of diseases it covered. This is noteworthy that the main 
purpose of the ISC was not establishing new quarantine measures; instead, it was mainly 
aimed at removing the unnecessary and burdensome practices and limit the allowable 
quarantine practice under the international law to the effective ones without unnecessary 
impeding or obstructing the flow of commerce and travelers across the borders. 41 
 The ISC needed an organizational structure to coordinate the efforts of different 
states and facilitate the communications and surveillance. For this purpose, the first 
international health organizations were founded in the first decade of the twentieth 
century. These organizations were the International Sanitary Bureau (ISB) that later 
changed its name to the Pan American Sanitary Bureau and then to the Pan American 
Health Organization; and the Office International d’Hygiene Publique (OIHP). 42 
 The trend of establishing organizations for global heath governance consequently 
continued by appearance of other major role players in the scene. Organizations such as 
the International Health Division (IHD) of the Rockefeller Foundation (RF), founded in 
1913, and the Health Organization of the League of Nations (HOLN), created in 1922.43 
The importance of the IHD was partly in this fact that it was the first noteworthy 
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appearance of a philanthropic organization belonging to the private sector in global health 
governance.  
After the WWII and establishment of the United Nation, the World Health 
Organization was founded as the most prominent international organization in the global 
health governance.44 Around the time of establishment of WHO as the United Nations 
(UN) specialized agency for health, other international organizations contributing to 
health were as follow: The UN Relief and Rehabilitation Administration (UNRRA) 
established in 1943; UN International Children’s Emergency Fund (UNICEF) founded in 
1946; and UN High Commissioner for Refugees (UNHCR) founded in 194945. 
However, in the second half of the 20th century, WHO remained the most important 
institution and focal point of global health governance46. Now it is obvious that it is 
losing its leading role in the global health governance and needs reforms to regain and 
preserve its leading role47.  
In sum, global health governance can be understood as a merging point of two 
major trends: (1) the trend of the change in the composition of global role players in a 
way that international relations gradually transformed into global governance, and (2) the 
trend of globalization in health sector, e.g. pandemics, migration of healthcare 
professionals, need for global surveillance systems, the global distribution of 
pharmaceutical products, and the effects of global patterns such and the climate change 
and global inequality on health. The health research enterprise has not been an exception 
for any of these two major trends. The following part of this chapter takes a closer look at 
the convergence of globalization and health-related research, that has taken shape to 
global governance for health research. 
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iv. Global Governance for Health Research 
  Health research enterprise encompasses all research activities that are related to 
human health, including biomedical, epidemiological, and ecological research. Research, 
as described in details below in this chapter, has developed into a global and cross border 
enterprise with various role players from states to corporates and from intergovernmental 
organizations to non-for-benefit ones. Therefore, research activities with transnational 
and supranational nature are subject to global health governance. This branch of global 
health governance, although has not been studies like the branches dealing with 
pandemics or disasters, play an influential role in the health and welfare of human 
societies all over the globe. 
 Taking a historical look reveals that the distinct separation between research and 
therapeutic clinical practice in health sciences, is a recent phenomenon, dates back to the 
first decades of the twentieth century. Before that time, for centuries, experimenting new 
treatments or interventions was considered as a part of the routine practice of physicians 
and was supposed to be aimed at providing the best health for the patient. It was in the 
twenties century that health-related research enterprise experienced an exponential 
growth, was recognized as separated from clinical therapeutic practice, and in the second 
half of that century international and multicenter research projects began to sprout and 
grow.48  
 Just like other global enterprises, the international health-related research 
established its own system of global governance.49 The global governance for health-
related research has mainly been established in the following ways: First, the 
international declarations, codes, and guidelines developed for setting global ethical 
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standards for health-related research; second, the national rules and regulations made by 
the countries that host the main funding bodies and institutions on international research; 
and third, the internal regulations, standards, and guidelines of the various sorts of 
organizations that fund international research.50 Therefore, for sketching a realistic 
portrait of the history of global governance for biomedical research, the best way is 
taking a look at the developments in the above-mentioned means of implementing global 
governance for biomedical research  and its main concepts and theories.51  
 The recent programs funded by Fogarty International Center (FIC) to establish 
research ethics capacity in developing countries is a noteworthy example.52 This program 
is aimed to transfer the research oversight and review capacity to the low and middle 
income countries. It has been accused to trying to impose Western values to developing 
countries. The FIC tried to nullify these accusations by emphasis on including local moral 
teachings in the curricula and planning for transferring the capacity (both educational and 
oversight) to the local participant institutions over the period of the programs. 
In an attempt for analyzing the theoretical aspects of global governance for health 
research, Wahlberg et al. introduced four spheres (or layers) of ethical governance for 
health research as follow: deliberation, regulation, oversight, and interaction . Some 
countries have established organized processes for national ethical deliberations. This 
national debate can produce ethical awareness and help to develop a democratic process 
of problem-solving in the ethical governance of biomedical research enterprise. In 
addition, ethical regulations at both national and global levels have been developed and 
shaped another layer of ethical governance for health research. The regulations pave the 
way for the next sphere or layer that is ethical oversight. As it is discussed in the 
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following chapters, establishing independent oversight for health research has been one 
of the major achievements and at the same time challenges of governance for health 
research. The last sphere or layer is interaction among the role players in research 
including researchers and research participants. 53  This four-layer model although seems 
helpful in portraying the existing models of governance for health research, does not shed 
light on the specific ethical challenges ahead of global governance for heath and cannot 
contribute in providing new answers and solutions for the existing problems. 
 v. A Historical Perspective 
  The historical developments of the above-mentioned concepts have been depicted 
under each topic. The history of conceptual development of the modern notion of 
governance partly dates back to the 1970s when Michel Foucault transformed this 
concept.54 Concepts such as governmentality and biopolitics that were coined or 
redefined by this French philosopher have been influential in the academic and 
intellectual discourse on governance. His intellectual role and its critical assessment have 
been provided in chapter three under the topic of biopolitics vs. bioethics. In this part, the 
developments of global research enterprise have been portrayed (see below). 
  In the very beginning of the twentieth century, for the first time in a research that 
can be called an international research in some senses, American researcher Walter Reed, 
obtained written informed consent for healthy volunteers in his yellow fever experiment 
in Cuba.55 At that time, obtaining informed consent had not been established as a 
standard of practice in clinical research. However, international reflections on the 
unethical behaviors in research began from the same years. For example, at an 1898 
medical meeting, William Osler, one of the giants in the history of medicine, condemned 
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the experiment presented by an Italian researcher. That researcher, who worked on 
yellow fever in 1897, declared that he had injected a bacillus to five people and produced 
yellow fever in them. William Osler’s reflection was frankly that to deliberately inject a 
poison like that into human subjects of research without their previous consent is 
criminal.56  
 The first known regulations governing research with human subjects were 
publicized in the first year of the twentieth century. These Prussian regulations were 
followed by a code in German in 1931 issued by the Reich Minister of the Interior.57 In 
the later decades of that century, the increasing awareness toward biomedical ethics and 
disclosure of some infamous instances of violation against human dignity and human 
rights in research projects, led to national, and then international endeavors aimed at 
establishing a set of ethical standards for health-related research.58  
 The first international code on health-related research ethics was developed and 
announced in the wake of WWII and in the response to disclosure of unethical behaviors 
of Nazi doctors on their human subjects during their experiments through the world war 
II.59 The most well-known and internationally embraced instrument in the field of health-
related research ethics, however, is the declaration of Helsinki. First adopted by the 
World Medical Association (WMA) in 1964, this declaration was subject to several 
revisions and amendments. These revisions and amendments kept this instrument updated 
and reliable until now.60 The declaration of Helsinki is a brilliant example of using soft 
law in the global governance . 
 In addition to the international instruments, some scholarly works and national 
laws, guidelines, and codes have had great influence on the global governance for 
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biomedical research ethics. The development of four principles of biomedical ethics by 
Beauchamp and Childress and the Belmont Report, both in the 1970s, were mammoth 
steps in establishing the ethical frameworks for global governance for biomedical 
research.61 
 As said above, the first known national regulations for governance of research 
enterprise have been developed in Germany in early 1900s, however, what happened in 
Germany in the following decades proved that just having well-written regulations is not 
enough to prevent unethical behaviors. As a matter of fact, the same story was repeated in 
other countries who hosted an established research sector. The most well-known stories 
happened in the United States. The ones that proved the crucial role of whistleblowers 
and the need to establish independent ethical oversight for research.  
In June 1966, Henry K. Beecher published an article titled Ethics and Clinical 
Research in New England Journal of Medicine. He introduced 22 cases of unethical 
clinical research on human subjects Drawn from the immediate postwar period from 1948 
to 1965 protocols from leading investigators in leading institutions, working on some of 
the most important questions in medicine, and published in the most reputable medical 
journals. Examples included purposeful infection with hepatitis of residents at the 
Willowbrook State School for the Retarded; injection of cancer cells into elderly and 
senile patients in which the subjects were merely told they would be receiving some cells; 
and insertion of a special needle through a bronchus into the left atrium of the heart of 
patients and healthy subjects. And suturing a mercury-filled resistance gauge to the 
surfaces of the left ventricles of the subjects. Beecher’s revelations caused a shift from 
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Researcher Paternalism to Regulatory Protection; Utilitarianism to Principlism; and 
Relying on researcher judgment to IRB review and informed consent.62  
Ezekiel J. Emanuel and Christine Grady, in their article and then book chapter, 
titled Four Paradigms of Clinical Research and Research Oversight explained four 
distinct paradigms that the research enterprise and research oversight has passed through 
during the last eight decades in the United States of America, namely: Researcher 
Paternalism, Regulatory Protectionism, Participant Access, and Community 
Partnership.63 Some other studies show the comparable historical trends occurring in the 
biomedical research enterprise in other countries.64 
According to Emanuel and Grady, in the late 1980s and early 1990s, a paradigm 
change from regulatory protectionism to participant access occurred in the United States. 
Before that time, the conception of clinical trial participant was a vulnerable patient that 
needs protection provided by oversight/regulatory bodies and institutions such as the 
Institutional Review Board (IRB) reviews and informed consent. This 
perspective/paradigm was based on a historical experience of abused and exploitation of 
research subjects of researchers that were exposed and led to establishment of oversight 
legislations and institutions.65  
However, in the late 1980s and early 1990s some events triggered a paradigm 
change. Two important ones among them were the AIDS epidemics and the breast cancer 
movement. In these cases, the patients advocate groups demanded earlier access of dying 
patients to experimental drugs.66 This was a dramatic change. The patients/research 
subjects had no longer been considered as vulnerable persons to be protected against 
unnecessary enrolment in clinical trials, instead, the protection was against unfair access 
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to the clinical trials as the only hope for survival in front of patients who had no other 
curative or therapeutic choice.67 
Therefore, through a paradigm change, (1) the key protection changed from IRB 
review and individual informed consent to individual autonomy; (2) the conception of 
clinical trial participant changed from a vulnerable patient to an informed consumer, (3) 
the role of research and healthcare changed from research priorities being seen as threat 
to clinical care to clinical trials being viewed as best, cutting-edge clinical care; (4) the 
underlying philosophy of research oversight changed from principlism to individual 
rights-based theories ; and (5) the highlighted ethical principle changed from independent 
review to informed consent.68  
The demand of HIV/AIDS patient for informal access to experimental drugs also 
was mirrored in the laws and regulations. The informal access to experimental drugs was 
made possible through legislations that passed in 1987 and was revised in 2009 (see 
below for details).69 
Similar changes occurred on the global scene. A prominent example of demanding 
compassionate use of experimental drugs occurred during the Ebola outbreak in West 
Africa. Although Ebola infection has no proven curative treatment, some experimental 
medicines have been used hoping to save patients who otherwise would be likely to die. 
The long process of approving experimental drugs for using in standard clinical practice 
has always been a subject to criticism. During the HIV/AIDS epidemics, sometimes there 
were competitions among potential participants (patients/infected people) for entering the 
clinical trials because they looked those clinical trials as the last resort and beacon of 
hope for receiving an effective treatment. In the case of Ebola infection, however, the 
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clinical trials were being conducted thousands of miles away from the foci of outbreak. 
Delivery of experimental drugs to those patients was not part of any research study or 
clinical trial. As a matter of fact, considering the especial context of chaos and shortage 
of healthcare workers and facilities, it was impossible to conducts sufficiently well 
designed and well-conducted clinical trial in those areas. Providing experimental drugs 
for those patients hoping to be effective in relieving their suffering and even saving their 
lives was an act out of compassion/philanthropy.70 
 The most important development in the realm of global governance for research 
ethics occurred in the past two decades. These developments are as follow: 
 1- The rapid growth of research enterprise in the Low and Middle Income 
Countries (LMICs) that made the health-related research and research ethics a global 
subject to concern and debate.71 
 2- The significant increase in the number and size of international and multi-
center research projects that also brought global attention and international concerns into 
the health-related research enterprise.72 The issues raised by these multi-center research 
collaborations can be classified into two major categories: 
 2.1. The issues raised by the collaborations between centers from developed 
countries with centers from developing (low and middle income) countries. The power 
and knowledge imbalance in these collaborations have raised concerns on the exploitative 
nature of them or imposing ethical standards by the powerful counterparts. Examples of 
the issues that can be located within this category are double standards in clinical trials 
and the lack of benefit sharing in research activities funded by developed countries and 
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executed in the low and middle income countries. These concerns have been discussed in 
details in chapter three. 
 2.2. The issues raised by the collaboration in which all the counterparts belong to 
the developed countries and no power imbalance exists. Even in these kinds of 
collaborations, emergence of new sources of ethical concern has been proved to be 
unenviable. Working on big data, large scale biobanks, and the relation between research 
sector and medical tourism are among the examples of this category. These concerns, as 
well, have been discussed in more details in chapter three. 
The ethical issues related to health research can be classified into several categories. 
Each category of health research ethics or each part of health research enterprise has its 
own history of developing a national and then global oversight or network of governance. 
The historical overview is not complete without a brief discussion on at least one of the 
examples that shows how ethical debates proceed in each of these categories or parts. For 
this purpose, research integrity can be a suitable choice. Research integrity, as a topic 
discussed in more detail later in this dissertation, also has its own history that can be 
depicted in more details and serve as an example on the above-mentioned historical 
courses and backgrounds:  
Some aspects of research integrity, such as avoiding plagiarism, are as old as the 
written history, itself. However, the notion of research integrity in its current dimensions 
and characteristics is a relatively new notion. For example, in the United States, research 
integrity became a public issue in 1981. In that year, a congressman named Albert Gore, 
Jr. who was the chairman of the Investigations and Oversight Subcommittee of the House 
Science and Technology Committee, held the first hearing that was provoked by the 
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public disclosure of certain research misconduct cases. Those cases had occurred at four 
major research centers in the previous year. About twelve cases of research misconduct 
were revealed in the US between 1974 and 1981. The attention of the US Congress to the 
issues related to research integrity was continued throughout the 1980s because of some 
added accusations of research misconduct and reports that the NIH, universities, and 
other research institutions were unsatisfactorily reacting to those accusations.73 
In 1985, the Congress of the United States passed the Health Research Extension 
Act. This Act required the Secretary of Health and Human Services to issue a regulation 
requiring applicant or awardee institutions to establish "an administrative process to 
review reports of scientific fraud" and "report to the Secretary any investigation of 
alleged scientific fraud, which appears substantial."74 
In March 1989, the PHS created the Office of Scientific Integrity (OSI) in the 
Office of the Director, NIH, and the Office of Scientific Integrity Review (OSIR) in the 
Office of the Assistant Secretary for Health (OASH). The reason behind foundation of 
these offices was to deal with research misconduct. 
 The establishment of OSIR also began the course of detaching responsibility for 
research misconduct from the funding organizations. In May 1992, OSI and OSIR were 
combined into the Office of Research Integrity (ORI) in the OASH.  
As the prominent examples of its activities, ORI published the ORI Introduction to 
the Responsible Conduct of Research in 2004 and began the RCR Program for Graduate 
Schools in collaboration with the Council of Graduate Schools to institutionalize RCR 
education in graduate training.75 
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The above examples show the process of legislative and regulatory attention to the 
issues of research integrity and research misconduct in other countries and in the global 
scene: First, some cases of violation of research integrity gain public attention, then 
gradually the related rules and regulations are passed in the legislative bodies and 
executive offices take shape to enforce those rules and regulations. The global 
governance for research needs the same process to take shape at the global scale to deal 
with the issues of research misconduct and research integrity through global governance 
for research ethics. 
In sum, the concept of global governance for research has two parallel lines of 
history: First, the history of the concepts of governance, global governance, and global 
governance for heath, as depicted under their respective titles above in this chapter. An 
overall look at this history shows that globalization along with the dramatic changes in 
the composition of role players on the global scene has resulted the development of these 
conceptual tools to be used in analyzing and solving the issues with global nature. The 
course of development of the concepts and their emergence out of their predecessors (e.g. 
international relations and world order) shows the significance and influence of values 
(i.e. moral theories and value systems) in their theoretical make and nature. These 
concepts have always emerged, used, and developed within ethical frameworks. 
Therefore, any scholarly and analytic discussion on them is deeply value-ridden and 
proceeds within specific ethical frameworks. As shown in the next chapters of this 
dissertation, the existing challenges and issues, also, are mainly of significant ethical 
nature or have major ethical components. And the best way to approaching them is seeing 
them within the respective ethical frameworks. Before taking a deeper look at the existing 
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issues, it is necessary to examine the exact composition of these role players in more 
details. This detailed examination can be found in the following chapter. 
Second, the history of health research itself. The other line of history that collides 
with the history of global health governance and takes shape to the concept of global 
governance for health research, is the history of health research. As a modern enterprise, 
as depicted above, health research is young, aging less than 100 years. However, over its 
relatively short lifespan, this enterprise has changed the way human beings give birth, 
live, die, and perceive themselves. Like any other intentional deed of human being, health 
research is a subject of ethical analyze and assessment. It is also true about the part of this 
enterprise that goes beyond and across the national borders and take shape to another 
facet of what is called globalization. Health research on the global scene has been an 
enormous source of ethical challenges and debates. Dealing with these challenges on the 
global scene and at the global level needs the respective ethical framework, that the next 




Chapter Two - Situation Analysis 
This chapter explores the existing situation and portrays the map of Global 
Governance for Health Research in the contemporary world. For this purpose, this 
chapter firstly provides a detailed description of the major role players, including 
institutions and instruments, and secondly, depicts a scheme of the global network 
through with the Global Governance for Health Research operates. 
The role players on the scene of Global Health Governance have generally been 
classified into two major categories: (1) States and Intergovernmental Organizations, and 
(2) Non-State actors.76 The same classification seems to work for classifying the role-
players of Global Governance for Health Research, although as it looks obvious through 
this chapter, there are two major differences: (1) major role players on the scene of 
Global Governance for Research are not the same as the ones in Global Health 
governance, and (2)  The more important part of Global Governance for Health Research 
is the international soft law rather that the existing organizations. 
As discussed in chapter one, the terms nation and state and the terms institution and 
organization can be used interchangeably. However, they also bear different meanings 
and connotations (see above). In this chapter, the term “international organizations” have 
been used with its current connotation in the political discourse that equates with 
intergovernmental organizations, however encompasses some significant exceptions, 
including the World Medical Association (WMA) that is an international, but not 
intergovernmental organization. A more detailed description can be found later in this 
chapter. 
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An important fact reveals itself through examining different role players in this 
chapter. This fact is that the most significant part of Global Governance for Research in 
the contemporary world is the body of the existing soft international laws. This body has 
been created by the involved organizations and has gradually found its place in the 
international discourse. The process through which the soft law gains popularity and 
acceptance and becomes hard law, such as what occurred for the Universal Declaration of 
Human Rights, is beyond the scope of this chapter, although it provides a good example 
by introducing the bioethical documents that have gone through the same process.  
Although there is no overseeing and governing organization for global research, the 
standards, values, principles, and guidelines that are developed, and delineated through 
the aforementioned instruments have been used as the normative and theoretical grounds 
and educational resources for local and regional governing bodies to develop their own 
systems of research regulation and oversight. Therefore, a significant part of the situation 
analysis of Global Governance for Health Research consists of examining the codes, 
declarations, and guidelines and their exceptional role in shaping the current situation and 
their potential to be used in developing a comprehensive and consensual ethical 
framework for Global Governance for Health Research. The same endeavor has been 
previously done by Emmanuel and Grady for creating an ethical framework for clinical 
research.77 
After describing the role players within each of the aforementioned two main 
categories, this chapter discusses the characteristics and mechanisms of the global 
network through with the Global Governance for Health Research operates. This part 
connotes the interrelated, sophisticated, and, in some senses, convoluted nature of this 
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network. The truth is that there is not such a thing as a defined and coherent network to 
oversee the Global Governance for Research. Instead, different parties with different 
scopes, agendas, interests, and extends of influence take part in governing the existing 
asymmetrical collection of activities that can be considered international research projects 
throughout the world. At the end of this part, an example of creating a comprehensive 
and systematic ethical framework with reliance on the extant guidance is provided. This 
example sheds light on the way ahead of normative scholarly work in the field and its 
general characteristics. 
 The situation analysis and map in this chapter also provides a basis for portraying the 
most relevant challenges and obstacles in the field that are discussed in the following 
chapters of this dissertation. Having a good knowledge of the situation and its main 
challenges lead this dissertation to its next chapters to discuss the ethical framework for 
good governance in this field. 
i. States and Intergovernmental Organizations 
In this part, three major intergovernmental organizations involved in Global 
Governance for Research Ethics are discussed: The World Health Organization (WHO), 
the World Bank, and the United Nation’s Educational Scientific and Cultural 
Organization (UNESCO). Then, other forms of the involvement of states in the global 
governance for research are discussed that include the role of the United States and the 
Council of Europe. 
This part shows that the significance and influence of these role players in Global 
Governance for Health Research is different from their significance and influence on 
Global Health Governance. While WHO is formally supposed to adopt the leading and 
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central role in Global Health Governance, it seems that its role in Global Governance for 
Health Research is more peripheral and tangential. On the other hand, UNESCO has 
played a more significant role in shaping the ethical frameworks for biomedical research 
and its governance at the global scale. In sum, while WHO has been mostly involved in 
the technical aspects of health promotion and Global Health Governance and the World 
Bank has exerted its impact in funding global projects and developing the concept of 
Good Governance at the political level, UNESCO has developed the most comprehensive 
and cultural-sensitive ethical instruments to be used in shaping an ethical framework for 
Global Governance for Health Research.   
WHO: In some cases in the scene of global governance after the WWII, an 
international organization, officially takes the leading role in one of the global affairs.78 
For example, the World Health Organization (WHO) is the organization in charge for 
global health issues.79 Such international organizations, including the WHO, work based 
on consensus among almost all the member states.80  In addition to WHO, the World 
Bank plays a major role in Global Health Governance (see below). Also, there are other 
United Nations agencies focusing on the international health issues. However, WHO is 
still, at least formally, the United Nation’s major body in dealing with Global Health 
Governance.81  
To act as the leading organization in international health-related affairs, the WHO 
was founded in the wake of the World War II in 1948.82 Its constitutional ratification 
meeting was held in New York City in 1946 and the first meeting of the body was held in 
Geneva in 1948.83 WHO has been the most important institution and focal point of global 
health governance in the 20th century.84 
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The highest decision-making body for WHO is the World Health Assembly. In the 
World Health Assembly, delegations of the 194 member states convene each year, 
generally in Geneva, Switzerland. The World Health Assembly appoints the Director 
General, governs the budgetary and financial affairs, and decides on its missions and 
main directions. The Executive Board, consisting of 34 members who are experts in 
health is in charge of giving effect to the decisions and policies of the World Health 
Assembly and provide it’s needed expertise and technical support and advice.85 The 
secretariat, the main administrative and technical part of WHO, operates as the third 
element of the governance of this organization. Finally, the picture of the governing 
bodies of WHO becomes completed by adding it’s six regional offices that enjoy degrees 
of autonomy and perform much of the programmatic work of this organization. These 
regions include: Africa, the Americas, the Eastern Mediterranean, Europe, South-East 
Asia, and the Western Pacific.86 
Although WHO was originally founded to take a leading role in global health 
governance, its leadership has always been a subject of fluctuations and criticism. This 
leadership or lack of leadership, however, have usually been pertaining to the public 
health issues. The role of WHO in governing the ethical aspects of the health research 
enterprise has mostly been tangential and not substantive. Research is relevant to the 
WHO’s constitutional roles, functions, and objectives in two ways:  
1- Research is essential for WHO to perform its health-related roles and functions and 
achieve its constitutional main objective that is “the attainment by all people of the 
highest possible level of health.” The health-related policies and practices should be in 
accordance and resulted from valid and reliable scientific knowledge which, in turn, is 
 36 
only achievable through well-designed and well-conducted health research. WHO has a 
good grasp of this mandate. For example, at the Ministerial Summit on Health that was 
held in 2004 in Mexico City, the participants (including the health ministers) asserted that 
health policy, public health, and health service delivery should be grounded in reliable 
evidence derived from high quality research.87  
2- The WHO’s constitution specified a research function of this organization: “to 
promote and conduct research in the field of research”. Therefore, WHO established its 
first Advisory Committee on Medical Research in 1959 (renamed to the Advisory 
Committee on Health Research in 1986) and afterwards the regional advisory committees 
were founded. In addition, the Sixty-Third World Health Assembly (held in May 2010) 
approved WHO’s strategy on research for health. This strategy was approved by the 193 
Member States of WHO. 88 One of the six core functions of WHO, as listed in The 
Eleventh General Program of Work is “shaping the research agenda and stimulating the 
generation, translation, and dissemination of valuable Knowledge.” Research in WHO, 
however, focuses mainly on “secondary and commissioned research” with a focus on 
health systems, health policy, and health advocacy. 89  
Therefore, WHO pays attention to conducting and promoting research as the basis for 
evidence-based for healthcare (encompassing all its elements from prevention to 
treatment and rehabilitation) and for policy making for health (for example, in its 2013 
report, WHO emphasized on the crucial role of research for universal health coverage).90 
Consequently, observing the ethical standards in research is important to WHO, although 
it was usually limited to the research inside or under direct supervision of WHO and has 
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not made this organization a world leader in shaping ethical frameworks for health 
research. 
 The WHO Strategy on Research for Health lists three main principles as the guiding 
principles for the type of research it supports: (1) Quality: WHO holds a commitment to 
high-quality research. High-quality research means being “ethical, expertly reviewed, 
efficient, effective, accessible to all, and carefully monitored and evaluated.91” (2) 
Impact: This principle implies that WHO prioritize research based on its potential 
consequences and achievements for health. (3) Inclusiveness: Adopting a multisectoral 
approach and collaborating with communities and civil society and collaboration among 
state members and stakeholders consist the meaning of inclusiveness to WHO.92 
In 2011, WHO published the Standards and Operational Guidance for Ethics Review 
of Health-Related Research with Human Participants. This document is aimed at 
providing guidance for Research Ethics Committees for reviewing the health-related 
research projects with human subjects. However, this document does not include 
guidance on how to approach and resolve ethical challenges in research ethics and is not 
intended to substitute ethical guidelines.93  
WHO has also published the International Ethical Guidelines for Biomedical Research 
Involving Human Subjects and the International Ethical Guidelines for Epidemiological 
Studies in collaboration with the Council for International Organizations of Medical 
Sciences (CIOMS) that are discussed below in the part dedicated to discussing the role of 
CIOMS. 
The World Bank: The World Bank has started funding global health-related 
programs from a few decades ago and became a major role-player in global health 
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governance.94 Since the 1980s the World Bank has become the largest financial supporter 
of global heath projects.95 Although the main role of the WHO and World Bank is in 
providing healthcare for in-need societies and dealing with global public health issues 
such as outbreaks and pandemics, they both fund health-related research projects and 
develop ethical guidelines for research activities.96 
Formally established in December 1945, this organization is based in Washington 
DC. The World Bank works like a cooperative and has 189 member countries. The 
highest policymakers at the World Bank are the representatives of the member states who 
convene at the Board of Governors that convenes once a year (Annual Meetings). The 
Executive Directors (appointed by the five largest stakeholders of the bank) who work at 
the Bank receive their specific duties from the Board of Governors. The World Bank 
Group President (selected by the Board of Directors for 5-year periods) chairs the 
meetings of the Board of Directors.97 The highest official of the World Bank is the 
president who has always been a US-citizen. This is among the facts that shows the high 
influence of the United States in this intergovernmental organization. 
The World Bank Group consists of five major financial organizations as follow: (1) 
International Bank for Reconstruction and Development (IBRD), (2) International 
Development Association (IDA), (3) International Finance Corporation (IFC), (4) 
Multilateral Investment Guarantee Agency (MIGA) (5) International Centre for the 
Settlement of Investment Disputes (ICSID).98 
 The World Bank has been among the main sponsors of some impactful health-related 
research projects, one of the most well-known among them being the project of Global 
Burden of Diseases. This project has invented a health economics unit for measuring 
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utility in health, named Disability-Adjusted Life Years (DALYs). This project, although 
it has gained vast acceptance in the world and has been useful in providing more reliable 
assessments of the burden of diseases (for example, providing a single measure for 
calculating premature deaths and disabilities), has also been criticized for many aspects 
of it such as putting economic value on human life, entailing sex or age discrimination, 
and not being cross-cultural.99 These ethical debates show the numerous ethical concerns 
that exist  in the way of creating measures for health measurement in different 
communities and providing fair estimates of the health needs and priorities and 
comparing them between different counties and communities. 
The World Bank has taken some steps in developing a guideline for research, 
however, no guidelines have been announced or adopted yet.100 Therefore, this 
organization, although very influential in Global Health governance and in raising ethical 
debates, has not contributed in Global Governance for Research Ethics by taking part in 
shaping the existing body of the related soft law. 
UNESCO: The United Nation’s Educational Scientific and Cultural Organization 
(UNESCO) though not considered directly related to the technical aspects of health 
issues, has had a noteworthy contribution in developing ethical standards and norms for 
global bioethics and healthcare ethics and accordingly, UNESCO has made a major 
contribution in global governance for biomedical research. The most prominent step 
taken by UNESCO for this purpose, has been developing, adopting, and disseminating 
the UNESCO Universal Declaration of Bioethics and Human Rights .101 The General 
Conference of UNESCO in its 33rd meeting on 19 October 2005, unanimously adopted 
this declaration.102 
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As one of the UN organizations, UNESCO is in charge of coordinating international 
collaborations in education, science, culture, and communication.103 The constitution of 
UNESCO ratified in November 1945 at the end of United Nations Conference aimed at 
stablishing an educational and cultural organization convened to create an organization to 
promote a culture of peace and intellectual and moral solidarity among human beings. 
Consequently, the first General Conference of UNESCO convened in Paris in November 
and December, 1946 with representations from 30 countries.104 
The governing bodies of UNESCO include the General Conference that consists of 
the representatives of the State Members (with participation of Member States, Associate 
Members, and observers from Non-Member States and intergovernmental and non-
governmental organizations) and meets every two years. The General Conference is the 
supreme governing body of UNESCO that determines its policies and missions, set its 
programs and budget, and elect its Director General and members of the Executive 
Board.105 
UNESCO operates through five major programs: education, natural 
sciences, social/human sciences, culture, and communication/information. As the 
specialized UN organization with a mission on science, including the life sciences, 
UNESCO has always focused on ethics in science and technology, including bioethics. 
Accordingly, since 1993, it has been hosting the International Bioethics Committee (IBC) 
and has dedicated part of its budget to pursuing specific objectives in the field of ethics in 
science and technology. In 1998, UNESCO established the World Commission on the 
Ethics of Scientific Knowledge and Technology to cover other areas of applied ethics and 
the Intergovernmental Bioethics Committee (IGBC) to fulfil the respect for cultural 
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diversity and geographic representation in its bioethical operations. As an international 
organization affiliated to the UN, part of the objectives that UNESCO defined for itself in 
the field of bioethics has been setting globally consensual standards. In the General 
Conference, held in 2001, ethics of science and technology was included among the five 
top priorities of UNESCO, confirming the organization’s leading role in bioethics. The 
same meeting of the General Conference invited the Director-General to examine the 
possibility of setting and adopting universal norms on bioethics. This was the practical 
starting point of a series of endeavors that ended to creating and adopting the UNESCO 
Universal Declaration of Bioethics and Human Rights in 2005.106 
The UNESCO Universal Declaration of Bioethics and Human Rights consists of an 
introduction and 28 articles organized under the following titles and subtitles:(1) Scope; 
(2) Aims; (3) Principles: Human Dignity and Human Rights; Benefit and Harm; 
Autonomy and Individual Responsibility; Consent; Persons without the Capacity to 
Consent; Respect for  Human Vulnerability and Personal Integrity; Privacy and 
Confidentiality; Equity, Justice, and Equity; Non-Discrimination and Non-
Stigmatization; Respect for Cultural Diversity and Pluralism; Solidarity and Cooperation; 
Social Responsibility and Health; Sharing of Benefits; Protecting Future Generations; 
Protection of the Environment, the Biosphere, and Biodiversity; (4) Application of the 
Principles: Decision-Making and Addressing Bioethical Issues; Ethics Committees; Risk 
Assessment and Management; Transnational Practices; (5) Promotion of the Declaration: 
Role of States; Bioethics Education, Training, and Information; International 
Cooperation; Follow-up Action by UNESCO; (6) Final Provisions: Interrelation and 
Complementarity of the Principles; Limitations on the Application of the Principles; 
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Denial of Acts Contrary to Human Rights, Fundamental Freedoms, and Human 
Dignity.107 
Some of the characteristics of this declaration that are relevant to global governance 
for health research are as follow:  
(1) This declaration provides the first and only universally and consensually created 
set of norms and principles for governing bioethics, including research ethics. The 
unanimous approval of all the members of UNESCO is one of the important features of 
this declaration. Therefore, this declaration provides another great example (like what 
was said about the Declaration of Helsinki) of the role of soft law in global governance, 
at all, and in global governance for health research, in particular.108 
(2) All the principles of the classic set created and adopted by the Belmont report and 
the Beauchamp and Childress’s four principles of biomedical ethics, which are the 
columns of principlism in bioethics, are included among the principles of this declaration. 
However, other principles are added to make it more comprehensive, inclusive, and 
global. Adding these principles expands the scope and view of these principles from a 
Western-oriented one to a globally and transculturally recognized set of principles. 
Therefore, these principles can also be called a part of the common intellectual heritage 
of mankind.109  
(3) UNESCO is one of the UN organizations, therefore, in creating ethical 
instruments, it should observe and consider the norms and principles once promulgated 
through The Declaration of Human Rights. The UNESCO Universal Declaration of 
Bioethics and Human Rights has been successful in keeping the necessary abidance to 
this great predecessor, and at the same time, encompass and observe other important 
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values such as cultural diversity, with this important caveat that no principle (including 
respect for cultural diversity) should be interpreted in a way that is contrary with human 
rights and fundamental freedoms.110 
In sum, one of the features that differentiate global governance for health research 
from global health governance is its strong relation with bioethics and medical 
humanities. Therefore, the relevance of UNESCO to global governance for health 
research seems to be even stronger that WHO’s, even if WHO is the main international 
organization in charge of global health governance, formally speaking. In the next 
chapters of this dissertation, the principles introduced and adopted by the UNESCO 
Universal Declaration of Bioethics and Human Rights are used for developing an ethical 
framework for the global governance for biomedical research.  
The United States of America: The contribution of the United States of America 
(USA) in Global Governance for Health Research actualize in three main ways: (1) 
developing theories and domestic guidelines and legislations that are pioneer, 
groundbreaking, standard-setting, and serve as prototypes and models for other countries 
and institutions; (2) influential participation and playing a unique role in international 
organizations and coalitions; (3) hosting the most prominent funding bodies for 
international health research both in the governmental and private sectors. Below, brief 
discussions on each of these roles are provided: 
1.Over the past decades, the US has always hosted the pioneer institutions and 
scholars in the field of biomedical ethics, including research ethics. One of the major 
developments, was the whistleblower article of Henry Beecher that showed that in health 
research it is not enough to rely on the personal virtues, respected characters, and good 
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intentions of researchers and their hosting institutions, because even in the most 
prestigious institutions and under supervision and leadership of the most reputable 
physician/researchers this is quite possible that extreme violations of the rights of human 
subjects take place. 111 Therefore, independent oversight backed by legislations grounded 
in solid principles and values are necessary for governance of health research 
enterprise.112  
In 1974, the National Research Act was passed and the National Commission for the 
Protection of Human Subjects in Biomedical and Behavioral Research was established. 
Consequently, according to the act and within the framework of the principles of the 
Belmont Report (see below), the federal regulations for protection of human subjects 
were developed and adopted by the Department of Health, Education, and Welfare. This 
name of this department was later change to its current name, the Department of Health 
and Human Services. These regulations are process-oriented; therefore, they look less 
relevant to the subject of developing an ethical framework for Global Governance for 
Health Research.113 
In 1978, the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research published a short but influential document 
delineating the moral principles for biomedical research that is called after its birthplace, 
the Belmont Report. It was in the Belmont Report that for the first time, a framework of 
general principles for biomedical research ethics (also known as the Belmont Principles) 
were introduced. These principles include: Respect for Person (applies to informed 
consent), Beneficence (applies to risk-benefit assessment, and Justice (applies to selection 
of research participants). Displaying such a close and obvious relevance between the 
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abstract moral principles and the practical ethical aspects of research ethics is one of the 
main features of Belmont Report. The principles of Belmont Report were not developed 
by referring to certain philosophical works or schools, but they were included in the 
report based on their widely acceptance in the cultural tradition or in other words, based 
on Social morality. 114  
Consequently, in 1978, Beauchamp and Childress introduced their four principle of 
biomedical ethics as follow: Respect for Autonomy, Beneficence, Non-Maleficence, and 
Justice. The differences between these two frameworks, although trivial, were grounded 
on some criticisms on the Belmont Report. For example: Respect for Person implies 
respect for all the persons, regardless of their possession or lack of autonomy, while the 
informed consent is developed to protect the subjects who are autonomous and for the 
subjects with reduced autonomy, the principles of beneficence and non-maleficence look 
more relevant. As another example, the concerns about using utilitarian justifications to 
endanger the human subjects of research (like what had occurred in a group or scandalous 
research projects revealed by Beecher) led Beauchamp and Childress in include Non-
Maleficence as a separate principle in their framework. 115 These principles were 
consequently included in the more comprehensive and global framework provided in The 
UNESCO Universal Declaration of Bioethics and Human Right.116 
2.The USA is an important member of almost all international organizations with 
noteworthy role in the Global Health Governance and Global Governance for Health 
Research (including intergovernmental organizations such as WHO and international 
nongovernmental organizations such as WMA). In addition, the USA has not limited its 
participation in Global Health Management to its role in international organizations. 
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Instead, this country has initiated a number of large unilateral and bilateral programs to 
promote global health that have been accused of weakening multilateralism in Global 
Health Governance.  
3.The USA is the most important state-funder of health research, including 
international health research in the world. This funding occurs in two major ways: (1) 
through for-profit organizations such as corporates, or non-profit organizations such as 
philanthropic institutions, that is discussed elsewhere in this dissertation; and (2) through 
the federal budget by government in the for of the projects funded by the National 
Institutes of Health (NIH). Therefore, the regulations overseeing the practice of US-based 
parties in these research projects are important parts of Global Governance for Health 
Research. Since these regulation are mostly grounded in the Belmont principles (see 
above), there is no need to examine them in more details in this part of this dissertation.  
The Council of Europe 
The Council of Europe had been a major role-player in Global Governance for Health 
Research in the past decades by its role in shaping the soft law. This organization should 
not be confused with the European Union although all the members of the European 
Union are also members of the Council of Europe. The Council of Europe was founded in 
1949 and is an intergovernmental organization having 46 members. One of more than 
200 multilateral conventions created by the Council of Europe over its history is The 
Convention on Human Rights and Biomedicine. 117  
The Convention on Human Rights and Biomedicine (its full title being: The 
Convention for the Protection of Human Rights and Dignity of Human Being with regard 
to the Application of Biology and Medicine) is the first international agreement created 
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regarding the newly emerged biomedical technologies. This convention is the first 
legally-binding international biomedical law and ethics document that 
considers human dignity a central concept and creates a legal framework for communities 
with various cultural and normative backgrounds.118 
This convention is a good example of international hard law that contains values such 
as human dignity that do not belong to a specific cultural or philosophical context, but 
belong to the common heritage of mankind.119 Another example that is made by this 
convention is the methodology through which a group of countries join a convention and 
then, the group expands by joining other members and adopting it as their on legally-
binding law. Although the recent trends of isolationism and protectionism augmented by 
political phenomena such as Brexit and the recent election of Donald Trump as  the 
president of the United States might shadow the efforts toward globalization in 
international law, the need to strengthen global governance in areas of research and the 
will of human kind to preserve and prevail its common moral heritage, such and human 
rights and human dignity, will finally overcome these temporary retreats and shape the 
future of global governance. 
ii. Non-State Role Players 
Civil society and private sector organizations are among the most important role 
players in the scene of global governance for biomedical research and in protecting the 
vulnerable groups in research.120  Their contribution can be divided into three main 
categories: philanthropic organizations, civil society, and for-profit organizations. In sum, 
the non-state role players participate in Global Governance for Health Research in two 
ways: First, by supporting, conduction, and promoting international research all over the 
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world. Second, by taking part in ethical regulation and oversight for research. Some 
international organizations that belong to civil society has taken important parts in this 
realm, e.g. the World Medical Association (WMA) that crated the Declaration of 
Helsinki and The Council for International Organizations of Medical Sciences (CIOMS) 
with the International Ethical Guidelines for Biomedical Research Involving Human 
Subjects. The Non-State organizations show that how globalization has changed the scene 
of global power relations in a way that the states are not the only major role players, but 
in some areas, they even lag behind the non-state role players in the governance of global 
affairs. 
1- Philanthropic organizations: This category includes all the organizations 
established to serve the public in the field of global health.121  These organizations either 
provide health-related support for in need societies around the globe or support activities 
that are in service of common good. The constitution of the WHO explicitly recognizes 
the potential contribution of civil society organizations in global health affairs. Part of the 
mission of these organizations is protecting vulnerable populations both inside and 
outside of research. Bill & Melinda Gates Foundation is an example of this category of 
organizations.  
Among the private organizations, the Bill & Melinda Gates Foundation is a 
noteworthy example. This foundation has been a major contributor to global health with 
profound influence on international health policy and the design of global health 
programs and initiatives. Although the foundation’s contribution to global health is a 
publicly recognized fact, its grant-making program may be less known even by the 
professionals. Between January 1998, and December 2007 the total value of these grants 
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was US$8. 95 billion. A wide range of global health organizations, such as WHO, the 
World Bank, the Global Fund to Fight AIDS, Tuberculosis and Malaria, prominent 
universities, and non-governmental organizations received grants. The share of 
supranational organizations was $3·62 billion (40% of all funding). Just the share 
allocated to research and development (mainly for vaccines and microbicides) or to basic 
science research was over a third ($3·27 billions) of funding.122 
This should be mentioned that a major part of global health governance is conducted 
through partnership between public and private sectors . Among the most prominent 
examples of such collaborations are the Albendazole Donation Program, Medicine for 
Malaria Venture, and International AIDS Vaccine Initiative. These partnerships are 
effective in protecting vulnerable groups and are sometimes more efficient that the more 
bureaucratic international organizations.123 It has been claimed that the concept of 
building collaborative partnerships with business is a central view of the United Nations 
(UN) organizations on the governance of globalization.124 
Private philanthropies have always been subject of criticisms. For instance, Bill & 
Melinda Gates Foundation is criticized because of its global agenda. The critiques argue 
that this foundation is too focused on technology and disease that shapes the vertical 
approaches that are easily quantifiable, while does not pay enough attention to horizontal 
approaches that focus on improving health systems.125  
2- Civil Society: Civil society that encompasses Non-Governmental Organizations, 
community movements, and other institutions that arise in the communities and act as 
non-governmental actors, are among the major role players in Global Health 
Governance.126 Professional associations are among the civil society actors. In the field of 
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global health research ethics, the World Medical Association (WMA) and the Council for 
International Organizations of Medical Sciences (CIOMS) have been one of the most 
influential role players in the past decades. This importance has mostly been because of 
the Declaration of Helsinki and the International Ethical Guidelines for Health-related 
Research involving Humans.  
The WMA: World Medical Association is a confederation of medical professional 
associations with members from 112 countries. Professional associations typically are 
independent institutions and are not part of or subordinate to any governments. Therefore, 
the WMA is an international organization, but not an intergovernmental one. The mission 
of the WMA, as stated on its website, is: “…to serve humanity by endeavoring to achieve 
the highest international standards in Medical Education, Medical Science, Medical Art 
and Medical Ethics, and Health Care for all people in the world.”127  
The first General Assembly of the WMA was held in Paris, September 1947.128 Being 
established in the wake of WWII and the shocking revelation of the violations against 
human rights occurred during the research experiments of Nazi physicians, the WMA 
was founded with a deep concern about human rights and the rope of physicians in 
safeguarding and promoting them.129  
Driven by the concerns about human rights and attending to its nature as an institution 
originated from civil society, from the very beginning, the WMA emphasized on the 
professional independence of medicine, and in delineating, declaring, and preserving 
ethical standards for medical professions.130 
What has made the WMA very special in the relevance with global governance for 
health research is the Declaration of Helsinki. Adopted by the WMA at its General 
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Assembly in Helsinki in 1964, the Declaration of Helsinki of the WMA has been the 
most influential and well-known international ethical guideline for health research in the 
past decades. 131 This declaration, created and adopted by a confederation of professional 
associations, provides a great example of the roles of independent institutions of civil 
society and their created international soft laws in global governance. The Declaration of 
Helsinki was lucky to be followed by the Beecher’s revelations in 1966 that showed the 
necessity of and the need for such an instrument in the research enterprise.132 
Being undergone multiple revisions and amendments until the last one in 2013, the 
current version of the Declaration of Helsinki consists of 37 articles organized under 12 
topics as follow: (1) Preamble; (2) General Principles; (3) Risks, Burdens, and Benefits; 
(4) Vulnerable Groups and Individuals; (5) Scientific Requirements and Research 
Protocols; (6) Research Ethics Committees; (7) Privacy and Confidentiality; (8) Informed 
Consent; (9) Use of Placebo; (10) Post-Trial Provisions; (11) Research Registration and 
Publication and Dissemination of Results; and (12) Unproven Interventions in Clinical 
Practice.133  
Of 37 articles of the Declaration of Helsinki, 12 of them depict “general principles”. 
These principles start with a recall of two mandated for physicians, one of them included 
in the Declaration of Geneva of the WMA as parts of a professional oath for them, as 
follow: “The health of my patient will be my first consideration,” and another one 
asserted in the international Code of Medical Ethics, as follow: “A physician shall act in 
the patient’s best interest when providing medical care”.134 
The next articles in the “general Principles” part of the declaration, other main values 
are asserted, such as (and not limited to): (1) the primary purpose of medical research 
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with human subjects being “to understand the causes, development, and effects of 
diseases and improve preventive, diagnostic, and therapeutic interventions” ;(2)  the duty 
of physicians “to promote and safeguard the health, well-being, and rights of patients,” 
including the research participants; (3 the priority of rights and interests of individual 
research human subjects to the ultimate purpose of research; (4) the necessity of the 
appropriate scientific and ethical credentials and qualifications as the prerequisites for 
conducting research projects; and the necessity of compensating the harms resulted by 
research activities.135 
The main claimed weakness of Declaration of Helsinki is its belonging and adherence 
to just one side of the parts involved in research. In other words, the Declaration of 
Helsinki is created and adopted physicians and addresses them, while for a 
comprehensive ethical guidance for research, the voice of other parts such as the 
participants and communities should be heard through their active participation in 
developing the guidance. It has also been claimed that the Declaration of Helsinki has 
taken a partial position in favor of physicians/researchers by loosening the tight criteria of 
informed consent that was included in its predecessor, the Nuremburg Code.136  
The CIOMS: The Council for International Organizations of Medical Sciences 
(CIOMS) is another example of the international nongovernmental organizations that 
ultimately belong to the global civil society and play a significant role in Global 
Governance for Health Research. Established jointly by WHO and UNESCO in 1949, 
and located in Geneva, CIOMS is dedicated to the international biomedical scientific 
affairs and coordination among the major role players in this area, e.g. UN, WHO, and 
UNESCO.137  
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One of the noteworthy features of the CIOM on the map of the existing situation of 
Global Governance for Health Research is its being a civil society organization (in the 
category of international non-governmental organizations) established by two major 
intergovernmental organizations. CIOMS represents the global health-related scientific 
community through having a large number or organizations among its members. In 2016, 
13 international organizations, 12 national organizations (USA not being among them), 
and 19 associate member organizations were among the members of CIOMS. 138 
Therefore, CIOMS represent many scientific and biomedical professions and disciplines 
in various countries. 
One of four CIOM’s main long-term programs is the bioethics program. Through its 
mission on bioethics, one of the CIOM’s functions has been developing and 
promulgating ethical guidelines for health research. In 1993, CIOMS published its 
influential guidelines titled International Ethical Guidelines for Biomedical Research 
Involving Human Subjects. The last version of this guideline is published in 2002 and has 
recently undergone a new round of revisions and the 2016 has been published under the 
slightly modified title of the International Ethical Guidelines for Health-related Research 
involving Humans.139 In addition, in 2008, CIOMS published the International Ethical 
Guidelines for Epidemiological Studies. This guideline was published as a book with a 
slightly modified title of International Ethical Guidelines on Epidemiological Studies in 
2009. 140 
 These two documents (International Ethical Guidelines for Health-related Research 
involving Humans and International Ethical Guidelines on Epidemiological Studies) are 
substantial and well-known parts of the existing global soft law on health-related research 
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ethics and shape the significant contribution of CIOMS in Global Governance for Health 
Research. In shaping the soft law of Global Governance for Health Research, these two 
documents are complementary additions to the WMA’s Declaration of Helsinki and The 
UNESCO Universal Declaration of Bioethics and Human Rights. 
3- For-profit organizations: For profit organizations are involved in the global 
governance for biomedical research, mainly by funding the international research.141 
Their supranational activities have raised ethical concerns regarding the vulnerable 
populations,142 even some scandals have occurred. However, they have also contributed 
to correcting the ethical flaws of their performance and developing ethical norms and 
standards for their research activities. In this way, they have contributed in the global 
governance for biomedical research and to the protecting of vulnerable human research 
subjects.143  
The ethical network for Global Governance for Research will not be successful, 
unless the private sector regards ethics as a competitive privilege. The reputation of these 
companies should be contingent to their observance for ethical standards. This shows the 
important role of media in overseeing the role-players in the global research enterprise 
and naming and shaming the ones who are not observant for ethical standards. Also, the 
role of civil society in convincing people and states to ban and boycott non-ethical 
corporations. 
  In sum, without active contribution of the private sector, this will be futile to 
develop ethical standards for global research enterprise. And the private sector will 
participate just when it finds this participation a competitive privilege in the market. 
 
 55 
iii. A Global Network 
 Organizations vs. Instruments: The existing map of the global governance for 
health research can be portrayed based on a Network Model.144 As is briefly shown 
above, no single organization has a monopoly on the realm of global health governance. 
However, different kinds of national and international institutions take part in this 
interconnected network throughout the world. As a matter of fact, the existing situation of 
global governance for health research is the sum of all the involved role players who take 
part in this network.  
As mentioned above, although WHO has been considered the leading organization in 
Global Health Governance, at least in the first decades after its foundation and as its 
formal and constitutional role, its leadership in the areas of healthcare ethics and research 
ethics has never been considered undisputable. Instead, other organizations such as 
UNESCO and WMA has always challenged the leading role of WHO in this ethical 
guidance of the health sector. In addition to the international organizations, bilateral 
initiatives, philanthropies, and private sector have been among the role players that put 
the leadership role of WHO in jeopardy.  
When it comes to the health research, although WHO has created and adopted some 
useful instruments such as guidelines and strategies, the most influential and well-known 
instruments have been created and adopted by other organizations. The best examples of 
such instruments are the World Medical Association Declaration of Helsinki and the 
UNESCO Universal Declaration on Bioethics and Human Rights, both introduced in this 
chapter.  
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The role of philanthropic and for-profit role players in global governance for health 
research is undeniable, as depicted above. However, none of them is, or can be, in the 
leading position of global governance for research. They are parts of a bigger network 
that should be guided by a larger and more consensual and global size, reach, and 
identity. Among the governmental role players, the United States, being the single largest 
funder and conductor of international research in the world, can take a constructive 
leading role, however, cannot be the sole and unilateral leader of global governance for 
health research. 
Therefore, the major weakness in the current network of global governance for health 
research is the lack of a capable and legitimate world leader in the form of a multilateral 
international (not necessarily intergovernmental) organization. These is no international 
organization established or considered to be the world leader for health research ethics. 
Even WHO that once was supposed to lead the global health, neither proved capable to 
establish a monopoly in this leading role, nor was supposed or considered to be the world 
leader in the field of health research. In addition, although managing everything in 
accordance with broad consensuses seems to be the most democratic way of managing 
global affairs, there are some instances where more powerful or wealthy members of 
international organizations decide to play unilateral roles.  
It seems that the most prominent ways through which Global Governance for 
Research is operated in the current world are the soft and hard domestic and international 
laws. The history of international soft laws on health research started with the Nuremburg 
Code just after the WWII.145 Afterwards, this primary code was replaced by more 
comprehensive and realistic ones. Nowadays, the UNESCO Universal Declaration of 
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Bioethics and Human Rights, the CIOM’s International Ethical Guidelines for Health-
related Research involving Humans, and the WMA’s Declaration of Helsinki are two 
complementary documents that play the most prominent role in this regard. In addition, 
the domestic law of the countries that host the major funding bodies for international 
research (USA and European Union) are impactful.  
One important feature of these instruments is that they do not specify one or more 
certain philosophies as the theoretical bases of their guidelines. Instead, they are 
generally based on the common accepted norms and values that can be considered the 
common heritage of mankind regardless of specific philosophical or religious traditions. 
This feature should be preserved in any ethical framework that will be developed for 
Global Governance for health Research.  
These guidelines and legislations, in addition to providing a legislative basis for 
Global Governance for Health Research, serve as the educational instruments and 
resources both for training local experts (including members of Research Ethics 
Committees and Institutional Review Boards) and for developing local guidelines. These 
instruments are helpful resources for local experts in developing local legislations and 
guidelines on health research because they provide them with a basis of globally accepted 
and scholarly elaborated set of principles and guidelines that can be tailored and modified 
based on their local needs and cultural sensitivities. 
Therefore, in the absence of a single world organization in the leading status, guiding 
the existing network by a set of principles (or a body of soft laws) can still be considered 
a pragmatic (and more realistic) solution for the lack of authority in global governance 
for health research. In other words, instead of a single organization, the global 
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governance for health research can be realized and exerted by a set of globally consensual 
principles and norms. The principles and norms that are accepted, adopted, promoted, and 
safeguarded by various role players in a non-hierarchical network. 
A Historical Precedent: The normative framework introduced by Emmanuel and 
Grady is a noteworthy historical precedent for using the existing instruments for creating 
a normative network for research. They argue that having a summative deduction from all 
the existing main “myriad guidance’ is helpful because the extant guidance accumulated 
in the shape of numerous instruments has some flaws, including:  
1.many of these instruments have been the results of scandals and revelations that 
shocked the community and led to creating some reactional guidelines that are not 
helpfully and comprehensively applicable to all the research projects. For example, the 
emphasis that the Nuremberg Code put on the absolute necessity of informed voluntary 
consent, was a conscientious reaction to the revelation of the experiments done by Nazi 
researchers on the restrained subjects without obtaining their consent. However, this 
absolute demand for informed voluntary consent made it almost impossible to do 
research on people with diminished autonomy, while they would benefit from such 
research addressing their problems and needs. Therefore, this mandate subsequently was 
modified by other guidelines. In the same way, the Belmont report was a reaction to the 
revelation the Tuskegee Syphilis studies.146  
2.Most of the extant instruments lack comprehensiveness. They have either created 
for a more inclusive or a less comprehensive purpose, such as the UNESCO Declaration 
of Bioethics and Human Rights or are most focused on procedural purposes, such as the 
Common Law (45 CFR 46) in the USA, or are developed by just one of the involved 
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parties, such as the Declaration of Helsinki. Although some of than have tried to be 
complementary to their predecessors, still the lack of a comprehensive and global 
research-specific framework is undeniable.147 
3.In addition to not being comprehensive, none of the extant pile of guidelines is 
systematic. Instead, they are “tend to be lists of claims or principles.”148 Providing a 
systematic framework that covers all the phases and steps of research from design to 
publication with guidelines that can be clearly interpreted, has been another argument 
behind developing this framework for clinical research.149  
Therefore, they developed a new framework for clinical research based on the 
previous guidance. This framework encompasses 8 principles that cover all the phases of 
clinical research from the very beginning to the end. In addition, each principle is detailed 
by benchmarks that provide an explicit explanation and interpretation of each principle. 
In other words, the benchmarks are practical clarifications of what is necessary to 
actualize each principle. The principles included in this framework are a follow: (1) 
Collaborative Partnership, (2) Social Value, (3) Scientific Validity, (4) Fair Participant 
Selection, (5) Favorable Riske-Benefit Ratio, (6) Independent Review, (7) Informed 
Consent, and (8) Respect for Participants.150 
In sum, taking all the precedent instruments and framework-making efforts into 
consideration, it seems that the next major step in Global Governance for Research 
Ethics, will be developing a comprehensive, systematic, impartial, and cross-cultural 
ethical framework. 
The Crucial Role of Civil Society: In addition to the role of the civil society 
organizations in Global Governance for Health Research, this is very important to note 
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that civil society as an infrastructure is fundamental and essential for establishing valid 
and reliable systems of governance and oversight for research, both at domestic and 
global levels.  
The main concern in development of the basic theories of civil society and research 
ethics has simply been protecting the less powerful and less privileged in social – and 
research – transactions.151 Having an organized and well-developed civil society is the 
best way to protect and preserve the basic rights and freedoms of vulnerable social 
groups. In the same manner, having well-established research ethics instruments and 
institutions safeguards the rights, well-being, and interests of research subjects, and their 
families, communities, and countries, as the less powerful parties in the related 
negotiations and transactions.  
As a though experiment for realizing the ethical norms and standards of research 
ethics, imagining one’s self on the other side of the table of negotiations will help the 
researchers to find the most ethical way to behave. This means that the researcher asks 
herself: “what I would like/do if I was the research subject or the representative of their 
community or country?”  In almost all cases, the answer of this question is compatible 
with ethical recommendations and requirements. 
One of the most important factors in strengthening the ethical quality of research in a 
sustainable manner is having professional bodies for researchers that develop, announce, 
support, teach, promote, and enforce the ethical guidelines and regulations for 
research152. Independent professional bodies are a main and major component of civil 
society. In the absence of civil society, there will be no independent professional 
organization. And in the absence of independent professional organizations, there will be 
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no substitute for them to accomplish this important mission. Governmental bodies cannot 
play this role. Up to down laws and regulations are of limited help in making research 
practices more ethical because such regulations should emerge out of the consensus 
among the professionals not as governmental commands or directions.  
As a historical perspective, one can argue that in both developed and developing 
countries, the strengthening of civil society and promoting research ethics follow 
correlated and interdependent trends. These trends, however, are more complicated and 
stumbling in developing countries.  
In almost all countries hosting research enterprise, research ethics instruments and 
institutions are thriving and flourishing.153 Many of these countries have compiled their 
own research ethics instruments that are in concordance with global values and 
standards.154 Developed countries help the developing countries that host collaborative 
research trials to develop and strengthen their research ethics infrastructures.155  
Some obstacles, however, have remained. The collective historical experience, shows 
that just having well-written instruments is not sufficient for preventing violations of 
ethical standards and basic rights of research subjects, especially the vulnerable 
groups.156 The key factor in effective implementation of the values and requirements of 
such instruments is the existence of independent and non-governmental bodies to do an 
array of key functions from performing independent review and oversight to advocating 
for vulnerable groups and research subjects. This is the main problem in some developing 
countries in them the civil society infrastructures are not established and developed.  
As a matter of fact, a strong disbelief toward the values of civil society and resistance 
against development of independent and non-governmental institutions are the underlying 
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causes of the lack of such institutions in the field of research ethics in many of 
developing countries. As a result, the instruments, such as guidelines and even laws are 
compiled and ratify and announced. In the absence of required civil society 
infrastructures, however, they don’t become fully implemented and are not taken 
seriously by the involved parties. For instance, in Iran, the research ethics committees are 
always consisted of the high brass of the related organization and their members are the 
principal investigators – or their bosses, subordinates, or close colleagues – that prevents 
them to be effective and make serious barriers against unethical behaviors and abuse of 
power. 
The other main obstacle in developing countries is the lack or underdevelopment of 
independent organizations including the professional bodies that make and represent the 
consensus among researchers and the advocate bodies that represent the patients and 
research subjects. Non-democratic governments do not tolerate independent civil society 
organizations in their territories157. They try to give the ethical role of such professional 
bodies to governmental ones. However, the governmental bodies, although possess power 
and wealth, are not able to generate consensus and represent all the parties in the power 
relations in the research enterprise. Therefore, in the absence of civil society and its 
resulted independent professional and advocacy bodies, this is impossible to strengthen 
the ethical quality of research in a sustainable manner. 
Therefore, actual establishment and strengthening of research ethics institutions in 
developing countries depend on prior strengthening of civil society in these countries. 
Without taking this crucial step, and in the resulted absence of independent oversight, 
relying on just creating new instruments and training efforts won’t do much in preserving 
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and safeguarding the basic rights and well-being of research subjects that is what research 
ethics is all about. 
In sum, describing the global network - through and within which the Global 
Governance for Health Research operates - won’t be complete without considering the 
crucial role and importance of civil society. Civil society at both national and global 
levels provide the infrastructures for implementation any sets of values, norms, and 
principles. In the absence of civil society, it seems futile to talk about research ethics and 
ethical governance for research at the institutional level. Therefore, this situation analysis 
of Global Governance for Health Research entails the crucial role that has already played 
by civil society organizations and the importance of civil society in the current and future 
situation of this institution. 
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Chapter Three - The Main Challenges and their Ethical Nature 
In this chapter, the main challenges of Global Governance for Health Research are 
presented and discussed. In addition, the ethical nature of these problems and/or their 
underlying ethical causes and roots are evaluated and analyzed. Following the conceptual 
and situation analyses provided in the previous chapters, shedding light to the main 
challenges seems to be the next logical step before presenting an ethical framework that 
will be depicted in the next chapters. For portraying a complete picture of the current 
situation of the Global Governance for Health Research, complementary to the situation 
analysis provided in the previous chapter, nothing is more illuminating than portraying its 
main challenges. The global network for governing health research has developed and 
took its current shape for solving the global challenges. On the other hand, the existence 
of challenges at the global level necessitates the existence of such a network for dealing 
with them. In other words, the frontiers and borders of Global Governance for Health 
Research has constantly been formed and reformed by the process of encountering these 
challenges over the past decades. This claim is true for and relevant to all other aspects of 
Global Health Governance, too.158   
The challenges that are identified, discussed, and analyzed in this chapter, are 
mainly resulted from power relations between parties involved in research. Most of these 
challenges arise when a powerful (wealthier and more informed) party conducts research 
projects in/on a less powerful party (country, community, or individual) and this power 
imbalance ends up to the formation of exploitative –or other kinds of ethically wrong – 
transactions/relations. The challenges for Global Governance for Health Research, 
however, are not limited to the relations between wealthier and poorer countries and 
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communities. Even in the relations and transactions that take place among the high-
income communities, the power imbalance resulted from the accumulation of 
data/information at the researchers’ side causes problems with ethical nature that needs 
the governance’s attention.   
As a result of globalization in research enterprise, over the previous decades, the 
number of health-related research projects and clinical trials conducted in the low and 
middle-income countries (LMICs) has significantly increased .159 Although this can be 
looked as a kind of scientific growth or transferring science and technology to the 
LMICs, there are some facts and issues that raise ethical concerns. These ethical concerns 
need the attention of both the national authorities and the global governance. These 
ethical concerns include:  (1) In some of these interventional studies and in some area in 
which these studies are conducted, the potential participants are mostly poor and illiterate 
and lack political power. (2) Due to the poverty of the participants and the weakness of 
heath infrastructures in their communities and countries, this may be too difficult for 
potential participants to get access to the modern and quality healthcare outside the 
research settings .160 (3) Multinational pharmaceutical companies and research funding 
institutions in high-income countries (HICs) sponsor most of these health-related research 
projects .161 Their focus on their financial interest and competiveness in the market and 
bearing the most possible amount of profit as the criteria of their success, may lead to 
undermining ethical responsibilities and moral duties. (4) Many of these research projects 
are designed in response to the health needs and priorities of the populations of the HICs 
and the hosting populations in the LMICs won’t benefit from the ultimate results and 
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products of the projects. Instead, the products will be produced and distributed and 
purchased only in the HICs.162 
The above ethical concerns that are the results of globalization, need global 
attention. In other words, they need to be governed globally. In this chapter, the most 
prominent forms in which the above-mentioned major ethical concerns are being 
materialized in the contemporary world (on the global scene of the expanding enterprise 
of international research) are discussed. Through this discussion, the following questions 
are answered: (1) What are the characteristics and details of the main problems and 
challenges confronting each aspect/sphere of governance in the Global Governance for 
Health Research? (2) To what extent the main problems confronting the Global 
Governance for Health Research are of ethical nature? (3) What are the ethical aspects or 
elements involved in each of these challenges or helpful in finding their solutions? What 
are the actual or potential roles of the role-players of global governance (e.g. scientific 
community, professional organizations, and educational institutions) in creating or 
solving these challenges? 
In this chapter, the following challenges for global governance for health research 
are recognized to be among the main challenges and depicted in a way that clearly shows 
the ethical nature or background or elements of them: Exploitation and Helicopter 
Research; the Problem of Double Standards; Ethical Imperialism and Colonialism; 
Bilateralism vs. Multilateralism; Biopolitics vs. Bioethics; and the problems associated 
with Data Sharing, Big Data, and International Collaborations. 
Among the above challenges, the first four ones are mostly relevant to research 
collaborations between developed and developing countries. The fifth one, however, is 
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more relevant to the collaborations among developed countries, although it is can also be 
relevant to the collaborations between developed and developing countries and even the 
collaborations among developing countries.163 
After analyzing the above-mentioned challenges, this chapter uses a model created 
by Thomas Weiss, titled the “frameworks of gaps”, for further analyzing these challenges 
in the context of the current theories of global governance. The elements of the above 
challenges are categorized within a five-fold set of gaps that exist in the following arenas: 
(1) Knowledge, (2) Norms, (3) Policies, (4) Institutions, and (5) Compliance.164 All these 
gaps can be demonstrated in the theoretical and practical elements of the challenges 
examined in this chapter. Applying the frameworks of gaps as theoretical tool sheds light 
on different aspects and implications of these challenges, provides a comprehensive and 
classified understanding of these challenges, and reveals that they should be discussed 
and their solutions should be sought in the field of Global Governance for Health 
Research. 
At the final part, this chapter provides some conclusive remarks holding that one of 
the main roots/causes of the existing problems and gaps is the absence of a 
comprehensive, consensual, and democratically constructed ethical framework. The 
existing frameworks are difficult to apply and have not been successful in overcoming 
these challenges, partly because they are top-down.165 Developing a comprehensive, 
consensual, and efficient ethical framework in one of the next major tasks/challenges of 




i. Exploitation and Helicopter Research 
On Exploitation: Exploitation is one of the most important, central, and well-
discussed concepts in the field of biomedical research ethics. Although not included as a 
distinct principle in the canonical set of principles of biomedical ethics, it has been 
argued that the imperative of “minimize exploitation” has been one of the most 
prominent (or even the only) moral rationales of these principles.166 This idea seems even 
more plausible by looking at the formal birthplace of the modern sets of principles of 
biomedical ethics that was the Belmont Report, that has been created in direct relation 
with the biomedical research.167 
Exploitation can be defined as “taking unfair advantage” of the subject of 
exploitation. However, with this definition, the ambiguity persists, because this should 
also be clear that which kinds of relations or transactions entail taking “unfair 
advantage”. For clarifying this concept and introducing an unblemished definition, 
Wertheimer developed a theoretical framework. Examining Wertheimer’s framework 
show that it includes different theoretical aspects for recognizing and defining 
exploitation in biomedical research. These aspects can be categorized as follow: (1) 
essentials of exploitation, (2) differential diagnoses of exploitation, and (3) different 
types of exploitation.168 In this part, Wertheimer’s framework in provided in more details 
since this framework is best fitted and tailored for discussing the concept of exploitation 
in the context of biomedical research ethics. The Kantian and Marxian concepts are also 
briefly introduced and discussed (see below). 
Essentials of Exploitation: First, the exploiter benefits from the relation or 
transaction that entails exploitation. Without an exploiter-benefactor party, the 
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relation/transaction falls into other differential categories (see below). Second, the 
exploitation is mainly about the unfair results rather than defective/unfair processes (e.g. 
in an exploitative research project, even if the subjects –for any reasons – had given their 
informed consent, the research project was still exploitative). In other words, regardless 
of the process and methodology, if unfair advantage is taken, exploitation occurred. 
Third, being unfair is an essential element of an exploitative transaction, however it is 
difficult to define “unfairness”. A proposed definition is that a transaction is unfair when 
a party gains more (exploiter) or less (exploitee) than what that party would have gained 
in a competitive market.169 In addition, it can be argued that for some transactions, no 
competitive and fair market can be theoretically imagined. Transactions that are in 
contrary with human dignity, such as selling organ parts or slavery, are exploitative in 
nature and such transactions/relations do not have any imaginable counterparts in a fair 
and competitive market. In other words, the existence of a market for such transactions is 
equal to exploitation. the Kantian notion is more helpful for differentiation the 
transactions for them no market is ethically considerable.170 
There are other well-known notions of exploitation that imply almost the similar set 
of necessities. According to the Kantian notion, exploitation occurs when a person (or a 
group of persons) is treated only as a mean. The verb “only” is very important in this 
definition, because in many ways where humans are treated both as means and as ends, 
no exploitation exists. In the account provided by Marx, however, exploitation occurs 
when a person (or a group or persons) does not receive the total and fair worth of their 
labor. Both the Kantian and Marxist accounts shed light to the concept of exploitation.171 
When it comes to clinical research, they add some significant and useful points to the 
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account formulated by Wertheimer. Especially the Kantian notion is very illuminating in 
recognizing the transactions that are exploitative in nature, regardless of their imaginative 
occurrence in a free market.  
On the other hand, there are elements that are not essential to exploitation. One of 
these elements is vulnerability. Vulnerability is neither essential nor sufficient to prove 
that exploitation has occurred. For example, if a researcher recruits a patient for a 
research on a new chemotherapy for cancer patients who are untreatable by the current 
treatments, and the patient is desperate and vulnerable because there is no other option 
available to deal with the cancer, no exploitation has occurred as long as the process of 
recruiting is standard and entail obtaining voluntary informed consent and observing the 
rights of the subject. As another example in which vulnerability is not a necessary 
condition for vulnerability, if an employer hires a vulnerable person with reasonable 
salary and with observance of all laws and rights of the employee, one cannot argue that 
the employee is exploited because of her vulnerability and having no other choice to 
make a living.  
 This is very important to note that although vulnerability is not an essential 
condition for exploitation, most of exploitative transactions or relations, including in the 
realm of health research, occur in the context of vulnerability. For example, the most 
important cases that raised the issue of exploitation in international research in the past 
decades were about enrolling pregnant women, as vulnerable people, to the HIV-
prevention trials in Africa.172 
Unequal benefits also cannot be considered essential for exploitation. For example, 
in the case of surgery, the doctor receives some (unfair amount of) money, and the patient 
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will have her life saved, therefore, the patient has received more and at the same time has 
been exploited. In addition, legal age or even legal status have not been criteria to limit 
the attribution of exploitation. For example, even using human embryos for research has 
been accused of exploitation, since the human embryos (who lack ethical status, at least 
according to the mainstream secular ethics) are being exploited. These accusations have 
mainly based on the Kantian concept of exploitation.173 
One of the issues that looks more relevant to international research is differentiating 
between “unfair backgrounds that leads to a transaction” and “unfairness of the 
transaction regardless of the backgrounds.” The latter always entails exploitation. The 
former, however, at least in some cases, may not entail exploitation. For example, when a 
company plans to conduct a research project in a poor country, in which the potential 
research subjects live under unjust and unfair conditions of poverty and diminished 
access to education and healthcare, this does not sound reasonable to argue that recruiting 
a group of this people for research necessarily entails some degrees of exploitation. 
Instead, what determines that exploitation has occurred or not, is the fairness of the 
transaction (the terms and conditions under which they are recruited for the research 
project, including the potential benefits for their community), itself. There is no need to 
explanation that the relevance between the unfair backgrounds and exploitation is 
stronger in the Marxian account.174 The duties of researchers toward the host community, 
especially when the research is conducted in developing countries or poorer communities, 
has always been a subject of debates. Whether the “local conditions’ can be influential in 
shaping these duties largely depends on the theoretical framework that defines 
exploitation (see below).175 
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Differential Diagnoses of Exploitation: One of the essentials of exploitation, as 
explained above, is that the exploiter benefits from the exploitative transaction or 
relation. By taking this essential into consideration, exploitation can be differentiated 
from discrimination, paternalism, and neglect. In all these types of usually unethical 
behaviors, there is no exploiter who “benefits” from the relation or transaction, therefore, 
none of them falls under the title of exploitation. 
In discrimination, a person is deprived from a specific right or benefit because of a 
non-relevant characteristic (e.g. not enrolling black or Jew or Muslim students in public 
schools); in denial, a person is not provided with something that she entitles to (e.g. not 
giving the prize to a person who really won it); and in paternalism one tries to benefit 
somebody by overriding her autonomy (e.g. forcing people to vaccinate their children or 
forcing a woman to keep her pregnancy against her wish). In these types of behavior, one 
essential component of exploitation is missing: the benefit to the exploiter. This is one of 
the important features that relying solely on the Kantian notion might overlook.176  
Discrimination and denial are almost always unethical, while paternalism can occur 
in both ethical and unethical forms. Many interventions in public health entail degrees of 
justified and ethical paternalism.177 For example, forcing people to fasten their seat belts 
while driving or avoid driving under the influence of alcohol or drugs are examples of 
justified paternalism, while forcing a competent patient to enter a research study as a 
participant (that is believed to be beneficial for his health) without obtaining his informed 
consent is an example of unethical paternalism. 
Types of Exploitation: The exploitation can be mutually beneficial or include 
harming one or more parties of the relation/transaction (harmful exploitation vs. mutually 
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advantageous exploitation). Also, the exploitation can be mutually consensual or include 
coercion, deception, or incompetence (consensual exploitation vs. nonconsensual 
exploitation). For example, when a surgeon demands and receives an unfair amount of 
money of a necessary and beneficial surgery, a mutually advantageous (the surgeon takes 
money and the patient receives the treatment he needs) and consensual exploitation has 
occurred. Combinations of these types exist, for example in the case of unfair fee for 
surgery, a mutually advantageous and beneficial exploitation has occurred, because both 
parties have bene benefited and consented to the transaction ad interaction, and one party, 
i.e. the surgeon, has taken unfair advantage from another party (the patient). In the case 
of Nazi experiments, harmful nonconsensual exploitation was in case because the 
research subjects neither consented nor benefited from the practice.178 
It is not always an easy task to differentiate a mutually advantageous exploitation 
from a harmful one. For example, in the cases of selling kidney for transplantation, the 
seller of the organ is harmed because of the surgery and losing an organ; at the same time 
and transaction, he is benefited because of the monetary reimbursement he has received. 
In this case, although the transaction is exploitative (unfair advantage is taken from the 
organ seller), he has had a net benefit (otherwise, he would not give consent to this 
operation), therefore, this transaction can be categorized as a mutually advantageous 
exploitation.179 As another example, in commercial surrogate motherhood is an example 
of exploitative transactions, this seems to be difficult to tell whether the surrogate mother 
is benefited or harmed from the transactions. The problem worsens when the surrogate 
woman has no actual control on the money she gained through this transaction and the 
benefits are controlled by his husband.180  
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In addition, the analysis should be ex ante (before) rather than ex post (after) the 
transaction. For example, in the case of kidney selling, since at the beginning of the 
transaction there was a reasonable likelihood that the kidney will be beneficial and work 
for the receiver, even if it won’t work (e.g. the immune system of the receiver rejects the 
transplanted kidney) one cannot argue that the seller had exploited the receiver. 
Examining validity of consent is not always an easy task. A valid consent should be 
free of coercion and undue inducement. These two terms “coercion” and “undue 
inducement” are very crucial terms in research ethics literature and have always been 
subjects of confusion and misunderstanding. Therefore, it seems reasonable to provide a 
clear definition of them. Coercion occurs when a person threatens another person that if 
she makes or does not make one or more certain choices, her rights will be violated. This 
is different from the cases in which the person has no choice other than accepting a 
certain option. For example, a patient who has just two potions: either accept a surgery or 
die from the illness, can still give a valid consent to that surgery. Undue inducement, on 
the other hand, occurs when an offer is too seductive in a way that twists the person’s 
ability to make a sensible choice. An example for undue inducement is offering a large 
reimbursement for participation of children in a research in a poor community that may 
lead to the parents entering their children to the research project, while otherwise they did 
not.181 
Ethical Grounds for Intervention: Exploitation is unethical. However, knowing that 
exploitation is ethically wrong is not enough to answer this question that when (or 
whether) a government – or governance - should intervene to prevent an exploitative 
transaction to takes place? In other words, if the predictable consequence of the actual 
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preventing a mutually advantageous and consensual exploitative transaction is that the 
potential exploiter leaves the transaction (and does not give an alternative fair proposal) 
and the potential exploitee loses the beneficial option provided by the exploitative 
transaction (and remain without any other fair or better option), does the governance still 
have a moral duty to prevent this ethically wrong transaction? For exploring this issue in 
the field of Global Governance for Health Research, the next part of this article provides 
a real-world example that has been considered as one of the most noticeable instances of 
exploitative transactions and most prominent challenges of Global Governance for Health 
Research in the past few decades.182 
Helicopter Research: Helicopter medical research entails that “researchers from 
HIC institutions flying into a LMIC, taking patient specimens and date, and flying out 
without providing any benefit to the host community .”183 Helicopter research typically 
entails exploitation. All the above-mentioned theoretical accounts of exploitation (the 
ones of Kant, Marx, and Wertheimer) fit with this kind of research.  
The significant increase in the number and size of research projects, including 
clinical trials, conducted in the LMICs in the past decades made the issue of exploiting 
the local vulnerable populations very considered and debated. It has been claimed that the 
lower ethical obligations in addition to lower costs of recruiting research subjects and 
keeping them in research projects have been the main drives of the pharmaceutical 
companies and other research bodies to conduct many of their clinical trials in the 
LMICs.184  
This has also been argued that these research projects are not aimed to respond to 
the health needs of the hosting countries, even are not aimed to benefit them by its 
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potential results and products, because these products are too expensive to be purchased 
and used by the local patients or their countries’ health sectors. The so-called 10/90 gap is 
another explanation of this problem .185 It has been internationally noticed and recognized 
that only a small proportion of global spending on biomedical research addresses the 
major health problems and needs of large vulnerable, marginalized, and disadvantaged 
populations . 186 
A part of the following chapter of this dissertation, titled “HIV/AIDS Research in 
Africa” encompass good examples of helicopter research. In this part, however, a more 
abstract example of helicopter research (using the historical models of HIV/AIDS 
research) is discussed to show how the theoretical elements of exploitation math these 
research projects. The overall line of argument is as follow: 
1- Helicopter Research entails exploitation and can be substituted with non-
exploitative research. 
2- Exploitation is ethically wrong and if it can be substituted with better options 
for the subjects, it should be stopped by the responsible governance. 
3- The Global Governance for Health Research should stop helicopter research at 
the global level. 
A paradigm case of helicopter research proceeds as described below. This paradigm 
case is delineated by a title and center text because the next parts of this chapter (the 
problem of double standards) also contain references to this case: 
A Paradigm Case 
1- Researchers from country A that is a HIC go to country B that is a LMCI to 
conduct a clinical trial that entails examining an experimental medication (or a 
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medication for a new experimental use or in a new experimental dose) on a group of 
patients. 
2- The researchers deign and practically follow a research protocol in which the 
rights of the participants are not considered and observed in the extent that is required by 
law and regulations and standards for potential research participants in domestic research 
in country A (in terms of risk/benefit analysis, access to ancillary healthcare, respect for 
research participants, etc.) 
3- The researchers argue that they have modified the risks for or benefits to the 
participants from country B because of local conditions in which they live. For example, 
they did not provide them with certain types of necessary clinical care that they would 
provide in research projects in country B, because these types of clinical care are not 
normally accessible for people in country B. Or they paid less to the research participants 
from country B. Or they used/examined a sub-optimum experimental dose of the 
experimental medication, only because to find a less expensive dosage of an already-
proven effective medication. 
4- If the medication they use/examine prove to be effective, using this medication 
will not be affordable for the people of country A (or even the research participants in the 
control group of the trial) and will mainly be marketed and used in country A and 
countries at the same level of income as country A. 
Base on the elements of exploitation explained above, this paradigm case entails 
exploitation, because: (1) at the smaller scale, the researchers from country A take unfair 
advantage from their research participants and their host community on Country B. (2) At 
the larger scale, this paradigm case entails taking unfair advantage from the hosting 
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community and country by the researchers and the ultimate benefactors of the research, 
including the pharmaceutical company and country A. 
As described above, the responsibility of governance to act to stop exploitation has 
been conditioned, at least by some philosophers, to having an available substitute for 
exploitative transaction available to the exploitees. In other words, although exploitation 
is ethically wrong, if the exploitative transaction is the only beneficial option for the 
exploitees, this is ethically wrong for governance to stop it. This premise can be subject 
of criticism, however, in the case of helicopter research, there is no need to discuss this 
condition, since helicopter research can be replaced by better options if the governance, 
including local governments, require the research enterprise to comply with ethical 
standards and avoid exploitation. For example, providing standard healthcare to the 
research participants or providing the medications, if they trial prove them to be effective, 
for a certain amount of time to the hosting communities with affordable prices can be 
included in the binding regulations at both domestic and global levels. The recent 
additions to the Declaration of Helsinki reflects these considerations.187  
Global Governance for Health Research has two general ways to deal with 
helicopter research: First, through international legislations; second, through domestic 
capacity-building.  
1- International Legislation: As described in Chapters 1 and 2, one of the most 
important instruments available to Global Governance for Health Research is 
international legislation. International soft and hard law makes and promotes ethical 
standards for global health research enterprise. Although in the first international codes 
on research ethics, such as the Nuremburg Code, the issue if international research was 
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missing, in the following decades, especially in the 1980s and 1990s when the 
international research enterprise blossomed and its ethical issues received international 
attention, the very issue of international research found its way into international 
discourse.188 Consequently, the international soft law adopted new additions dealing with 
international research aimed at preventing exploitation in the form of helicopter 
research.189 
2- Domestic Capacity-Building: The most important agents that have to be aware 
of the rights of research participants and hosting communities and protect and preserve 
them in the negotiations with the research enterprise are the health authorities and 
officials of the hosting countries, specially their research policy-makers, and research 
ethics committees. In other words, the hosting communities need well-established 
research review and oversight bodies that have the essential knowledge, skills, and 
capacity for protecting the rights of local research participants and communities. In the 
absence of such review and oversight bodies, the international guidelines cannot be 
implemented and efficiently used to protect the basic rights of the vulnerable subjects and 
communities. Therefore, one of the major tasks of Global Governance for Health 
Research is capacity-building in the countries/communities that host the vulnerable 
people who have been exploited for research purposes.190 
The last version of the CIOM’s International Ethical Guidelines for Health-related 
Research Involving Humans explicitly asserts:  
“Health-related research often requires international collaboration and some 
communities lack the capacity to assess or ensure the scientific quality or ethical 
acceptability of health-related research proposed or carried out in their jurisdictions. 
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Researchers and sponsors who plan to conduct research in these communities should 
contribute to capacity-building for research and review. Capacity-building may include, 
but is not limited to, the following activities: research infrastructure building and 
strengthening research capacity; strengthening research ethics review and oversight 
capacity in host communities […]; developing technologies appropriate to health care 
and health-related research; educating research and health-care personnel and making 
arrangements to avoid undue displacement of health care personnel; engaging with the 
community from which research participants will be […]; arranging for joint publication 
consistent with recognized authorship requirements and data sharing […]; and preparing 
a benefit-sharing agreement to distribute eventual economic gains from the research.”191 
In the clinical trials conducted in the LMICs there have been many instances of not 
observing the rights and freedoms of research subjects as asserted in the related laws, 
regulations, and guidelines. Also, the ethical roots of this problem are common with the 
problem of helicopter research, however this problem can be discussed more under the 
title of the next part of this paper: the problem of double standards. 
ii. The Problem of Double Standards 
Most of the HICs have a recent history of adopting strict regulations and 
establishing efficient organizations to protect the basic rights and fundamental freedoms 
of their citizens, especially the vulnerable groups, when they are recruited as research 
participants. However, it has always been claimed that in dealing with people of other 
countries, the powerful parties who are from the HICs (who observe all these rights and 
freedoms inside their national borders and for their own people) are less willing and 
driven to observe the same profile of rights and freedoms in other countries. This claim 
 81 
shapes the problem of double standards in a large scale. Part of this problem has showed 
itself in the research enterprise and international research activities, that is the subject of 
this part of this dissertation. 192 
The main question is that if the researchers are ethically obliged to observe the 
same ethical standards when they are dealing with different people with different cultural 
and geographical contexts and situations? The proponents of “Uniform Care 
Requirement” have a positive answer for this question. They argue that in the absence of 
uniform care requirements and if decision-making on the quantity and quality of care is 
left to the individual agreements between involved parties, then the policy-makers and 
other research counterparts in LMIC may overlook the rights and benefits of the 
vulnerable potential research participants.  
On the other hand, the proponents of a negative answer to the above question argue 
that insisting on the uniform care requirements may deprive LMICs from the research 
projects that otherwise could be carried out and benefit the local patients and 
communities.193 For example, in some infamous examples researchers gave placebo to 
the control arm of their clinical trial while the life-saving treatment did exist in the HICs. 
Their justification was that in the hosting country that treatment was not available for the 
patients because of the high costs. Therefore, if their subjects did not participate in the 
research project, they would not have access to that treatment in contrast to the similar 
patients in the HICs. Therefore, that treatment is not considered “the standard treatment” 
given the special satiation of their research subjects and there are not ethically obliged to 
provide that for their control group.194 
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Others, however, have commented against the above claim, arguing that the 
researchers are ethically obliged to have a single definition of “standard treatment” 
especially when it comes to the vital and life-saving treatments. As described below, the 
global principles set by UNESCO supports this perspective .195 This perspective is rooted 
in the principles such as justice and equity. These principles imply that all the people are 
entitled to the same basic rights and it is ethically unjustified to deprive people from life-
saving treatments based on their place of birth or living or their socio-economic status.196 
Therefore, they have to provide the standard treatment based on the standards of their 
original HIC rather than the realities of their host countries. 
In the paradigm case described above (under the title of Helicopter Research) this 
part is related to the problem of double standards: “The researchers argue that they have 
modified the risks for or benefits to the participants from country B because of local 
conditions in which they live.” In other words, when the researchers have two (or more) 
different sets of standards (in terms of the rights of participants and their relatives and 
their hosting communities) for their research subjects based on the conditions they live in, 
the problem of double standards arises. The cases of double standards may include or not 
include exploitation.  
Having double standards is ethically wrong because it violates the principles of 
justice in the canonical Western set of biomedical ethics. In addition, having double 
standards is a violation to the ethical principles promulgated in the broader and wore 
global set of principles introduced by the UNESCO Declaration of Bioethics and Human 
Rights such as equity, human dignity, and solidarity. 197 
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Whether the governance, including Global Governance for Health Research, should 
get involved to stop practices that entail double standards, follow the same reasoning as 
explained for exploitation above. When the practice that entailed double standard can be 
replaced by another practice that is more beneficial for the research subjects and their 
communities (the weaker party of the power relation) the governance has aa duty to act 
against practicing based on double standards. Therefore, in the cases that are similar to 
the paradigm case described above, this line of reasoning can be applied: 
1- These cases entail practicing based on double standards and can be replaced by 
practices that do not entail double standards and are more beneficial for the research 
subjects and their hosting communities.   
2- Practicing based on double standards is wrong and when can be replaced by 
practices that do not entail double standards and are more beneficial for the research 
subjects and their hosting communities, the governance should act to stop it.  
3- The Global Governance for Health Research should act to stop the cases that 
match with the main characteristics of the paradigm case (entail double standards). 
The necessity of avoiding double standards had been implicitly or explicitly 
included in the international soft law for Global Governance for Health Research, 
including The WMA’s Declaration of Helsinki and the CIOMS International Ethical 
Guidelines. Although the term “ethical standards” has not been defined in the relevant 
literature and can be considered a part of common knowledge.198 
Avoiding double standards does not imply ignoring all the contextual necessities 
and requirements of designing and conducting research projects. The standards that are 
part of unalienable rights of research participants should be uniformly observed, while 
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the technical adjustments should be considered based on local contexts. For 
differentiating the universal ethical standards from technical and contextual requirements, 
the US National Bioethics Advisory Committee (NBAC) has provided a useful 
classification that is explained below. 
Substantive vs. Procedural ethical requirements: For differentiating between the 
global standards that are essential to preserving the rights of research participants and the 
standards that can be subjects of cultural variations (in attempt to avoiding ethical 
imperialism), the classification provided by the US National Bioethics Advisory 
Committee can be helpful. The 2000 report of this committee classifies the ethical 
requirements in international research into the substantive and procedural categories.199 
The substantive ethical requirements entail fundamental ethical principles that are derived 
from and are necessary to observe the main ethical principles of the Belmont Report: 
respect for persons, beneficence, and justice. These requirements are global ethical 
standards that should be observed globally and are not subjects of cultural variation or 
interpretation. However, the procedural requirements are the ones that depend on the 
local circumstances and are not essential to preserving fundamental human rights and 
freedoms. For example, obtaining informed and voluntary consent from each competent 
subject of a research is a substantive requirement and should be considered a global 
standard. However, in the communities with hierarchical orders, such as tribes, obtaining 
a separate collective consent from the local authorities in addition to the individual 
consents does not violate the ethical standards and can be considered a procedural 
requirement rooted in the cultural necessities.200 
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In conclusion, the problem of double standards in the field of health research is 
translated into having double standards of care, double standards for human rights and 
human dignity, and even double accounts for defining the “standard treatment”. This 
problem is of a strong ethical nature and having such double standards, as mentioned 
above in this part, entails obvious violation of the ethical principles of justice, equity, 
human dignity, and solidarity.  
Although having double standards is ethically wrong, adopting sets of universal 
standards has also been criticized. The critiques argue that the standards and values vary 
based on the cultural contexts, therefore, adopting or formulating universal standards is 
nothing but imposing the values and standards of a culture to the others. In a surprising 
way, two conflicting arguments, one in favor of adopting universal standards and the 
other one in favor of adopting local and contextual standards, both have presented to 
preserve the rights of vulnerable research subjects and their communities. The latter 
argument is explained in more details in the following part of this chapter that deals with 
the claims of ethical imperialism and colonialism.  
iii. Ethical Imperialism and Colonialism 
The terms "imperialism" and "colonialism” have been used in order to describe a 
country’s superiority, domination and influence upon other countries or societies.201 In 
the contemporary literature, these words have negative connotations and are usually 
being used for criticizing the influence of powerful countries on the less wealthy and less 
powerful societies.  
On Colonialism: Colonialism refers to a practice in a certain historical period in 
which newly-modernized European powers expanded their dominance to the continents, 
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countries, and communities is Africa, America, and Asia that were less developed. 
Settlers from the powerful countries formed colonies in the newly “discovered” lands and 
acquired political power and military dominance. They usually exploited the natural and 
human resources of host communities and at the same time, exported their cultural norms 
and ways of life, along with different features of modern civilization such as modern 
governments, judiciary systems, press, parties, and technical advances such as modern 
architecture and transportation to the host countries. In addition, a generation of nstive 
people acquired modern education (by traveling to the colonizing countries or by 
enrolling in the educational institutions established in the colonized countries) and 
imported and presented these new and modern ideas and lifestyles into the traditional 
communities. These developments have always been shocking and confusing for the host 
communities. Conflicts occurred as a result of the clash of values, traditions, lifestyles, 
and perspectives and a strong sense of being exploited, dominated, and humiliated 
conveyed to the colonized communities. The relations between colonizing powers and 
local people were not based on respect and equality.202 Many other countries and 
communities were not formally colonized (e.g. Iran), however, the same effects of 
confrontation with modern powers occurred within their traditional social institutions and 
changed almost all the aspects and trends of their collective lives. 
Because of the injustice that was generated (or the sense of injustice that was 
induced) by colonialism, resistances arose in the colonized communities and after years 
of mostly bloody and violent battles and revolutions, over the last decades of the 
nineteenth century and the first decades of the twentieth century, all the colonized 
countries gradually became independent. However, with some exceptions (such as the 
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United States of America), their conflicting dependence to the former colonizing powers 
did not disappear, but remained in two major forms. These two major forms shape the 
characteristics of the post-colonialism era: (1) the new cultural norms and ways of life 
imported, imposed, and promoted by the colonizing powers attracted layers of local 
people, especially the elites and people who were educated from Western or Western-
style universities. The contrast of the values, norms, and practices of these modern 
lifestyles fell in contract with traditional beliefs, values, norms, and standards and in 
some cases these contrasts led to violent confrontations with local authorities and people. 
(2) the economic and industrial infrastructures of newly independent countries have 
remained largely dependent to the colonizing countries. Modern developments such as 
modern educational systems, healthcare systems, industries, and enterprises along with 
governmental and civil society institutions such as modern judiciary systems, 
parliaments, and political parties, although significantly improved the life conditions of 
local people, led to a variety of conditions such as unplanned population growth and 
urbanization that became major sources of internal instability and dependency to the 
former colonizing powers.  
The moral analysis of colonialism, itself, is a challenging task. Although nowadays, 
almost nobody justifies colonialism as an acceptable or suggestable practice, assessing 
this phenomenon in the context in which it occurred, shows that colonialism, along with 
numerous unwanted effects on the colonized countries, had some positive consequences 
for them such as modernization and improvements is various areas such as health, 
industry, and agriculture. In addition, this is not right to judge a historical practice by 
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today’s standards. The moral analysis of colonialism, however, is beyond the scope of 
this chapter.  
The history of colonialism is intertwined with a rise and expansion in the activities 
of Christian missionaries. New transportation means and geographical discoveries opened 
the doors of the Christian Europe to the vast lands and large populations in other 
continents that were not Christians. Christian missionaries had two major effects in their 
hosting communities. First, the positive effect that was their promoting humane values 
such as unconditional love and charity. Unforgettable figures such as Albert Schweitzer 
and Mother Teresa are examples of this effect. Second, the negative sense of threatening 
local values, traditions, and lifestyles by imposing the new religion. Cases of violent 
forcing local people to convert to Christianity or exploiting Christian teachings for 
devaluing local people or traditions (such as what occurred by Spanish conquers in Latin 
America) were examples of this kind of effect. Ethical colonialism in the form of 
promoting Western-Christian values without respect and consideration for local cultures 
and values entails a reminder to the latter negative effects of Christian missionaries in the 
former colonized communities. 
Ethical colonialism, that means imposing the moral standards and values of 
previously colonizing countries to the previously colonized societies, is a concept that has 
been used for criticizing the transfer and promulgation of Western ethical values and 
standards – including the bioethical ones – in the LMICs. This term implies the negative 
account of colonialism that entails ignoring the local and traditional values, standards, 
and lifestyles of non-Western countries and undermining their cultural and moral heritage 
 89 
and imposing alien and conflicting values that are considered superior to the local ones 
without any justification.  
On Imperialism  The term “imperialism” has mainly been used in the left and 
revolutionary discourse throughout the twentieth century. Vladimir Lenin (1870-1924) 
considered it as the highest and last stage of capitalism.203 Although the revolutionary 
forecasts of the Marxist-Leninist doctrine concerning Capitalism and Imperialism proved 
wrong (and practically harmful), this word did not disappear from the global discourse. It 
remained as a way of formulating and expressing suspicion and mistrust on the power 
relations between the wealthy and powerful countries and the poor ones. When it comes 
to ethical standards, this word is obviously revitalized and viral .204 
Ethical imperialism is defined as “imposing the ethical values and practices of the 
West on communities for whom these values were foreign.”205 In the fields of bioethics 
and biomedical research ethics, these debates have been serious .206 The endeavors aimed 
to advocating and teaching the ethical principles as were developed and formulated and 
expressed by Western scholars and organizations, have been subject of this kind of 
criticism, a clear example being the NIH’s initiative for training health research ethics 
experts in the LMICs.207   
Colonialism and Imperialism in Research Ethics: The terms colonialism and 
imperialism, although different in meanings and implications, have been used with 
similar connotations and intentions in the discourse of Global Governance for Health 
Research. As explained above, they both have been used to criticize the efforts aimed at 
importing and promulgating Western-born standards and values of research ethics to and 
within the developing non-Western countries and societies. For example, this has been 
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argued that the mandate of obtaining informed voluntary consent from the competent 
research participants is a standard that belongs to the individualistic Western societies 
and may not be applicable to many of Eastern communities in them such decisions are 
not made by individuals but are made by the families or tribes or the heads of families or 
tribes. This has been argued that the different notion of “person” in non-Western 
communities necessitated different notions and practices regarding obtaining informed 
consent.208  
This kind of arguments that attribute norms such as voluntary informed consent to 
the values of Western aliens, in some cases, have also been appealed by local authorities 
to deprive their subordinates and local vulnerable population from their basic rights and 
freedoms guaranteed by so-called Western bioethical standards and values. The main 
challenge is differentiating the values and standards that are really cultural-dependent and 
belong to Western cultures and ways of life from the values and standards that belong to 
the humanity as a whole and cannot and should not be considered as belonging to a 
specific geographical or cultural area or tradition. These values and standards are, as a 
matter of fact, the common heritage of mankind regardless of their geographical or 
cultural origins or denominations. 
Common Heritage of Mankind: The concept of ethical imperialism is mainly 
related to the issue of cultural diversity. Respect for cultural diversity is an inalienable 
part of biomedical research ethics. It is one of the global principles of bioethics set by the 
UNESCO.209  However, there are moral standards and principles that cannot be simply 
considered as Western or Christian. Instead, a certain group of principles as delineated by 
universal declarations and conventions, are supranational and their legitimacy is beyond 
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specific cultural or philosophical traditions, but the belong to all the humanity and can be 
called the common heritage of mankind.210 The principles delineated in the UN Universal 
Declaration of Human Rights and UNESCO Declaration of Bioethics and Human Rights 
can be considered common heritage of mankind. Therefore, the implications of the 
principle of respect for diversity can be divided into two main and ethically different 
categories: 
1- The cultural practices and behaviors that violate the fundamental human 
rights and freedoms, such as not allowing women to take informed decisions on their own 
participation in a research or taking collective informed consent from the local authorities 
without taking informed and voluntarily consent from each of the human subjects of 
research. Respect for cultural diversity never justifies these kinds of practice. As a matter 
of fact, human rights, as a significant part of intellectual common heritage of mankind, 
are ethically superior to culture-specific local norms and standards .211  
This is not a sort of ethical imperialism or colonialism because the principles of the 
Universal Declaration of Human Rights do not belong just to the West. They are the 
common heritage of the mankind .212 Violating the rights of vulnerable groups under the 
title of cultural diversity and accusing the opponents to advocating ethical imperialism is 
an unacceptable practice and it has explicitly asserted in the UNESCO Universal 
Declaration of Bioethics and human Rights that no principle of this instrument should be 
interpreted in a way that violates human basic rights and fundamental freedoms. 213 The 
United Nations as an international organization and its affiliated organizations, such as 
WHO, are in charge of protecting the vulnerable groups by strictly observing the 
principles of human rights and freedoms .214 
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2- the cultural practices and norms that do not contradict the principles of basic 
rights and fundamental freedoms: This part of local cultures is to be observed according 
to the principle of respect for cultural diversity. As an example related to research, the 
researchers can take the agreement and permit of the local authorities such as the chief of 
the tribe in addition to taking informed voluntary consent from each of their potential 
research subjects.215 
According to the above discussion, ethical imperialism, as another challenge for 
global governance for health research, entails obvious ethical components. Both the 
proponents and opponents of this theoretical criticism, appeal to ethical reasoning to 
support their side of discussion. Although this criticism entails some real and noteworthy 
ethical concerns, it should not be allowed to be misused by the violators of human rights 
and by local authorities who want to safeguard their illegitimate power over the rights of 
their subjects.  
When it comes to health research, this debate shows itself in some areas, one of the 
most important of them being the process of obtaining informed consent. The right of 
giving individual voluntary and informed consent is an inviolable right of every research 
subject in clinical trials and taking collective consents from the local authorities (e.g. 
head of tribe or governor of the county) does not override the right of each individual 
subject.216 
Therefore, adhering to global ethical standards for health research in the research 
carried out in developing countries and within local communities is an ethical mandate. 
At the first look, this can look like ethical imperialism. However, in the absence of 
universal standards, each local power and authority can set its own standards, appealing 
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to the local culture and values, in a way that violate the rights and freedoms of vulnerable 
populations and benefit a part of the community that is intended by that power or 
authority.217 
The projects conducted by HICs for capacity-building in LMICs in the fields of 
research review and oversight, have been criticized to be aimed for promoting Western 
values and standards and imposing them to the local and host communities.  
iv. Bilateralism vs. Multilateralism 
International Organizations (IOs) such as the WHO have been established based on 
the concept of multilaterality.218  Acting based on consensus among state members 
guarantees the democratic nature of such organizations. These IOs are also responsible 
for observing the ethical principles of global bioethics in their instruments and 
interventions. In recent years, however, some major and powerful players in global health 
governance have launched bilateral programs. One of the most prominent examples of 
such bilateral programs is the US Government’s Global Health Initiative (previously the 
President’s Emergency Plan for AIDS Relief or PEPFAR) .219 These bilateral programs, 
although being so fruitful in fighting serious pandemics like HIV/AIDS, have allegedly 
weakened the multilateral role players and in the case of global health governance, the 
threat was mostly pointed to the WHO .220 
As described above the monetary helps of wealthier nations usually come with their 
own price tags, least of them being the power granted to the wealthier and more powerful 
countries to govern health affairs – and use the gained influence in other political matters- 
in developing countries, which need and receive these helps. Having financial control in 
bilateral relations with other countries makes it possible for richer and more powerful 
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countries to play their own role in global health governance. In some cases, the impact of 
trade agreements worsens this power imbalance. Avoiding the possible abuse of this 
power in political affairs is another reason behind the existing need to move toward more 
multilateralism.221  Multilateralism in global health governance make it possible to make 
sure that the values of solidarity and benefit sharing (rather than political agendas of 
powerful countries) rule in managing global health affairs and in practicing global health 
governance. 
Some examples of multilateral programs/institutions are as follow: (1) WHO (that is 
supposed to assume the leading role), (2) World Bank (in recent decades became a major 
role player in funding health-related programs), and (3) The Joint United Nations 
Program on HIV/AIDS (UNAIDS). UNAIDS, itself, is cosponsored by several 
international/multilateral organizations. Taking a look at the list of these organizations 
reveals the very multilateral nature of this program. These cosponsoring organizations are 
as follow: (1) United Nations Children’s Fund (UNICEF), (2) World Food Program 
(WFP), (3) United Nations Development Program (UNDP), (4) United Nations 
Population Fund (UNFPA), (5) UNESCO, (6) WHO, (7) World Bank, (8) United Nations 
Office on Drugs and Crimes (UNODC), and (9) International Labor Organization (ILO). 
Bilateral programs, however, are formed and conducted by an agreement between a 
powerful/wealthy nation state and a country or a group of countries in need. When it 
comes to HIV/AIDS the most influential bilateral program has been the US 
Government’s Global Health Initiative (previously the President’s Emergency Plan for 
AIDS Relief or PEPFAR). 
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As mentioned above, bilateral programs, although sometimes successful and 
efficient, potentially weaken the role of IOs, in this case WHO, in leading international 
efforts against pandemics and other heath crises. This weakening may also become 
extended to ethical principles and norms of global bioethics, which guaranties pluralism 
as the source of trust and ethical infrastructure for global health interventions. Therefore, 
there is a need to a comprehensive ethical analysis of bilateralism and its benefits vs. 
risks for global governance for health. In a comprehensive ethical framework for global 
governance for health, the bilateral partnerships should be developed and directed in a 
way that entails minimal risks for consensus-based multilateral mainstream that is in 
charge of finding and executing fair and unbiased solutions for global health challenges 
in the future. 
One of the most important feature that differentiates and recognizes the principles 
and guidelines promulgated by UNESCO or WMA is their consensual nature and 
multilateral structures of the organizations that developed, adopted, and announced them. 
This consensually and multilateralism makes these principles a part of the common 
heritage of mankind regardless of their historical origins. Otherwise, if the ethical 
standards and values are imposed, transferred, or dictated in the bilateral relations, they 
will always remain the subjects of criticisms as ethical imperialism and colonialism (see 
above). 
v. Biopolitics vs. Bioethic 
The main question behind the concept of biopolitics is “how bioethics can be 
independent?” In other words, this concept, since the very time it was coined, has 
prompted reflecting, exploring, and investigating on the influences of politics on 
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bioethics. The concerns over the influence of political powers and interests on bioethical 
discourses is a legitimate concern at both national and international levels. Considering 
that health has moved from the soft politics to hard politics over the past decades, and the 
importance of health research, this concern is also valid when it comes to Global 
Governance for Health research.   
In the realm of the history of thoughts and theories, everything started with a lecture 
series delivered by French philosopher, Michel Foucault (1926-1984), at the Collège de 
France in 1978 and 1979. The term of biopolitics had been coined before these lecture 
series, however, its accompaniment by some other key words ended up to a change in the 
meaning of this term in the political and ethical literature. Below, this chapter provides a 
closer look to this debate that has played a crucial role in the theoretical evolution if the 
concepts of governance and bioethics. 
The concepts of “governmentality” and consequently, the concepts of “bio power” 
and “biopolitics” have been coined by Michel Foucault, and then expanded by other 
thinkers have noteworthy implications in different fields including bioethics and the 
ethics of global governance and research ethics.222    Accordingly, political interests and 
powers influence the decisions in the field of global governance.223   This influence has 
the potential of competing and conflicting with bioethics as directed just by ethical 
norms/principles.224 Therefore, the influence of political powers and their interests can be 
considered as another major source of ethical concern in the field of Global Governance 
for Health Research.225  
The ethical nature of this concern/issue is not covert. As a matter of fact, the undue 
influences of political power over biomedical decision-makings have always been 
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sources of ethical concerns. In the realm of health research, the influence of biopolitics at 
every level of research from priority setting and funding decisions to development of 
international collaborations and even the decisions on recruitment of subjects and the 
methodology of the studies is a subject of ethical concern. For example, prioritizing the 
health issues for research budget allocation can be influenced by political interests. In 
some cases, the political attention to specific types of diseases can result unproportioned 
research budget of effort allocation. On the other hand, ideological interests or even 
taboos can be influential in the governance of research enterprise. Limitations on 
conducting certain types of research that might entail results in conflict with dominant 
ideologies in some countries is an obvious example. At the global level, also, this 
problem is present. The debates on patent rights of pharmaceutical industry or mass 
transfer of biological samples from developing countries to developed ones are among 
the topics that need attention to biopolitics and are discussed in the following chapters of 
this dissertation. 
When it comes to the problems caused by the influence of politics on bioethical 
decisions, this is self-evident that a top-down world order will never be able to solve 
these problems. As a matter of fact, this very issue clearly shows how the global 
governance for health and health research needs to replace its current top-down ethical 
framework with a new collaborative one with emphasis on global justice, equity, and 
solidarity.226  
vi. Data Sharing, Big Data, and International Collaborations 
Data sharing has been called “an ethical and scientific imperative.” Numerous 
evidences and arguments support this claim, for example: (1) The data of previously 
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published trials may entail new information for the researchers who come afterward and 
can take a new look and shed a new light to the previously analyses data; as studies show 
that reanalysis of the data of the previous clinical trials, in a significant proportion of 
cases, have ended to different interpretation compared with the original studies, although 
the numbers of studies that entail reanalysis is very small in comparison to 500000 
clinical trials that are published in MEDLINE. (2) Data sharing makes meta-analysis 
studies possible that produce more strong evidences for clinical practice compared with 
each single study that is included. (3) This is possible that the investigators of the original 
studies inadvertently were not reported some important findings that may be revealed 
through the data sharing with other researchers who may take a fresh look at the data and 
unreported findings. And (4) ethical responsibility to the participants of the clinical trials 
who put themselves at risk for producing the data that may be beneficial for the society, 
therefore, the obligation of research community is unearthing the greatest amount of 
benefit that may be extracted from these data which, for the aforementioned reasons, is 
achievable through data sharing.227  
One of the most important features of data obtained for research purposes –and the 
information resulted from them - is their belonging to the humanity as a whole. In other 
words, scientific data and information is a part of common heritage of mankind. As 
explained above (number 4 in the list of arguments that support data sharing) human 
subjects of research projects put themselves at risk for producing knowledge that benefit 
all the humanity. This is the basis of a social contract according to which, the scientific 
community has an ethical obligation to maximize this benefit for all the humanity and 
this is not possible without making data available to other researchers to extract all the 
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possible information from it. i.e. data sharing. 
In addition, the scientific knowledge (that is used for and increased by analyzing 
these data) cannot be produced and accumulated without relying on the great resources of 
common knowledge produced by the previous generations of scientists even in ancient 
times. Researchers and scientists do not work in isolation or from the scratch. Their ideas, 
premises, previous knowledge, and supporting evidences are based on the knowledge 
accumulated through centuries by the collective efforts of scientists from almost allover 
the world and all the civilizations on earth. Therefore, the research data and scientific 
knowledge, at least partly, belong to (and produced intended to benefit) all the humanity. 
Therefore, this is an ethical responsibility of the Global Governance for Health Research 
to maximize the benefit of all the humankind from the data and knowledge produced by 
research by (1) making datasets shared and available, and (2) making scientific 
knowledge accessible for all (as much as possible).   
Data sharing, however, brings about a series of ethical concerns. When data sharing 
occurs among trials that were conducted in different countries, these ethical concerns find 
their ways to the realm of Global Governance for Health Research. Among these ethical 
concerns are: (1) Privacy of participants: the shared data mush be deidentified. Through 
the process of obtaining informed consent, the participant must be informed about this 
fact that their deidentified data will be shared. (2) Fairness to researchers: considering the 
intellectual right of the original investigators over the data, some relevant ethical issues 
are still under the clouds of ambiguity, such as the right to authorship, the time period 
between the publication of the original study and the reanalysis, and the fair process for 
handling the requests for access to the shared data. (3) Efficiency of the system of data 
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sharing: considering the increasing complicated and sophisticated nature of the 
methodology of clinical trials, having an efficient system for data sharing proves to be 
more difficult than any previous time. In some cases, the support and assistance of the 
original investigators in still necessary for reanalyzing the data. Therefore, this mandate 
should be included in the original contract between the funder(s) and original 
investigators, or can be requested/purchased from them in other ways.228 
Other types of international collaborations that involve sharing data or biological 
material include biobanks. Biobanks collect and store human biological specimens for 
research purposes. It seems that the international collaborations are eager to accelerate 
the sharing of genomic and health-related data, including through collaborations with and 
among biobanks. This practice raises its own ethical issues.229 Some of these issues, such 
as privacy of participants and necessity of modifying informed consents are discussed 
above. 
Another issue raised as a result of scientific collaborations and data sharing is the 
issue of large datasets or “big data”. Big data is the product of a group of recent 
developments such as invention and establishment of electronic health records and 
formation of national health databases that integrate huge amounts of health-related 
information, as well as large scale national and international collaborations that produce 
massive databases and other kinds of data storing means. Creation of these large datasets 
has been facilitated by new technologies such as the portable computers and mobile 
devices, large digital data storages, and widely accessible high-speed internet. These 
technological facilities pave paved the way for international collaborations in data 
collection and data accumulation. Also, with expansion of digital and electronical 
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infrastructures and facilities to developing countries, they have gradually joined the large 
projects that collect and create these big data. Therefore, a large part of the current 
health-related big data is developed through international collaborations. Accordingly, 
part of ethical issues raised by them and their solutions are covered by Global 
Governance for Health Research. 
The advantages and benefits of access to big data have been enormous. For 
example, conducting research projects with larger amounts of data, samples, or subjects 
can lead to more valid and reliable results. In addition, in the realm of public health, the 
phenomenon of digital disease detection using electronic data sources and availability of 
global real-time data have improved the ability of the health sector in dealing with health 
crises such as outbreaks because they have accelerated detection of outbreaks by digital 
surveillance channels, as was actualized during the 2014 Ebola virus outbreak in West 
Africa.230 
Development of big data, on the other hand, have led to new ethical concerns about 
privacy, confidentiality, technical efficiency, informed consent of the participants, and 
the justified uses and users of these “big data” resources. Vayena et al. have classified the 
ethical challenges of digital disease detection into three categories: First, “Context 
Sensitivity” that encompasses ethical challenges of differentiating between commercial 
and public health use of data and include concerns on identification and informed 
consent; the privacy of uses of electronic means; and the openness of private data into 
global health-related use; second, the “Nexus of Ethics and Methodology”  that entails 
the concerns on the valid and reliable functioning of the involved technologies and the 
public use of personal data in aggregated from; and third, the “Legitimacy Requirements” 
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that encompasses the standards of best practice and existence of a globally shared code of 
practice, monitoring and response to the inaccuracies and the resulted harms and finally, 
communication to the public and dealing with general expectations.231 They have also 
proposed an ethical framework for dealing with these ethical challenges. Their 
framework encompasses values such as: “Privacy and Contextual Integrity; 
Transparency; Global Justice; Risk of Harm; fair use of resources; Trust, Transparency, 
accountability; Trustworthiness; Justice; and Common Good.”232  
This is also part of the mission of Global Governance for Health Research to 
establish efficient and ethical regulation and oversight for big data. 
vii. The Ethical Nature of the Challenges and Five Major Gaps 
 The Ethical Nature of the Challenges: This chapter examined some of the most 
important challenges facing Global Governance for Health Research. A brief look at 
these challenges show that they have major ethical roots and components. In other words, 
the major challenges of Global Governance for Health Research are mostly of ethical 
nature. Therefore, the possible solutions of these main challenges are to be sought in the 
realm of ethics and its relevant branch to this subject, that is global bioethics. Therefore, 
the Global Governance for Health Research needs a new and properly constructed ethical 
framework to deal effectively with these challenges. For depicting the ethical nature of 
these challenges in more details, some of the ethical concepts that are closely and deeply 
related with these challenges are discussed below. A comprehensive and more detaild 
description of the involved ethical principles will be provided in chapter 5. The involved 
ethical concerns include but are not limited the ones in this list: 
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Respect for Vulnerability: When it comes to some of the ethical debates, concerns, 
controversies, and discussions surrounding the Global Governance for Health-related 
Research, including exploitation and helicopter research, ethical imperialism and 
colonialism, and double standards, one of the central concepts is vulnerability. The 
debates are around the vulnerability of weaker parties in the global power relations (and 
in this case, international research) and the ethical obligation of global governance to 
protect the vulnerable parties, including countries, populations, communities, and even 
the future generations. Like other conflicts that involve vulnerability and power relation, 
these debates are of a clear ethical nature.233 As stated above in this part, the solutions for 
the above challenges are to be sought in the realm of healthcare ethics/global bioethics. 
Establishing an ethical framework for Global Governance for Health Research is the 
solution that global bioethics can provide for answering the above questions, challenges, 
and needs. 
Human Dignity: The concept of human dignity is the fundamental basis of the 
human rights and freedoms.234 Problems such as exploitation and double standards entail 
explicit violation of this principle. Human dignity as a cross-cultural and universal ethical 
principle is a certain part of the common moral heritage of mankind and stands beyond 
the accusations of ethical imperialism and colonialism. Violation human dignity is the 
root and reason behind moral badness of the research practices that entail using human 
subjects as mere means. At the same time, human dignity is the basis of a moral 
framework that can deal effectively with these challenges. 
Justice:  Justice is another cross-cultural and universal ethical principle that stands 
behind the global ethical norms and values.235 Challenges such as helicopter research, 
 104 
double standards, bilateralism, and even biopolitics involve sorts of violation the 
principle of justice. As a constant part of all the sets of principles for biomedical ethics, 
justice is an inseparable part of any type of ethical framework for Global Governance for 
Health Research. 
The Role of Organizations: The involved scientific community and professional 
organizations have a crucial role in establishing the needed ethical framework. Also, 
different aspects and levels of ethics education, as a well-developed field, play an 
important role in bringing the theoretical findings into practice and integrate them with 
the routine practices of all the role players who are involved in global governance for 
health. This is a continuous and never-ending process. Similar to the technical 
knowledge, ethical knowledge is subject of constant change and development. Therefore, 
ethics education is an endless endeavor. This endless endeavor is also crucial for 
safeguarding the basic rights of all the parties involved in heath research and ensuring the 
best performance of global governance for health research. 
Although the majority of challenges, which global governance for health faces, 
have arisen from the ground of HICs-LMICs collaborations, there are other challenges 
that are pertaining to HICs-HICs collaborations, too. A perfect example of such 
challenges (big data, data sharing, and international collaborations) has been discussed 
above in this essay. Therefore, even in the relations between parties of the same power 
and influence, there are still challenges ahead of Global Governance for Health Research 
that, as argued in the relevant part in this chapter, demand ethical attention and ethical 
solutions.  
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Five Major Gaps: Thomas Weiss, a renowned world scholar in the field of Global 
Governance has described five major gaps in the current situation of global governance. 
This analytic framework is helpful in portraying the status and challenges of global 
governance. In addition, this framework is dynamic because the characteristics of each 
gap are subjects of evolutions and variations over time. These gaps are in the following 
areas: (1) Knowledge, (2) Norms, (3) Policies, (4) Institutions, and (5) Compliance. The 
order of this list is also important in the analytical framework, for example, the gaps in 
knowledge are partly the roots of the gaps in norms and policies.236  
This model of gaps is developed for understanding the current situation of global 
governance in general. In this part, this model is applied specifically to the challenges of 
Global Governance for Health Research as listed and described in this chapter. 
Formulating the current situation and challenges in a pre-developed model of gaps will be 
helpful in developing an ethical framework that is well-situated with the status of the 
issues and challenges. 
1- Knowledge Gaps: There is no theoretical agreement on the characteristics 
and nature of the challenges. This knowledge gap has multiple sources, including (1) the 
impact of ideologies as was discussed above in this chapter under the title of ethical 
colonialism and imperialism. The ideological and political suspiciousness to the efforts 
originated from Western countries in addition to the same kind of intention to 
undermining values such as human rights and fundamental freedoms in developing 
countries have led to a part of challenges in Global Governance for Health Research that 
shows itself in the form of resistance against promotion and promulgation of the 
universal research ethics norms and standards. (2) the areas of ethical controversy and 
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lack of consensus such as the exact definition of standard treatment as discussed above 
under the title of double standards is also a major source of knowledge gap that takes part 
in creating the main challenges ahead of Global Governance for Health Research. 
Another example of such controversies as shown in the discussion of the challenges is on 
the meaning of exploitation and the need of action through governance to prevent it. The 
existing variation among the ethical guidance provided by different declarations and 
guidelines is a feature of this knowledge gap. (3) the emergence of new concerns and 
challenges are the result of gradual shaping or filling of the existing or new knowledge 
gaps. The same is true for global governance at the larger scale. For example, the 
population problem in the 1970s and the global warming in the last decades of the 
twenties century were the results of new scientific knowledge that was created and 
crossed the lines of deniability. The historical predecessors of this issue in global health 
governance is discussed in chapter 1, such as the resistance against the proposed 
European sanitary regulations because of the lack of belief to the germ theory and 
reliance on the alternative, even superstitious, theories for disease and outbreaks. This 
knowledge gap sometimes is the manifestation of underlying ideological, religious, or 
material interests rather than merely difference in knowledge and understanding of the 
facts. 
In the field of Global Governance for Health Research the improvements and 
updates in the international soft law and guidelines fill the previously existed knowledge 
gaps in a gradual manner. The new consensuses and consensual declarations are new 
pieces of knowledge that partly belong to the common intellectual heritage of mankind. 
At the same time, on the other hand, the new challenges are also being resulted from the 
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new knowledge on the developments and evolutions of international research enterprise. 
For example, before revealing the research methods used in HIV prevention trials in 
African countries, the problems of helicopter research and double standards had not been 
on the list of major challenges of Global Governance for Health Research. The process of 
creation and filling of knowledge gaps in Global Governance for Research can be 
summarized and portrayed through this simplified model:  
New Scientific Knowledge/Questions  New Research Methodologies/ Designs  
New Ethical Challenges/ Controversies  New Ethical Knowledge  New/Updated 
Ethical (Governance) Soft and Hard Law 
This model shows the continues creation and filling of knowledge gaps in the field 
of Global Governance for Health Research.  
2- Normative Gaps: The normative gaps are about the difference between the 
norms and values and the levels of abidance by the standards and norms among different 
role players (state and non-state) of Global Governance for Health Research. In the 
absence of a single global government or global authoritative body, the process of 
ratifying and enforcing the standards and norms is more complicated in the realm of 
global governance than in the nation-states. Norms, like knowledge, follow their own 
cycles of emergence, growth and popularity, globalization, modification, and sometimes 
fading and elimination. There is a typical trajectory: A group of norms first emerge as 
local ideals, then find their way into domestic laws and then into international soft law, 
and after a while, the global consensus paves their ways into taking the shape of 
international hard law.  
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The most prominent example of such norms are human dignity and human rights as 
are embodied in the Universal Declaration of Human Rights.237 The examples of fading 
norms are the sanctity of state sovereignty that today is questioned by the right of nations 
to exit the nation-states and join to of form new nation-states. In the realm of Global 
Governance for Health Research many of the widely accepted norms have passed through 
the similar trajectories. Informed consent, as an example, was defined and promoted in 
the form of domestic standards over the first decades of the twenties century. It was in the 
wake of the WWII that this norm showed itself as a part of international soft law, the 
Nuremburg Code.238 The repetition and promulgation of the necessity of obtaining 
informed consent from competent subjects made it a universally accepted norm that can 
be considered a piece of the common intellectual heritage of mankind in the realm of 
research ethics.    
3- Policy Gaps: Policy is defined as “an interlinked set of governing principles 
and goals, and agreed programs of action to implement those principles and achieve those 
goals…. Moreover, at the national level, policy can also be used to refer holistically to 
the entire package of actions and attitudes.”239 In the realm of Global Governance for 
Health Research, policies are embodied in the form of research ethics codes, declarations, 
guidelines, laws, and regulations. The Nuremberg Code, Declaration of Helsinki, the 
CIOMS guidelines, and the Belmont Report are among the examples of policies that are 
related to health research.  
Who is in charge of global policy-making for research enterprise? This is a major 
question that reveals the existing policy gaps. Each of the above-mentioned pieces of 
policy have formulated, adopted, and implemented by a different party involved in 
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research. As described in chapter 2, the Declaration of Helsinki, as the most well-known 
and influential international policy regarding international health ethics has been 
formulated by civil society bodies that represent physicians. In addition, the membership 
of such organizations that have created such policies (e.g. WMA for Declaration of 
Helsinki) do not necessarily cover all the involved role-players in the world. For 
example, there are many medical professional bodies that are not among the members of 
WMA. On the other hand, one may argue that in the intergovernmental organizations 
such as WHO and UNESCO, the voice of non-governmental actors is missing.  
Therefore, at the current situation, the challenge of the lack of globally legitimate 
and agreed-upon policy-maker forms a part of policy gaps for the Global Governance for 
Health Research. The role of experts and networks in influencing the process of policy-
making in international bodies is undeniable. The collective efforts of all these role-
players have already led to formulation, adoption, and even implementation of a large 
and valuable body of policies in the realm of Global Governance for Health Research. As 
a matter of fact, these policies are the far most prominent way through with the Global 
Governance for Health Research has been actualized in the contemporary world. 
However, policy-making in this realm still has the gaps resulted from the diversity and 
incompatibility of the bodies of policy making. 
4- Institutional Gaps: The weakness of the existing international organizations 
and institutions in dealing with the challenges ahead of Global Governance for Health 
Research, or the absence of effective ones with sufficient coverage and authority forms 
the fourth set of gaps: the institutional gaps. In the previous chapter, in describing the 
existing situation of international organizations, such as WHO, their weaknesses in taking 
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the leading role in confronting the challenges of health and health research are 
discussed.240 Although some international organizations such as UNESCO, CIOMS, and 
WMA have been successful in developing soft law for Global Governance for Health 
Research, there is no single world institution in charge of dealing with the challenges of 
global research enterprise.  
The global trend of weakening of international organizations, as described in 
chapter 2, shows itself in the field of health research, too. WHO has been supposed to 
take a leading role in global heath governance. Regardless of its success in taking this 
important role, this is questioned that whether this supposed leading role can be extended 
to the governance of health research and research ethics? Are there any differences 
between the leadership of WHO in technical aspects of global health and leadership in the 
realm of bioethics? The obvious preeminence of other global organizations such as 
UNESCO, CIOMS, and WMA in taking part on Global Governance for Health Research 
shows that the WHO, even in theory, does not have a monopoly in Global Governance 
for Health Research.  
This lack of centrality and divergence of leadership efforts and institutions is a 
major feature of institutional gaps in Global Governance for Health Research. 
Accordingly, this can be argued that the institutional gaps in Global Governance for 
Health Research are deeper and more severe and significant than the same gaps on global 
governance and global health governance. In developing an ethical framework for Global 
Governance for Health Research, the existing institutional gap should be noticed and 
considered. 
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5- Compliance Gaps: In a global order made of sovereign nation-states, the 
most obvious gaps in the fivefold set of gaps are the gaps in compliance. Since the trials 
of Nazi doctors after WWII there has never been any serious enforcement of research-
related regulations at the international level. Therefore, the compliance to the existing 
body of the soft and hard laws on research ethics constantly is a subject of doubt and 
question. The real picture of Global Governance for Health Research consists of a large 
body of laws in the absence of a global low-enforcement authority. 
In the contemporary world, almost all major and international research project is 
reviewed and monitored by at least one Institutional Review Board (IRB) or Research 
Ethics Committee (REC). The funding of the projects and publication of the result are 
highly dependent on the confirmation and ethical clearance provided by these oversight 
bodies. Therefore, one can argue that the research ethics norms are being enforced in the 
global research enterprise. However, the frequent revelation of scandals such as the HIV 
research projects in Africa shows that some other factors such as corporate greed and 
rivalry may create noteworthy obstacles against complete enforcement of research 
standards and norms. Therefore, the compliance gaps in some shapes and degrees persist 
and show themselves. 
For overcoming the compliance gaps there is no need to an international court of 
justice for research. Instead, collective efforts of all role players, including the funders, 
representatives of research subjects, oversight bodies, and publishers for optimizing the 
current system of research monitoring and oversight can create an ever-increasing 
improvement in filling the compliance gaps. 
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Conclusions: In this chapter, the main challenges of Global Governance for Health 
Research are discussed and their ethical nature is shown. The discussions provided above 
about each of the main challenges showed that all these challenges have ethical roots and 
components. Principles such as human dignity, respect for vulnerability, justice and 
equity, and respect for cultural diversity are involved in all the discussed challenges. In 
addition, the possible solutions of these challenges are tied to improvement in the existing 
ethical frameworks.  
After portraying the challenges and their characteristics and ethical roots, this 
chapter analyzed the challenges using the gaps model created by Thomas Weiss and 
showed that all the gaps described in that model (Knowledge, Norms, Policies, 
Institutions, and Compliance) can be traced and depicted in the Global Governance for 
Health Research. As a matter of fact, the main challenges described in this chapter are 
various manifestations if these gaps. 
This chapter concludes that one of the main roots/causes of the existing problems is 
the absence of a comprehensive ethical framework. The existing frameworks are difficult 
to apply because they are top-down. Developing a comprehensive, consensual, and 
efficient ethical framework in one of the next major tasks/challenges of the Global 
Governance for Health Research. Consequently, the main question that is to be dealt with 
in the next steps of this theoretical endeavor is “What would be an appropriate normative 
framework for global health governance for international health-related research?” For 
answering this question, in the previous chapter of this dissertation, a conceptual, 
historical, and situation analysis of Global Governance for Health Research and its major 
role players is provided. In the following chapters, after providing a detailed examination 
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of some prominent cases, an ethical framework for Global Governance for Health 






































Chapter Four: Case Studies of Global Governance for Health Research 
In this chapter, some of the historic ethical cases of Global Health Governance and 
Global Governance for Health Research are introduced and discussed. Exploring real and 
historical cases is helpful for portraying a realistic picture of the existing situation and 
problems in Global Governance for Health Research and how an ethical framework can 
be useful in solving these problems. In other words, each case entails certain lessons to 
learn. Also, certain ethical principles are relevant to each case (Table 4.1). 
For starting with a broader scope, the first case, Zika pandemic is more related to 
Global Health Governance at the large scale. This part shows how Global Health 
Governance uses previous experiences to deal with newly-emerged problems. The 
following parts are pertaining to different aspects of Global Governance for Health 
Research. Research integrity in Iran describes the problem of local practices on research 
integrity and how they can affect global research collaborations. HIV/AIDS Research in 
Africa depicts a well-discussed case of exploitation in research. Sending Biological 
Specimens Abroad deals with the problem of bio-piracy and how international 
collaborations may be seen from the weaker sides. Research on Pre-Implantation Human 
Embryo shows how different religious and seculars perspectives collective take part in 
shaping ethical grounds for Global Governance for Health Research, and Local and 
International Alternative Medicines deals with the globalized aspects of science-
pseudoscience debate. 
By analyzing the above cases, this chapter shows the real and practical need of Global 
governance for Health to certain elements in the form of principles and regulations that 
along with other ones will shape a comprehensive and efficient ethical framework. A 
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general scheme of the topics of lessons and principles of each case is depicted in Table 
4.1. The resulted ethical framework will be discussed in chapter 5.  
Table 4.1. The cases, the learned lessons, and the involved principles in Global 
Governance for Health Research 
Cases Topics of Learned Lessons  Involved Principles 
Zika Pandemic  The existence and 
functioning of Global 
Health Governance 
 Need to a comprehensive 
set of principles 
 The variety of role-
players 
 Importance of the leading 




 The need for improving 
healthcare and research 
infrastructures of 
developing countries 
 The importance of local 
cultural sensitivities   




Solidarity, Sharing of 
Benefits, Social 
Responsibility, and 
reciprocity, Respect for 
Cultural Diversity, 
Compassion as a Virtue 
Research Integrity in Iran  The importance of 
research integrity in global 
collaborations 
 Global consensus on the 
definition and importance of 
research integrity 
 Inconsistency in 
knowledge, attitude, and 
practice regarding research 
integrity among different 
countries 
 The role of Global 
Governance for Health 




Heritage of Mankind 
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 The importance of ethics 
education in promoting 
research integrity 
HIV/AIDS Research in 
Africa 
 The problem of double 
standards 
 The problems of 
exploitation and helicopter 
research 
 The problem of inability 
of poor communities to 
afford the vital medications 
 Undue influence of 
religious or political 
interests (the problem of 
bio-politics) 
 The problem of 
bilateralism (vs. 
multilateralism)  
Sharing of Benefits, 
Social Responsibility, 
Informed Consent, 
Respect for Cultural 






 The role of bio-politics 
 The role of bio-
economics 
 An example of hard law 
that protects vulnerable 
populations (Nagoya 
Convention) 
 The problem of bio-
piracy 
Respect of Common 
Heritage of Mankind, 
Sharing of Benefits, 
impartiality and 
independence of global 
bioethics 
Research on Pre-
Implantation Human Embryo 
 The need for protecting 
early human life and the 
responsibility of global 
governance 
 The role of religious 
institutions 
 The importance of global 
ethical standards for 
research 
 Global consensus on 
dignity of early human life 
 The need for hard law for 
some aspects of health 
research 
Human Dignity, 
Sanctity of Human 




Local and International 
Alternative Medicines 





Validity, Respect for 
Scientific Methods as a 
 117 
 The problem of Bio-
piracy 
 Alternative and 
Complementary medicine as 
a rich resource of 
therapeutically hypotheses 
part of the Common 
Heritage of Mankind 
 
i. Zika Pandemic 
Pandemics are among the health issues that best reflect the necessity, functioning, 
and effectiveness of Global Health Governance.241 Global Health Governance can be 
defined by a two major defining elements: First, the variety of role players, including 
states, international organizations, and non-state organizations that are involved and 
shape a global network;242 second, the issues that are cross-border and raise cross-border 
concerns and demand cross-border attention and interventions.243 Therefore, Global 
Health Governance is a network of the above role-players that deal with cross-border 
health issues in our globalized world.  
Like any other social institution, Global Health Governance uses a body of 
collective experience and wisdom accumulated through many years of experience in 
dealing with various health problems. The pandemics are not exceptions. A precious 
body of collective experience and knowledge has been achieved through fighting 
different pandemics in various geographic areas and in each case, some valuable lessons 
are learned and added to the existing body of experience and knowledge. Therefore, this 
is not surprising to say that Global Health Governance learned from this body of 
knowledge and experience in dealing with newly emerged pandemics like the Zika virus 
pandemic. 
In this part of this chapter, after explaining the current situation of Zika virus 
pandemic and a brief description of previous similar experiences in dealing with other 
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pandemics such as Pandemic Influenza and Ebola, this is argued that the main lessons 
learned from the previous experiences and applicable to the current efforts in fighting 
Zika virus pandemic (and the potential future pandemics of other infectious diseases) are 
as follow: (1) The need to an expanded account of ethical principles that govern the 
Global Health Governance and Global Governance for Health Research, (2) The need to 
strengthening the leading role of the World Health Organization (WHO) in Global Heath 
Governance (that implies the importance of having a leading organization in Global 
Governance for Health Research) while preserving the “network” nature of global health 
governance that facilitates the involvement of more role players and wider array of the 
forms of leadership, that is at the same time, an emphasis on multilateralism as described 
in the previous chapter as the best model of international collaboration for Global 
Governance for Health Research; (3) The need to improve the healthcare systems 
especially in lower and middle-income countries along with research facilities that focus 
on local health needs and priorities ; (4) The necessity of providing universal health 
coverage for all (including affordable medications), as a goal for global health 
governance; (5) The need to empowering the mechanisms of governance from below; and 
(6) Relying on shared global and cultural sensitive values such as cooperation and 
solidarity and benefit sharing as the overarching values of Global Health Governance and 
Global Governance for Health Research. 
Situation Analysis: This part of this chapter sketches the main factual 
characteristics of the recent Zika virus Pandemic. For this purpose, first a brief 
description of scientific facts regarding this viral infection is provided. Then, the 
epidemiological situation of the recent pandemic is portrayed and then, the predictions 
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and expectations on the future trajectory of this pandemic are explained. Having a 
realistic portrait of the problem is one of the first major steps of each study and helps the 
researchers to ground their arguments and analysis on a firm and reliable basis. 
Scientific Facts: Zika virus is a mosquito-borne virus that belongs to the Genre of 
Flavivirus. This virus is transmitted through the bite of an infected mosquito from the 
Aedes genus, mainly Aedes aegypti.244 These mosquitoes inhabit in tropical regions. 
They transmit other viral diseases such as dengue, chikungunya and yellow fever, too. 
Sexual transmission of Zika virus has also been reported. Other types of transmission, 
including blood transfusion and perinatal transmission have not been proved or 
rejected.245 
 The mosquito that carries Zika virus bites during the day with higher rates during 
afternoon hours.246 The incubation period of Zika virus disease is estimated to be a few 
days. The signs and symptoms of this viral disease are usually mild and last between 2 
and 7 days and include fever, skin rashes, conjunctivitis, muscle and joint pain, headache, 
and malaise. However, what have caused a large scale of global fear of this viral disease, 
are its potential neurological and autoimmune complications, the most infamous one 
among them being microcephaly in babies born to mothers infected with Zika virus.247  
Diagnosis of infection with Zika virus is based on suspicion according to 
symptoms and history of recent travel to an area where Zika virus is known to be 
present and confirmation according to laboratory testing for the presence of Zika 
virus RNA in the blood or other body fluids, including urine or saliva.248 
Prevention and control is mostly based on reducing the population of 
mosquitoes through source reduction and reducing contact between mosquitoes and 
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human beings. Source reduction means removal and modification of breeding sites of 
mosquitos. Reducing contact between mosquitoes and human beings can be done by 
the following methods: regular using insect repellents; wearing clothes that shields as 
much of the surface of body as possible; installing physical barriers such as window 
screens in houses; keeping doors and windows closed; and additional personal 
protection, including sleeping under mosquito nets during the day. In addition, 
removing mosquito-breeding sites such as water containers, flowerpots, roof gutters, 
sites of accumulation of still water after rains or in discarded containers and waste 
materials in and around houses. Special attention and help should be bestowed to 
those who are less able to protect themselves sufficiently, such as young children, the 
sick or elderly. In addition, during outbreaks, spraying of insecticides can be helpful 
and may be suggested by health authorities.249  
Travelers should observe the essential precautions to protect themselves from 
mosquito bites. Since sexual transmission is one of the methods of transmission of 
Zika virus, the infected individuals and their sexual partners should practice safe sex 
that means using condoms. Especially the sex partners of pregnant women who live 
in or travel to the areas where local transmission of Zika virus happens, should 
practice safe sex, wear condoms, or refrain having sex throughout the pregnancy. 
Individuals who return from areas where local transmission of Zika virus occurs 
should practice safe sex or abstinence for at least 4 weeks after their return.250  
The disease resulted by Zika virus is usually mild and does not need any 
specific treatment. No vaccine has become available yet for Zika virus infection and 
disease.251 
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Epidemiological Facts and Predictions: Zika virus was first identified in 
1947 in rhesus monkeys and then in 1952 in human beings, both in Uganda, a 
country in east Africa (first identifying in human beings concurrently occurred in the 
United Republic of Tanzania). Historically, outbreaks of Zika virus have previously 
occurred in Africa, the Americas, Asia, and the Pacific. Zika virus disease outbreaks 
were reported for the first time from the Pacific in 2007 and 2013 (Yap and French 
Polynesia, respectively), and in 2015 from the Americas (Brazil and Colombia) and 
Africa (Cabo Verde). In total, 64 countries and territories have reported transmission 
of Zika virus since 1 January 2007.252 
 The recent pandemic that occurred in the Americas and the Pacific began in 
April 2015 in Brazil and spread throughout most of Americas.253 The fear from vertical 
transmission of virus caused several warnings about avoiding pregnancy for women 
residing in or traveling to the affected areas. Also, restricting traveling to the affected 
areas and even cancelling events that attract tourists to those areas have been proposed 
and discussed.254  
 Later, it was claimed that Global Health Governance has showed a kind of 
“over reaction” to this pandemic. This alleged overreaction was also partly a reaction to 
claims about late and insufficient response to previous pandemics, especially the recent 
case of Ebola. Therefore, assessing the approaches of Global Health Governance to those 
outbreaks and comparing them with the current epidemic of Zika virus, can entail 
valuable lessons for the future. For this purpose, the next parts of this chapter, after 
examining the concept of global health governance, will provide a detailed comparison 
among these world experiences. 
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Comparison with Previous Pandemics: Pandemics as a major concern of public 
health have been among the main issues that caused and underpinned a paradigm shift 
from bioethics to global bioethics and have embodied the nature of globalization in this 
field of theory and practice.255 This part of this chapter, assesses and explains the 
historical experience of global health governance with three major outbreaks: Pandemic 
Influenza, HIV/AIDS, and Ebola and explores how the lessons learned through these 
experiences prove useful in approaching the current pandemic of Zika virus. 
Pandemic Influenza: There have been about three influenza pandemics in each 
century for the last 300 years, the most recent one being the 2009 Influenza pandemic. 
This part of this part of this chapter provides a brief examination of the lessons learned 
through the approach of global health governance to this pandemic. 
One of the issues raises during all pandemics is the issue of surveillance of 
infectious diseases. Among the first missions of the WHO was governing the 
international efforts for controlling, and in some cases, finally eradicating infectious 
diseases. For this purpose, the international community needed a system of surveillance. 
This system had been in place before the foundation of the WHO, in the form of 
numerous scattered international conventions. The International Sanitary Regulations 
(ISR) replaced those conventions with a single internationally agreed upon law with an 
organization in place to enforce it at the global level. ISR was adopted by the Fourth 
World Health Assembly of the WHO in 1951 and entered into effect in 1952. Then, in 
1969 the ISR were revised and renamed into the International Heath Regulations 
(IHR).256 
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The process of creation and enforcement of the IHR is noteworthy in assessing 
the global governance for controlling infectious diseases, including pandemics. This first 
major global experience showed that: (1) this is feasible and practical to create and 
enforce a global law, system, and organization for collaboration among different 
countries with different and conflicting political systems and economical statuses; (2) the 
IHR proved effective and ended up to some noteworthy successes such as the eradication 
of small pox; (3) this experience showed that how a health-related international law gets 
old and reveals its shortcomings through the time and can be revised and updated by the 
agents of global health governance; and (4)  the last revision of the IHR in 2005 showed 
how the international nature of health governance is transforming into a global nature, i.e. 
more involvement of non-state actors in the surveillance of infectious diseases in addition 
to more flexible and liquid definition and determination of key factors such as the list of 
notifiable diseases.257 
Isolation, meaning the practices that restrict the free transportation, contact, and 
social activities of individuals for the purpose of preventing the spread of a pandemic, is 
another important topic. Therefore, quarantine and compulsory hospitalization are also 
considered as forms of isolation. One of the first priorities of health systems in 
controlling pandemics is preventing further spread of the infection. For this purpose, the 
minimum necessary level of restriction of freedoms is to be executed. However, the 
principle of reciprocity demands that the individuals, who are subjected by these 
restrictions, receive reciprocal benefits such as the best possible quality of stay during the 
quarantine and provisions for substituting the lost possible trips.258 
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As discussed above, the healthcare workers have a duty to provide health services 
during the times of pandemics. This duty is of moral, professional, contractual, and legal 
natures.259 At the same time, the principle of reciprocity implies that the governance 
provides the best compensation and recognition for their efforts. 
At the global level, the principle of cooperation and solidarity requires that even 
non-involved countries get engaged in controlling the pandemics in the afflicted areas. In 
the current globalized world, no pandemic remains confined in a certain geographic area 
for a long time.260 Therefore, in addition to the moral demand out of solidarity, the 
national interests of countries, especially the ones that or the major destinations of 
immigrants and refugees, demand their attention to timely and efficient controlling of 
pandemics. 
Ebola: Although Ebola, as a viral disease, had been identified from the 1970s after 
its first detected appearance in Central Africa, its 2014 pandemics resulted a new and 
specific attention to this disease.261 This specific attention was because of the following 
facts. These facts also make this pandemic relevant to the subject of this chapter that is 
the lessons learned by Global Health Governance from this pandemic:(1) the spread and 
severity of this pandemic was extraordinary. Several African countries were affected and 
many people died, (2) the spread of this disease to the wealthier/developed countries, 
specially to the USA, (3) various debates with ethical nature that rose during the Ebola 
pandemic such as compassionate use of experimental drugs that relates this subject to 
Global Governance for Health Research, and (4) the struggle of Global Health 
Governance, especially failure of WHO in effective and timely controlling of the 
pandemic.  
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Started in 2013 and traced to a 2-year-old girl in Guinea as the index case (who died 
from this infectious disease), the outbreak of Ebola virus infection/disease in West Africa 
in 2014 is the most widespread and persistent outbreak of this viral infection ever 
recorded since the time of discovery of this virus in 1976.262 This outbreak has killed 
thousands of people in West African countries during this outbreak.263 It also has 
disrupted the activities and programs of the health sector of those countries (like 
programs to control Malaria) and imposed huge deals of economic lose to those 
countries.264 
Some important features and facts about Ebola outbreak, which are relevant to the 
subject of this part of this chapter, are as follow: 
1- Ebola, like HIV/AIDS, has no curative treatment. Although some antiretroviral 
drugs have been successfully discovered to be effective265. Although not curative, the 
current available treatment of Ebola virus disease mostly consists of supportive measures 
like providing adequate nutrition and hydration.266  
2- The recent pandemic of Ebola first started in Western African countries.267 Health 
officials in the United States hoped that by adopting reasonable measures, the infection 
would not enter inside the borders of the United States. It did. Although this event arose 
some discussions about the ethical limitations and requirements of quarantine as a public 
health intervention, but the greater lesson was that in the contemporary globalized world, 
with this huge network of interconnectedness and huge amount of international travelers, 
heath crises, especially outbreaks of infectious diseases, don’t remain confined within the 
national borders. Both the experiences with HIV/AIDS and Ebola virus disease simply 
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shows the global nature of public health crises and the global impact of outbreaks that 
originate in an area but never remain confined to that geographic area. 
3- Occurrence of this outbreak in some developing countries showed the challenges 
of fighting such outbreaks in regions with people who have various sets of beliefs and 
different cultural/economical contexts. For example, the very issue of mistrust resulted 
from long lasting political chaos, civil wars, economical poverty, and political 
dictatorships in the region is discussed separately in this part of this chapter which shows 
the importance of contextual issues in public health interventions within the frameworks 
of Global Heath Governance. The same issues can affect research projects in such areas. 
The problem that also should be covered by Global Governance for Health Research. 
4- Comparing the treatment provided for few cases of Ebola infection in the United 
States, with the chaotic situation of healthcare for Ebola patients in affected countries in 
the West Africa, uncovers a bitter reality of the current world: the huge disparity and 
inequality between these countries in term of health care resources and facilities, both in 
treatment and research sectors.268 Equality and justice are among the most emphasized 
values of global bioethics. If Global Heath Governance does not take measures to fight 
these unacceptable inequalities, the next pandemics will occur in developing countries 
and will cause human tragedies again and again. 
When this deadly outbreak of Ebola found its way to the inside of borders of the 
United States, the very important role of Global Health Governance in dealing with 
health crises showed itself again.269 Mass media and social networks extensively covered 
this outbreak and the related ethical issues were being discussed in academic circles, and 
in the public sphere in the house and days after their causes took place. Several issues 
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about quarantine, the function and efficiency of governmental bodies like the Center of 
Disease Control (CDC), and the organizational ethics within the US hospitals have been 
fiercely discussed inside the United States. There are also other lessons learned from 
ethical features of this experience, which are more relevant to the very concept of Global 
Health Governance.  
It has been argued that in the recent outbreak of Ebola, an existing and ongoing crisis 
in global health leadership cost thousands of human lives because of delayed and 
ineffective emergency responses.270  At the time of crisis, WHO was not able to exert 
proportional reaction in timely manner to this public health emergency at international 
level271. Although this inability and late reactions have been attributed to shortage of 
monetary funds available to WHO, however, regardless of the possible causes, it shows 
the existing need for strengthening the functionality of this leading global organization.272 
The problem of double standards in Global Health Governance is explained above, in 
chapter 3, by discussing the example of double standards in treating human research 
participants in different parts of the world.273 This problem also exists and should be dealt 
with at the level of leadership of Global Health Governance. 
The problem of double standard in Global Health Governance, however, has other 
faces, too. The reaction of mass media to two cases of death from Ebola in the United 
States was fiery and sweltering! The related governmental bodies like the CDC were 
criticized for not providing guidelines and facilities for preventing transmission in a 
timely manner. In addition, the very issue if quarantining of a nurse who had come back 
forms an infected area became a subject of boiling debates. At the same time, thousands 
of people were dying from this infection in a few African countries and the coverage by 
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mass medical and reaction of people and public opinion were dilute comparing with the 
ones evoked by the relatively tiny domestic events. When thousands of people are dying 
and other countries do possess facilities for preventing such human tragedy, do they have 
a kind of social responsibility out of solidarity and cooperation to help them more than 
what happens currently in the real world? Is it justified for governments and nation states 
to regard the death and suffering of foreigners less important than their own citizens? 
And is it ethically accepted to refuse to help desperately needy people who are struggling 
with a deadly disease in the presence of enough resources and capacities?  
Responding the abovementioned questions in not easy at all. Different factors like 
respecting the sovereignty of local states, the responsibility of governments towards their 
own people, the scarcity of resources, and lack of real trustful collaboration among the 
major world powers, all should be considered in formulating a response/solution for these 
ethical questions/problems facing global heath governance. But difficulty of finding a 
compelling and practicable answer does not shrink the very importance and vitality of 
these questions and should not cover this very fact that the way the major role players in 
Global Health Governance respond to these questions is a matter of death and life for 
thousands and even millions of people in the present and future of human civilization. 
Amid the crisis of Ebola infection, when several institutions where working in that 
area and collaboration with local health officials for controlling the outbreak, one of the 
most important obstacles against their efforts was the deep mistrust of local people 
toward any governmental or international agency or intervention. For example, it was 
reported that in Guinea, panicked residents in a village killed all the members of a team 
that had been sent to that area to raise awareness about the disease.274 
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The long history of dictatorship and abuse of power in African countries, along with 
the inevitable side-effects of dictatorship like widespread corruption of police force and 
their abuse of power, have resulted in the lack of trust, while trust is crucially needed for 
efficient collaboration among various involved parties and for eliciting people’s 
partnership which is so central and critical in controlling such health-related crises. 
Although Ebola infection has no proven curative treatment, some experimental 
medicines have been used hoping to save patients who otherwise would be likely to die. 
The long process of approving experimental drugs for using in standard clinical practice 
has always been a subject of criticism. During the HIV/AIDS epidemics, sometimes there 
were competitions among potential participants (patients/infected people) for entering the 
clinical trials. They looked those clinical trials as the last resort and beacon of hope for 
receiving an effective treatment. In the case of Ebola infection, however, the clinical 
trials were being conducted thousands of miles away from the foci of outbreak. Delivery 
of experimental drugs to those patients was not part of any research study or clinical trial. 
As a matter of fact, considering the especial context of chaos and shortage of healthcare 
workers and facilities, it was impossible to conducts sufficiently well designed and well-
conducted clinical trial in those areas.  
Providing experimental drugs for those patients hoping to be effective in relieving 
their suffering and even saving their lives was an act out of philanthropy.   It seems that 
outlining the regulations and principles under which this kind of premature release of 
experimental drugs can happen again in the future is part of the duties of the institutions 
in charge of Global Governance for Health Research. However, it is obvious that the 
guiding principles of this action are benefit sharing solidarity and cooperation275. 
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Ebola pandemic has been called as a failure for Global Heath Governance.276 
However, as explained above, many lessons learned by global health governance that 
could be applicable to Zika pandemic. 
In sum, although Global Health Governance is accused of “over-reacting” in 
approaching to Zika virus pandemic, this over-reaction that might have saved many lives 
and prevented births of many defected babies, as a result of previous experiences, such as 
the criticism of Global Health Governance because of its late and insufficient reaction 
during Ebola pandemic. 
In conclusion, in this part of this chapter, the following lessons learned from the 
previous pandemics for applying in Zika virus and other future pandemics have been 
discussed: First, an expanded account of ethical principles (compared with the classical 
ones) is needed for establishing and shaping an ethical framework for Global Health 
Governance and Global Governance for Research in dealing with pandemics. This 
expanded account includes some restrictions to the original principles such ad respect for 
autonomy and addition of new principles such as cooperation, solidarity, and reciprocity. 
Second, through discussing more concrete practical concerns, it is depicted that how this 
modified account of ethical principles can lead and help in dealing with those concerns 
and show the point of balance among the various and conflicting ethical principles, 
norms, and obligations. This model needs to be expanded and include other ethical 
considerations and practical concerns to provide an inclusive and comprehensive ethical 
framework for global health governance in dealing with pandemics. Third, the above 
review and comparison shows the need to strengthening the leading role of the World 
Health Organization (WHO) in Global Heath Governance while preserving the “network” 
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nature of Global Health Governance and multilateralism on Global Governance for 
Health Research that facilitates the involvement of more role players and wider array of 
the forms of leadership. Fourth, the need to improving the healthcare systems and 
research governance especially in lower and middle-income countries is one of the points 
that are obvious through the above parts of this part of this chapter. Fifth, the above 
review and comparison clearly show necessity of providing universal health coverage for 
all (including affordable medications), as a goal for Global Health Governance in which 
the research sector can be helpful. Sixth, the need to empowering the mechanisms of 
governance from below is another point that can be concluded from the above part of this 
chapter. And seventh, relying on shared global and cultural sensitive values such as 
cooperation and solidarity and benefit sharing as the overarching values of Global Health 
Governance and Global Governance for Health Research is the best way for founding an 
ethical framework for the future of Global Governance for Health Research and its future 
encounters with pandemics. 
ii. Research integrity in Iran  
During the second half of the twentieth century, the number of international and 
multi-central research projects increases with a fast rate.277 This rate was continued in the 
first two decades of the next century. This phenomenon is a part of a bigger picture that 
has been named “globalization”. Globalization in any aspect of social human life 
necessitates global governance as well as global ethics for that aspect. 278 Research 
enterprise has not been an exception. Therefore, the governance and ethics of the 
international research ethics are parts of global health governance and global bioethics, 
respectively.279 
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Among the different topics of research ethics as it pertains to Global Governance for 
Health Research, research integrity is one of the most important ones. The reasons of this 
importance (in addition to the reasons of the importance of research integrity of research 
in general, that is beyond the scope of this part of this chapter) include: 
1- Multinational and multi-central research collaborations are based on the values of 
honesty and trust. When multiple parties from different parts of the world decide to 
collaborate in a research project, they have to trust each other’s honesty and reliability in 
following the same methods and standards and in correct and accurate reporting of 
results, including the possible adverse effects or inabilities to achieve the expected goals 
or milestones. Therefore, having global ethical norms and regulations that support this 
mutual trust and a global governance to ensure and promote these norms and regulations 
will be an integral part of international research enterprise. Otherwise, the high costs of 
mutual monitoring and verifications will render such research projects too expensive to 
be practical. 
2- Research integrity is among the topics on them it seems possible to achieve a 
global consensus. When it comes to global consensus on bioethical issues, it is obvious 
that on some controversial topics (such as abortion or discrimination) it is very hard – if 
not impossible – to reach to a form of global – and even local - consensus. However, 
there are certain areas in them it is possible to found a common ethical ground for global 
ethics. Research ethics is a good source for such grounds. The values that shape the 
ethical foundations of research include honesty, accuracy, efficiency, and objectivity.280 
These values – at least to the extend they pertain to research – are globally accepted and 
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justified and can be used as a common ground for founding and ethical framework for 
Global Governance for Health Research. 
Like other areas of practical ethics, historical experiences are the engine that produces 
force for ethical deliberations, legislations, and enforcement to move forward.281 Without 
the bitter experience of human experiments in Nazi Germany, we would not have the 
Nuremburg Code282, and without the unpleasant disclosures made by Henry Beecher, we 
would not have the Belmont Report283, at least at their current time and place in the 
history. The same fact is true about research integrity. Historical cases of research 
misconduct and the related scandals have resulted noteworthy achievements in this area. 
Therefore, studying, exploring, and analyzing the similar experiences are also valuable in 
improving research integrity in the future. This part of this chapter is intended to be a step 
in this direction. Therefore, the main question this part of this chapter deals with is: how 
the systems of Global Governance for Health Research can learn from the experiences of 
collaborative/multinational research in countries like Iran for optimizing their approach to 
the issues related to research integrity? 
For answering this question, after a conceptual analysis of the notion of research 
integrity, and a history review, the concept of global governance for research integrity is 
introduced and its achievements and shortcomings are explored. Then, some infamous 
cases are introduced and analyzed. Afterward, a historical review and situation analysis 
of research integrity in Iran is provided and accordingly, the roots and causes of existing 
problems and the way ahead are explored. Finally, this part of this chapter concludes that 
expanding international research collaborations is expected to have beneficial effects in 
term of improving research integrity in developing countries such as Iran. In addition, 
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research integrity can be considered an agreed upon basis for developing a part of 
globally accepted ethical framework for Global Governance for Health Research.  
The Concept of Research Integrity: In this part, first, a definition and conceptual 
analysis of the notion of research integrity is provided, then some of the most important 
historical landmarks are introduced and discussed. 
Definition and Conceptual Analysis: According to the National Institutes of 
Health, Research integrity includes: “(1) the use of honest and verifiable methods in 
proposing, performing, and evaluating research, (2) reporting research results with 
particular attention to adherence to rules, regulations, guidelines, and (3) following 
commonly accepted professional codes or norms.”284 Therefore, the mandates of research 
integrity cover all the activities of researchers through all the major phases of thesis 
development, conducting research/study, drafting and finalizing the report/paper, and 
publishing the results. Research integrity is very important because of numerous reasons 
including the following ones asserted by the NIH:  
(1) “Researchers rely on trustworthy results of other researchers to make scientific 
progress.”285  Therefore, research misconduct; including fraud, falsification, and 
fabrication of data can destroy not only the current but also the subsequent researches that 
destroy the reliability of science.286 
(2) “Researchers rely on public support, whether through public investments or their 
voluntary participation in experiments, to further science.”287 Therefore, violating 
research integrity can be considered as betrayal against public trust and support and 
finally can deprive the academic/research society from the support provided by the 
public, both funding and participating.288 
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(3) “The public relies on scientific progress to better the lives of everyone.’289 
Therefore, scientific misconduct can also gas deteriorating effect on one of the final 
products and goals of science that is the quality of human life.290 
(4) “Researchers who are dishonest and act without regards to integrity could 
actually harm the public.”291 Therefore, research misconduct is not only a violation of the 
trust and norms and rights within the professional community, but also is a violation 
against the public and common good. 
All the reasons mentioned above for the importance of research integrity can be 
defined and mirrored in the global level. The notions of trust, public, and common good 
can be defined at the global level. In this level, the public encompasses both the 
community of people of the world and the community of nation-states.292 For the 
abovementioned reasons, the notion of research integrity has gained increasing attention 
in the past decades and should be considered as an integral part of research governance in 
both local and global levels. 
A Historical Review: Some aspects of research integrity, such as avoiding 
plagiarism, are as old as the written history, itself. However, the notion of research 
integrity in its current dimensions and characteristics is a relatively new notion. For 
example, in the United States, research integrity became a public issue in 1981. In that 
year, a congressman named Albert Gore, Jr. who was the chairman of the Investigations 
and Oversight Subcommittee of the House Science and Technology Committee, held the 
first hearing that was provoked by the public disclosure of certain research misconduct 
cases. Those cases had occurred at four major research centers in the previous year. 
About twelve cases of research misconduct were revealed in the US between 1974 and 
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1981. The attention of the US Congress to the issues related to research integrity was 
continued throughout the 1980s because of some added accusations of research 
misconduct and reports that the NIH, universities, and other research institutions were 
unsatisfactorily reacting to those accusations.293 
In 1985, the Congress of the United States passed the Health Research Extension 
Act. This Act required the Secretary of Health and Human Services to issue a regulation 
requiring applicant or awardee institutions to establish "an administrative process to 
review reports of scientific fraud" and "report to the Secretary any investigation of 
alleged scientific fraud, which appears substantial."294 In March 1989, the PHS created 
the Office of Scientific Integrity (OSI) in the Office of the Director, NIH, and the Office 
of Scientific Integrity Review (OSIR) in the Office of the Assistant Secretary for Health 
(OASH). The reason behind foundation of these offices was to deal with research 
misconduct. The establishment of OSIR also began the course of detaching responsibility 
for research misconduct from the funding organizations. In May 1992, OSI and OSIR 
were combined into the Office of Research Integrity (ORI) in the OASH.  As the 
prominent examples of its activities, ORI published the ORI Introduction to the 
Responsible Conduct of Research in 2004 and began the RCR Program for Graduate 
Schools in collaboration with the Council of Graduate Schools to institutionalize RCR 
education in graduate training.295 
The above examples show the process of legislative and regulatory attention to the 
issues of research integrity and research misconduct in other countries and in the global 
scene: First, some cases of violation of research integrity gain public attention, then 
gradually the related rules and regulations are passed in the legislative bodies and 
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executive offices take shape to enforce those rules and regulations. The global 
governance for research needs the same process to take shape at the global scale to deal 
with the issues of research misconduct and research integrity through global governance 
for research ethics. 
Global Governance for Research Integrity: In this part, a situation analysis of the 
global governance for research (a general picture) and the global governance for research 
integrity (with more details and specifics) is provided. Then, an infamous case is 
portrayed to discuss the lessons learned from them to improve the global governance for 
research integrity.  
Achievements and Shortcomings: Distinct separation between research and 
therapeutic clinical practice in health sciences, is a recent phenomenon, dating back to the 
first decades of the twenties century.296 Before that time, for centuries, experimenting 
new treatment or interventions was considered as a part of the routine practice of 
physicians and was supposed to be aimed to providing the best heath interest for the 
patient.297 In was in the twenties century that health-related research enterprise 
experienced an exponential growth, was recognized as separate from clinical therapeutic 
practice, and in the second half of that century international and multicenter research 
projects began to sprout and grow.298  
 Just like other global enterprises, the international health-related research 
established its own system of global governance.299 The Global Governance for Health-
related Research has mainly taken place and been mirrored in the following ways:  
 First, the international declarations, codes, and guidelines developed for setting 
global ethical standards for health-related research. Many of these instruments have 
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specific part pertaining to research integrity, a prominent example being the declaration 
of Helsinki.300 Almost all the countries involved in international research collaborations 
have generally accepted this declaration. Therefore, the standards exerted by this 
declaration, although they are very concise and brief, consist a major regulation part of 
global governance for research. In addition, other international instruments such as the 
Singapore Statement on Research Integrity of 2013 have been promulgated in this 
relevance.301 
 Second, the national rules and regulations made by the countries that host the main 
funding bodies and institutions on international research, the most prominent one being 
the United States. There are many law and regulations in this country setting the 
standards and enforcing them in regard to research integrity.302 In addition, many of the 
hosting countries have announced their laws and regulations in this relevance, Iran being 
an example.303 
 And third, the internal regulations, standards, and guidelines of the various sorts of 
organizations that fund international research.304 These funding organizations have their 
policies and regulations on research integrity. NIH305 and National Science Foundation306 
(NSF) are two prominent examples. 
 Therefore, for sketching a realistic portray of the history of global governance for 
biomedical research, the best way is looking at the developments in the above-mentioned 
means of implementing global governance for biomedical research. 
A Review of an Infamous Case: The case of Hwang Woo-Suk has some 
noteworthy lessons for global governance for research integrity; therefore, this part of 
this part of this chapter explores this case with more details. Hwang Woo-Suk, a 
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professor of theriogenology and biotechnology at the Seoul National University (SNU) 
was considered a pioneer and ground-breaking researcher in the field of stem cell 
research up to 2006. In his country, South Korea, he was treated as a national hero. His 
claimed research achievements including cloning of different mammals got extensive 
media coverage and made him a public and admired national figure in South Korea.307  
He invited famous global figures to his team.308 His works also gained widespread 
international attention, were published in the highest-ranked journals such as the Nature 
and he appeared in numerous international meetings as an invited lecturer.309 In two 
articles appeared in Science in 2004 and 2005 he claimed that he had created human 
embryonic stem cells by cloning. However, in 2006 it was revealed that his claims were 
fraudulent and he faked the reported data and results. This was a scandal for him and a 
big damage to the scientific reputation of North Korea.310  
He also was convicted for obtaining human eggs for his research through unethical 
sources that was his female subordinates that raised concerns about coercion.311 In 
addition, Gerald Schatten, a professor of cell biology at the University of Pittsburgh, who 
was one of two corresponding authors of Hwang’s second article, was accused of 
research misconduct, but later a university investigation found that Schatten was not a 
party to the fabrication of data and was unaware of it. However, it was also reveled that 
his contribution in the study was not at a level that make him eligible for authorship. In 
fact, he has also committed research misconduct by accepting a “guest authorship”.312 
The case of Hwang Woo-Suk shows that when a research project or a researcher 
gains public and political attention, this may have beneficial and adverse effects for 
him/her. Beneficial in terms of obtaining more research fund and personal/institutional 
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honor and prestige, and adverse in terms of putting pressure to him/her to have 
noteworthy results/products and being under the light of media and monitoring bodies. In 
addition, political support may cause at least temporary immunity of regular scrutiny and 
inspection that postpones the exposure of research misconduct to a time that it has been 
worsened and irreversible.  
In addition, this case study shows that how detrimental such research misconducts 
can be in international research collaborations. Such researchers and research projects 
that gain widespread global attention and work on hot topics of health, science, and 
technology are very successful in absorbing global funds and collaborations. A case of 
research misconduct from each party of such collaborations will damage and deteriorate 
the achievements and reputations of all involved parties. The case of Hwang Woo-Suk is 
a noteworthy example that shows the importance of research integrity in multinational 
health research collaborations and the importance of the attention of global governance 
for research to this subject. 
Iran’s Experience as a Case Study: This part of this chapter is committed to 
exploring Iran’s experience on research integrity and research misconduct as a case 
study. After a review and situation analysis, this part will explore and analyze the roots 
and causes of existing problems and later in this part of this chapter, it will be discussed 
that how global governance for research and use this experience for promoting research 
integrity in a global scale. 
A Historical Review and Situation Analysis: In the past decades, the health-related 
research sector in Iran experienced a fast growth.313 This growth, like other parts of the 
world, raised some concerns about ethical issues including research integrity.314  In the 
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recent years some cases of research misconduct reported from Iranian researchers has led 
to discussions and debates that shed light to different aspects of research integrity and 
research misconduct in Iran.315 This attention was partly because some of the holders of 
high-ranked offices in the cabinet of previous president, Mahmoud Ahmadinejad were 
among the people who were accused of research misconduct.316 In one case, a faculty 
member tried to answer to the accusations saying that the person who committed the 
plagiarism was my student and my name in the authorship byline was because I was the 
instructor/professor and I had not even read the manuscript.317 This kind of answering 
just shows deep unawareness of some of these people from the basic mandates of 
research integrity. 
Few empirical studies in this regard have been published. Two studies show that the 
knowledge and attitude of Iranian students318 and faculty members319 toward plagiarism 
shows there are rooms for more education and improvement. These studies, however, 
does not reflect a complete picture of the existing situation because they have been 
conducted in Tehran University of Medical Sciences that hosts the most elite students and 
faculty members in the country. Also, some papers in this regard have been published by 
non-Iranian authors, some of them tried to show a darker-than-reality picture of the 
existing situation in Iran.320  
In one noteworthy development, a group of Iranian scholars launched a blog named 
“Professors Against Plagiarism” in which they openly discussed the cases of plagiarism 
occurred in Iran. They showed that some high-ranked officials of the government have 
committed some severe cases of plagiarism.321 The reaction of government is banning 
(filtering) that blog and accusing them to produce anti-regime propaganda.322 
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In the medical universities of smaller cities, it seems that the rate of research 
misconduct is higher. Personal experience of the author of this part of this chapter and his 
colleagues form conducting research ethics workshops and many medical universities 
throughout Iran and their conversations and discussions with faculty members, students, 
and researchers who took part in those workshops shows that in some cases, some 
practices such as guest authorship, ghost authorship, and gift authorship are common. Of 
course, this high prevalence is mostly occurring in the literature published in Persian. 
Among the researchers who write and publish in English, research misconduct still 
occurs but with a lower rate. The reasons of this phenomenon are discussed below in this 
part of this chapter. 
In some parts of larger cities such as Tehran, some private institutions that target 
graduate students (who are obliged to publish a certain number of ISI-indexed articles for 
their graduation) advertise for selling research services, including fully-completed 
dissertations and published articles for certain amounts of money! These businesses have 
been criticized however have not been removed and continue their marketing and 
activities.323  
In one case, the Iranian party of a multinational research project was accused of 
research misconduct and their contribution was withdrawn from the published results of 
the study. This case occurred in Isfahan, a central city of Iran and in a prestigious 
research center. The problem was that the main investigators, as usual, had many 
academic and administrative jobs and duties, so the work they accepted was being done 
by a team of junior researchers with insufficient training about research integrity and 
especially with lower interest and dedication to the project and the integrity of its results. 
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Therefore, they allegedly committed data fabrication that was reported by a fired 
employee to the central team of research and they remover Iranian tem from that 
collaboration. 
Roots and Causes of the Existing Problems: With a review of the historical review 
provided above and a deep look at the related developments and their dynamisms in the 
past decades, one can explore the roots and causes for the existing problems regarding 
research integrity in Iran. This part of this part of this chapter discusses some of the most 
important ones of these roots and causes in more detail and digs deeper in the underlying 
grounds of the existing problems regarding research integrity in Iran. 
The first point is that Iran is not totally different from other countries regarding the 
causes and drives that may push the researchers and academics towards violating the 
norms and values of research integrity. These causes and drives include:   
1- The need –and sometimes- greed toward achieving higher academic ranks, 
prestige, money and power in academia.324 
2-  Interpersonal and professional rivalry and competitions that urge people to have 
more academic achievements.325 
3- The monetary or academic gain of reaching to significant results in analytical 
researches that assesse new theories or products.326 
However, there are some factors that are more relevant to the situation in Iran as 
explained below. 
Iranian academic centers rely on the number of articles published in the journals that 
are indexed in the directories of the US National Library of Medicine (PubMed) or 
Institute for Science Information (ISI) for academic ranking and promotion. Therefore, 
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each academic institution or faculty member has to have a number of articles published in 
the above journals to achieve academic status, promotion, prestige, or recognition. 
Otherwise, that person may fall to backwardness in academic rankings and competitions. 
Therefore, the faculty members and institutions (including research centers, higher 
education schools, universities, and other academic centers) feel obliged to have a 
number of such papers in their report card at the end of each year. This system, i.e. 
relying on the indexing databases such as PubMed and ISI has been extensively 
criticized. The critiques have mentioned the below weaknesses for this system of ranking 
and promotion: 
1- Some journals are being indexed in these databases/indexing systems while they 
do not have enough scientific and academic status to be used for this purpose. Some of 
these journals had been included in the list of the journals indexed by those databases, 
however before they lost their academic standards. In some cases, these journals accept 
manuscripts even with a monetary cost. This phenomenon has even led to appearance of 
some private institutions in Iran that sell the indexed and published articles to their 
student or faculty costumers! 
2- Many valuable and highly ranked academic journals, especially in certain fields 
such as healthcare ethics, are not being indexed in these databases. Therefore, a student 
or faculty member who has published an article in one of these journals will gain no or 
less credits in comparison with a colleague who has published in a very weaker journal 
that is published in an indexed journal! 
3- The credit gained by an article should not be defined and calculated just by the 
indexing status and Impact Factor of the journal in which that article is accepted or 
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published. Instead, other factors related to that article such as its scientific value, being 
innovative or ground breaking, relevance to the real problems of the country of the field 
of study have to be considered while these factors are foregone in the current system of 
academic promotion. 
On the other hand, the defenders of the current system argue that by using indexing 
sites such as PubMed and ISI, the academic authorities rely on an objective and impartial 
source for judging about the scientific value of the articles. Otherwise, if they substitute 
this system with an internal system in the ministry of health, ministry of science, 
universities, or departments, they will be alleged to being unfair and partial and may be 
influenced by the authorities or pressure groups to give unfair value/rank/score to certain 
papers or authors. Therefore, relying on those foreign-based impartial and agreed-upon 
websites is the best among the available options.  
In addition, the proponents of the current system notice that a significant group of 
the critiques and opponents of the current system are the scholars who have entered the 
academia using the rant of political power. They typically are unable to contribute in the 
current scholarly debates by authoring publishable articles. Instead, they write weak and 
worthless papers and publish them in domestic journals and websites taking advantage of 
their power and influence. Therefore, if the reliance on the objective systems of PubMed 
and ISI is removed, this group will be able to force their institutions to accept their 
worthless papers as valuable articles and basis for their academic promotion. 
The debate on whether to continue the current system of academic ranking and 
promotion or not is continuing in Iran. Even in one time the Supreme Leader warned 
about over-relying on the ISI indexing system.327 However, because of the 
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abovementioned concerns, this system has not been substituted yet. As regarded to 
research integrity, the problem with the current system is that many of the Iranian 
students, researchers, and faculties are not well prepared and trained for doing research 
and writing scholarly papers, especially in English. The causes of this unpreparedness 
include: 
1- The weakness of English language education in pre-academic and academic 
educational centers. After the revolution of 1979, the new Islamic government removed 
the foreign language programs from elementary schools and limited them in the middle 
and high schools. The weakness of English language education had several causes 
including (a) the political and ideological challenges and conflicts of the Islamic Republic 
with Western countries that caused hesitation of the educational system to promote 
Western languages; (b) the overall weakness of educational system because of the long-
lasting Iran-Iraq war and other factors that led to a struggling economical situation; and 
(c) the isolation of Iranian people from the global community and diminished 
encountering and transactions with foreign people that necessitate learning a foreign 
language. The resulted weakness of English language skills among Iranian students and 
faculty members led to (a) their overall inability or difficulty in contributing in scholarly 
debates and communicating with their colleagues from other parts of the world, and 
authoring scholarly papers in English and (b) some kinds of plagiarism in the form of 
copying the paragraphs of the previously published articles in English and substitute their 
findings (numerical values, measurements, etc.) with the original ones. Before the recent 
movements toward improving research integrity in Iran, even some well-recognized 
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scholar advised their students to use this technic for overcoming their inability in writing 
in English from the scratch. 
2-  The weakness in research skills training that begins from as early as the 
elementary school. The educational system mainly relies on memorizing the content of 
textbooks and has little room for training innovation and research. Therefore, the students 
and even faculty members who enter the academia have little previous training on 
research and research methodology. In the medical schools and during the residency 
programs, the main emphasis is on memorizing the content of textbooks and learning the 
skills, not understanding and conducting clinical trials or other kinds of research. 
However, the system expects its medical residents, PhD students, fellows, and faculty 
members to write and publish scholarly papers as to fulfill the requirements of graduation 
or promotion. This pushes them to find fast tracks and short cuts to have enough 
published articles that are indexed in the ISI to fulfill this requirement. 
The other cause of the existing problems had been the lack or scarcity of education, 
training, and regulations regarding research integrity until recently. Research ethics is a 
young filed in the world and even younger in Iran.328 The first national code for 
publication ethics was promulgated in 2009.329 Inclusion of current standards of research 
integrity on formal content of research training courses and workshops has started a few 
years before that time. Therefore, part of the reason of the cases of research misconduct 
has been the lack of enough and correct education. For example, during the author’s 
clinical residency in Shiraz University of Medical Sciences (2002-2005), it had been 
considered a standard that the dissertation is an intellectual property of the instructing 
 148 
faculty member (the director of thesis/dissertation) and s/he has the right to exclude or 
include the name of anybody in the byline of the resulted paper(s) as an author!  
The other noticeable problem is that many of faculty members hold high-ranked 
official and governmental offices at the same time. In one case, a faculty member of a 
medical university in Tehran had at least 18 other executive positions simultaneously. 
These faculty members try to keep their status in the academic race by relying on their 
students or other subordinates to write papers and include their names in the authors’ list. 
This phenomenon has sometimes leads to cases and scandals of plagiarism. 
When it comes to international research collaborations, the same factors explained 
above in this part of this chapter, cause the problems. It seems that the rate of research 
misconduct in international collaborations is lower than the one in the general research 
sector in Iran, because the researchers who are involved in international research are 
usually among the best and best trained and experienced researchers who are unlikely to 
commit research misconducts. However, in some cases factors such as the weakness of 
management and monitoring in the cases in them the high-ranked officials got the 
privilege of involvement as a partner in international research projects, such cases and 
scandals occurred.  
The Way Ahead: As mentioned above, in 2010 the Iranian Ministry of Health and 
Medical Education has promulgated a national guideline for publication ethics.330 In 
addition, many courses and workshops have been conducted to make Iranian researchers, 
students, and faculties more familiar with research integrity.331 This can be expected that 
in the predictable future the trend toward higher degrees of research integrity will keep 
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continuing in Iran, especially in more central and higher ranked institutions and 
universities that are typically engaged in International research collaborations.332 
This is also expected that after lifting the economical sanctions, more Iranian centers 
will get involved in international research collaborations. This phenomenon will result in 
importing and getting more familiar with the ethical standards of research ethics 
including research integrity as they exist and are being practiced in the developed 
countries. The funding institutions, universities, pharmaceutical companies, and other 
research partners in the developing world demand their partners from the developing 
world to observe and fulfill certain level of ethical mandates, standards, and 
requirements. This, per se, will entail some degrees of education and requirement for self-
education in this field for Iranian researchers. Therefore, it seems that having 
international collaborations, per se, will have positive impacts on research ethics and 
research integrity in the field of health-related research in Iran. Although many ethical 
problems arose during research collaborations in LMI countries in the previous decades, 
considering the awareness of research policy-makers and governing bodies in Iran, it is 
unlikely that those problems, such as exploitation of research subjects, helicopter 
research, or double standards, will be repeated in future international and multi-central 
research projects in Iran.333  
Some organizational changes can also improve the situation in the future, one of 
them being strengthening internal review systems for academic ranking and promotion to 
substitute the current system of relying on the quantity of papers indexed in the ISI. Also, 
not expecting the people who hold executive offices to publish in academic journals 
unless they had enough time to contribute as an author in producing that paper. 
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Global application of Iran’s Experience: Iran’s experience, although has local 
characteristics and specifics, has also some valuable lessons for global governance for 
research. This part explores the possibilities and limitations of using Iran’s experience at 
a global level and for improving global governance for research integrity. 
Possibilities: Growing international research partnerships is anticipated to have 
valuable effects in promoting research integrity in developing countries. Iran’s 
experience shows the higher standards of research institutions in the developed world will 
be transferred to the developing countries through research collaborations and the 
unfavorable effects such as double standards and exploitation are avoidable through 
suitable global and local governance for research.  
Research integrity can be considered as a field with mostly agreed-upon norms 
and standards among different cultures, traditions, ideologies, and political systems. 
According to the NIH, the shared values in scientific research are (1) Honesty that 
means to convey information truthfully and honoring commitments, (2) Accuracy that 
means to report findings precisely and take care to avoid errors, (3) Efficacy, that means 
to use resources wisely and avoid waste, and (4) Objectivity that means to let the facts 
speak for themselves and avoid improper bias.334 All these values can be considered 
cross-cultural and globally acceptable.  Therefore, research integrity and research ethics 
and be considered as a core and first step/chapter for compiling the ethical standards for 
global governance of heath research. 
At sum, Iran’s experience shows the importance of research integrity in 
establishing research partnerships that shape global research network and enterprise. In 
addition, it shows that how promoting globally accepted ethical standards can help local 
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and global governances in establishing and maintaining acceptable foundations and 
practices in the field of research and research integrity. 
Limitations: Using a local experience at a global scale always has some 
limitations. The specific cultural context of Iran makes some of its experiences locally 
valuable but non-generalizable to other regions. The specific characteristic of health 
system in Iran, such as the faculties holding high ranked executive offices, are not 
common in other countries, especially in the developed world. 
Also, Iran’s relative isolation during the past decades has had specific consequences, 
such as the relative scarcity of international collaborations that may not be found in many 
other parts of the world. This is possible that in future, with gradual removing the 
sanctions, the situation will change in Iran and more international partnerships will be 
possible, however, still great obstacles remain in front of realization of this development, 
at least in the near future.  
Some other specifics of Iranian universities also contribute in shaping more 
limitations. For clarifying this source of limitations, one can mention two examples as 
follow: 
(1) The leadership of universities is largely influenced by the political sector. 
Presidents of universities are appointed by the suggestion of the minister of health or 
minister of science and technology and approval of the Supreme Council for Cultural 
Revolution. Therefore, after each election that leans to change in the leadership of the 
executive branch, the presidents of universities and consequently the heads of schools 
and sometimes departments change. This instability of academic positions is a source of 
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some difficulties that do not occur in countries whose academic sector is more 
independent from the political sector. 
(2) In 1988, after the end of Iran-Iraq was, the Islamic parliament passed a 
legislation according to that, the veterans of the war and the relatives of martyrs of the 
revolution and war, bestowed with a specific quota (more than 40% of the capacity of 
universities for admission) for entering the universities.335 This legislation led to entering 
a huge number of unqualified students to the universities including medical schools.336 
Many of these students when needed to do research and prepare scholarly works, 
compensated their inability with purchasing research credit from the black market. This 
also has been a problem rarely encountered in developed countries. 
Conclusions: The main question of this part of this chapter has been: how the 
systems of Global Governance can learn from the experiences of 
collaborative/multinational research in countries like Iran for optimizing their approach to 
the issues related to research integrity? 
For answering this question, this part of this chapter first provided a conceptual 
analysis of the notion of research integrity. Then a historical review showed the main 
related historical milestones and examples. Afterwards, this part of this chapter 
introduced the concept of global governance for research integrity and explored its 
achievements and shortcomings. Then, some infamous cases are introduced and 
analyzed. In the next part, a historical review and situation analysis of research integrity 
in Iran is provided and accordingly, the roots and causes of existing problems and the 
way ahead are explored. 
 This part of this chapter concludes that: 
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(1) Expanding international research collaborations is expected to have beneficial 
effects in term of improving research integrity in developing countries such as Iran. As 
described above, the higher standards and practices of research institutions in the 
developed world will be transferred to the LMICs through research collaborations. The 
adverse effects of such collaborations such as double standards and exploitation are 
preventable through a good global and local governance of research sector.  
(2) Research integrity can be considered an agreed upon basis for developing 
globally accepted research ethics for global governance for research. In contrast with 
many other ethical topics (e.g. topics pertaining to the beginning and end of life issues), 
research integrity can be considered as a field with mostly agreed-upon norms and 
standards among different cultures, traditions, ideologies, and political systems. 
Therefore, research integrity and research ethics and also be considered as a core and 
first step/chapter for compiling the ethical standards for global governance of heath 
research. 
(3) Establishing an effective and efficient global network for health-related research 
won’t be possible without having global standards for research integrity and promoting 
and training these standards in all the countries that host centers taking part in 
multinational research projects. There are some international instruments available in this 
regard. Continuous updating and optimizing these instruments, transforming the soft rule 
into hard rule, and promoting and enforcing them in the global research network is a 




iii. HIV/AIDS Research in Africa 
In this part, the case of “the experiment of preventing vertical transmission of HIV in 
Africa” is discussed. The central concept is the problem of double standards and the 
importance of benefit sharing.  
The AIDS research was among the first that attracted a global attention to the global 
governance for research. The high costs of antiretroviral drugs lead to different debates 
about the ethics of intellectual property and patent. 337 The high costs made such drugs 
unavailable for many people who were in desperate need of such drugs. Even people of 
countries that tolerated the burdens of hosting the clinical trials that resulted in the 
creation and production of such drugs could not afford those final products while many 
people in those countries were in desperate and emergent need of them. 338 
HIV/AIDS: First reported in 1981 in the Morbidity and Mortality Weekly Report 
under the title “Pneumocystis pneumonia — Los Angeles” denoting a new infectious 
disease found in a cluster of homosexual men, human immunodeficiency virus infection 
and acquired immune deficiency syndrome (HIV/AIDS) is a disease spectrum of the 
human immune system caused by infection with HIV.339 Soon after its discovery, 
HIV/AIDS became pandemic with millions of infected people and millions of deaths all 
around the works with huge cultural, political, and economic impacts. The importance of 
HIV/AIDS in addition to the size of infected and diseased populations is originated in 
several factors including: 
1- Its perceived relevance to sexuality, especially to homosexuality, which made 
this disease a taboo in some communities and even a subject of anti-Western propaganda 
in other countries as explained below. This relevance to sexuality and sex education was 
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one of the main obstacles for the prevention of this disease in the societies in them 
speaking about sexual subjects in public, including sexual education for young people, is 
not permitted by cultural/religious authorities. Because when it is impossible to speak and 
educate about sex and sexuality, it will be impossible to provide effective education for 
preventing the sexual transmission of HIV/AIDS. Also, the resulted stigmatization and 
discrimination (from the communities, families, social partners, and even from the 
healthcare workers and political systems) against infected people, which instigates a large 
deal of ethical debates.  
2- The lack of effective treatment and 100% case-fatality rate of this disease 
which exacerbated the panic around the world and resulted sometimes in unnecessary and 
unfounded fear which acted as an obstacle in fighting this infection/disease.340 
3- The long latency period which resulted in a relatively long period (medium 10 
years) in which an apparently healthy infected person (even may be unaware of his 
infection) is able to transmit the virus to other people through sexual contact or other 
means of transmission.341 
4- Its global feature (being a pandemic that affected almost all the countries 
around the world) that makes it relevant to Global Health Governance342. During the past 
decades, treatment, prevention, and research on HIV/AIDS arose fierce ethical debates 
and challenged the existing models and frameworks of Global Heath Governance and 
Global Governance for Health Research in various technical and ethical ways. The 
lessons learned from this global experience are useful for enlightening the way ahead of 
global health governance in fighting inevitable future pandemics. 
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The pandemic of HIV/AIDS have had a huge impact on different aspects of Global 
Heath Governance. Different ethical issues arose during the past few decades when the 
pandemic of HIV/AIDS developed, affected millions of people and several countries and 
communities, and a huge deal of scientific, political, philanthropic, and economical 
activities were conducted in dealing and fighting with this deadly infection/disease. Some 
of the lessons learned from different aspects of this crisis, which are relevant to global 
health management, are discussed in this part of this dissertation. 
 Research Activities and Intellectual property: The high costs of antiretroviral 
drugs lead to different debates about the ethics of intellectual property and patent. The 
high costs made such drugs unavailable for many people who were in desperate need to 
such drugs. Even people of countries that suffered the burden of clinical trials ended to 
production of such drugs could not afford those final products while many people in 
those countries were in desperate and emergent need to them.343  
 The high costs of medicines and allegedly unfair profit margin of pharmaceutical 
industry has always been a subject of fierce debates. The so-called HIV/AIDS activism 
was a social movement appeared in reaction and response to uncovering of such ethical 
shortcomings and aimed to protection the community and HIV/AIDS patients.344 
 The pandemic of HIV/AIDS alongside with globalization of biomedical research 
industry added to the heat and extent of this debate. It has been argued that the scandals 
resulted from uncovering the unethical behavior of biomedical research enterprise in 
relation to HIV/AIDS has been one of the major causes behind the last paradigm shift in 
research overview at least in the United States of America. This paradigm shift led to 
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more emphasis on the very concept of “collaborative partnership”. Thank means more 
involvement of communities is designing of research and setting research goals.345 
As a matter of fact, collaborative partnership as far as it is related to the subject of 
ethics in international biomedical research, can be red under the abovementioned 
principles of the UNESCO Universal Declaration on Bioethics and Human Rights, 
especially respect for cultural diversity and pluralism346. Other principles, also, are 
relevant to this issue like equality, justice, and equity; solidarity and cooperation; Social 
responsibility and health; and Sharing of benefits.347 
 Bilateralism vs. Multilateralism: Both multilateral and bilateral programs have 
been efficient in combating the pandemic of HIV/AIDS. Some examples of multilateral 
programs/institutions are as follow: (1) WHO (that is supposed to assume the leading 
role); (2) World Bank (in recent decades became a major role player in funding health-
related programs); and (3) The Joint United Nations Program on HIV/AIDS 
(UNAIDS).348 
 UNAIDS, itself, is cosponsored by several international/multilateral 
organizations. Looking at the list of these organizations reveals the very multilateral 
nature of this program. These cosponsoring organizations are as follow: (1) United 
Nations Children’s Fund (UNICEF), (2) World Food Program (WFP), (3) United Nations 
Development Program (UNDP), (4) United Nations Population Fund (UNFPA), (5) 
UNESCO, (6) WHO, (7) World Bank, (8) United Nations Office on Drugs and Crimes 
(UNODC), and (9) International Labor Organization (ILO).349 
Bilateral programs, however, are formed and conducted by an agreement between a 
powerful/wealthy nation state and a country or a group of countries in need. When it 
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comes to HIV/AIDS the most influential bilateral program has been the US 
Government’s Global Health Initiative (previously the President’s Emergency Plan for 
AIDS Relief or PEPFAR).350 As mentioned above, bilateral programs, although 
sometimes successful and efficient, potentially weaken the role of IOs, in this case WHO, 
in leading international efforts against pandemics and other heath crises. This weakening 
may also become extended to ethical principles and norms of global bioethics, which 
guaranties pluralism as the source of trust and ethical infrastructure for global health 
interventions. 
 Politics, religion, and medicine: Respect for cultural diversity is one of the 
ethical principles, which guide global health governance, and is a separable part of its 
obligation to plurality.351 As a sexually transmitted infection/disease, the prevention and 
control of HIV/AIDS in communities, inevitably faces with cultural/religious 
conventions, beliefs, taboos, and dogmas, especially in developing countries. To be 
effective, Global Governance for Health Research has to find a way for dealing with such 
obstacles. A way, which takes advantage of potentially useful cultural features, like 
avoiding extramarital high-risk sexual behaviors, and at the same time get rid of obstacles 
resulted by other sets of such features like resistance against sexual education especially 
for women and young adults, resistance against availability of preventive measures like 
condom, stigmatization and discrimination against certain groups like patients and 
homosexual/transsexual persons. 
In some countries such as in Islamic Republic of Iran, The governmental media 
took advantage from the information about HIV/AIDS outbreak, which was firstly 
discovered in Western countries and among homosexual males, to claim that this 
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outbreak is a result of non-obedience to moral norms in Western countries.352 
Consequently, for many years, some high-ranked officials of the Ministry of Health 
ignored the need to taking preventive measures, including proper education, in the 
country claiming that this disease is pertaining to immoral Western countries and has 
nothing to do with the people of Islamic Republic. This resistance and ignorance replaced 
by an expensive program for controlling HIV/AIDS after the government realized that 
this disease was spreading with a fast pace in the country353. Even now, however, the 
resistance of the Islamic government and religious leaders against taking some proposed 
preventive measures like sex education in schools and easy availability of condom for 
young and unmarried people is part of the reality behind the rising prevalence of this 
disease in Iran.354 
An Infamous Case in Africa: One of the paradigm cases of global research ethics 
that has been very influential in shaping the ethical frameworks for Global Governance 
for Health Research has been the trial on preventing vertical transmission of HIV virus in 
Africa. This case drew a large deal of attention and raised ethical concerns on the 
research in developing countries. Issues such as exploitation and double standards and 
benefit sharing were discussed seriously after revelation of the ethical concerns of this 
study. 
The effect of oral use of zidovudine in prevention vertical transmission (i.e. 
transmission of virus from pregnant mother to her future child) was shown in clinical 
trials in the United States in 1994. Afterwards, the US Public Health Service 
recommended a regimen containing zidovudine as the standard treatment for pregnant 
women in the United States. However, the recommended dosage was not affordable for 
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most affected people in developing countries. Afterwards, several research projects, 
including 15 placebo-controlled clinical trials were conducted in developing countries, 
mostly in Africa, most of them funded by US funding bodies and assessing the effects of 
prescribing lower doses of zidovudine (in some cases, combined with other medications) 
for pregnant women in preventing the vertical transmission of HIV virus. Two major 
ethical questions were raised concerning these trials: (1) were these trials ethical? In other 
words, is this ethical to examine a lower than effective dose of a vital medication, while 
its efficacy is proven in higher doses, just for financial reasons? (2) Was it ethical to have 
placebo arms in these trials?355 
The major ethical concern was that whether the research subjects of these trials and 
their communities were exploited because of their contextual poverty? Does the poverty 
as a contextual factor can be ethically relevant in deciding to examine a lower-than-
effective dose or having a placebo arm with this justification that these subjects, if not 
recruited in research, had no access to the standard treatment (the full or even reduced 
dose of the medication that was proven as standard treatment in JICs)?356 
This case raises the challenges of double standards and exploitation and can be 
discussed in the light op principles of human dignity, justice and equity, non-maleficence, 
and non-discrimination. 
iv. Sending Biological Specimens Abroad 
Bioethical and Biopolitical Concerns: This part of this chapter deals with the 
problem of real and imaginary threats and their implications on research policy and 
research ethics. Research on samples derived from human body and other living 
organisms (biological samples) and transporting these samples through international 
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research collaborations has raised its specific ethical concerns. Since the exchange of 
biological specimens is a frequent and integral part of global research collaborations, the 
challenges associated with this issue is relevant to Global Governance for Health 
Research. 
This part of this chapter describes the bioethical and biopolitical challenges of 
sending biological specimens abroad under two main topics: the biopolitical concerns 
regarding possible genome mapping and the ethical/economical concerns (can be called 
bioeconomical concerns) regarding commercial benefits and patents produced by the 
specimens collected freely from developing countries, the problem that has been also 
discussed under the title of biopiracy.  
Biopolitics of Biological Specimens: In some countries, including Russian 
Federation and Iran, there have been some concerns about sending biological specimens 
with human origin that are containing DNA to other countries, especially the Western 
countries. It is argued that the information that is potentially obtainable from such DNA-
containing samples may include sensitive information about the biological characteristics 
of the people living in those countries that may be used even in producing weapons that 
target that people in a specific way. In addition, in countries with racial/ethnic tensions 
such as Iran, the local authorities are sensitive about research on racial/ethnic issues, such 
as the origin of local ethnic groups. For example, in Iran, governmental authorities 
including the research officials in the ministry of health are suspicious about any research 
activity trying to attribute the origin of ethnic groups who live within the national borders 
of Iran to other countries. 
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The question is that to what extent these sensitivities are realistic and based on real 
existing threats in the real world and to what extent they are just imaginary threats raised 
from their over-suspiciousness towards the Western world? Although no reliable answer 
can be found for this question in the available literature, the sure thing is that with 
escalating the tensions among countries and hostile rhetoric from the both sides, this kind 
of mutual suspiciousness will persist and will act as an obstacle for the research 
enterprise. Therefore, this can be considered as a biopolitical issue that makes challenges 
for research and as the interface of biopolitics and Global Governance for Health 
Research. Although the ultimate solutions of these problems are mainly beyond the scope 
of bioethics or Global Governance for Health Research, creating and adopting reliable 
and consensual international guidelines in this regard can be useful to promote trust and 
facilitate international research collaborations hat entail exchange of biological 
specimens.  
On the other hand, it can be argued that the biological samples are a part of common 
heritage of mankind and cannot be restrained for political reasons or patented for 
commercial purposes. This argument can be used to suggest a free and uncontrolled 
network of sample sharing for non-profit research purposes. This suggestion, although 
looks humane and remarkable, seems to be far from practicality in the current political 
and commercial atmosphere of the world. 
Bio-economics of Biological Specimens or Bio-piracy: In the recent decades, it has 
been argued that the companies and research enterprise of developed countries use the 
natural and genetic resources of developing countries and less powerful communities 
(e.g. tribes and indigenous people) to make products that are beneficial for the companies 
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and researchers while the communities that provide the natural resources do not have a 
share of this benefit.357 This practice is a violation of the principle of benefit-sharing.358It 
has been claimed that using the natural resources and knowledge of indigenous 
communities and developing countries without benefit-sharing is a sort of colonialism 
and can be called bio-piracy. A term coined in the 1990s that became popular in the 
relevant discourse afterwards.359   
The result of these debates and arguments was the adoption of The Nagoya Protocol 
on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising 
from their Utilization to the Convention on Biological Diversity by 92 UN Member States 
and the European Union. This protocol was a by-product of the Convention on Biological 
Diversity and was ratified in Nagoya, Japan, therefore it is also known as the Nagoya 
Protocol on Access and Benefit Sharing (ABS). 360  This protocol is a supplement added 
in 2010 to the 1992 Convention on Biological Diversity (CBD) and came fully into force 
in October 2015 in the form of a treaty. This protocol mandates that any company that 
uses genetic resources obtained from each of the countries signed this protocol, must 
have a contract that ensures benefit sharing. Research-related benefits are included.361  
Although the arguments demanding benefit-sharing have been very strong and even 
named using the natural resources without adequately benefit-sharing as bio-piracy,362 as 
a counterargument, it has been claimed that the insistence on benefiting the source 
countries from exporting biological specimens may cause delay in producing or 
inadequacy in coverage of vital medications. For example, each year, the seasonal 
influenza vaccine is produced based on the prevalent strains of influenza virus of that 
year determined by a panel of experts that meet twice a year (once ahead of each 
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hemisphere’s winter) through a process conducted by the WHO’s Global Influenza 
Surveillance and Response System (GISRS). Then, the pharmaceutical companies have 
to produce vaccines against the specified strains and for this purpose they need the 
biological samples from all over the world. If some countries refrain to deliver the 
samples or put unreasonable price tags on them or require long negotiations to reach the 
benefit-sharing agreements, this may undermine the efficiency, timeliness, and coverage 
of the new vaccines. This problem will cause risk and harm to public health at least in 
some parts of the world.363 
Conclusions: Sending biological specimens abroad and the arguments, discussions, 
and controversies around this issue is another good example of the ethical challenges 
ahead of Global Governance for Health Research. It seems that there are not enough 
reliable and consensual international guidelines in this regard available to the countries 
that express concern on political or military misuses of biological specimens. In addition, 
the attempts for safeguarding the fair share of the source countries and communities, such 
ad the Nagoya Protocol have had adverse implications in timely and effective production 
of vaccines. In the case of sending biological specimens abroad, in addition to explaining 
the com the complex and complicated nature of the existing issues, the principles of 
benefit sharing along with solidarity and attention to the concept of common heritage of 
mankind have been used to provide an ethical framework that has been helpful in 
approaching and solving this challenge and its related problems. 
v. Research on pre-implantation human embryo 
The ethical status of human embryo from the time of conception until its implantation 
in the womb has been among the most controversial topics in the field of biomedical 
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ethics during the past decades.364 In this phase, the human embryo can be called Pre-
Implantation Human Embryo (PIHE). Various interventions with various purposes, 
including research, treatment, and enhancement can be done on the PIHE.365 In some 
cases, these interventions cause damage, change genetic make-up, or destroy the PIHE. 
Are these interventions ethically permissible?  The answer to this question depends on 
one’s perspective toward ethical status of the PIHE.  
The ethical debate on the ethical status of the PIHE is a relatively new and modern 
one. For many centuries, these phases of human life have been out of reach of scientists 
and physicians. Although abortion has always been an uptight subject of moral debate, 
nobody could isolate, create, or manipulate a PIHE; therefore, the artificial creation or in 
vitro destruction of human embryo has been out of scope of such debates.  
In the recent decades, the technology if In Vitro Fertilization (IVF) made it possible 
for scientists to conduct the fertilization of human gametes and produce human embryos 
in their labs.366 This new technology opened the black box for human fertilization and 
made the PIHE exposed and vulnerable to experimental interventions and manipulations, 
the most notable among them being stem cell research and human cloning (see below). 
Now, human being has the power of –even mass- production, manipulation, destruction, 
and transformation of some of their own in the very earliest stages of their lives.367 
As described below, different religions and moral schools have different views on 
ethical status of the PIHE. At one end, some ethical schools totally condemn producing or 
killing the PIHE in the laboratory. On the other end, there are some who consider the 
PIHEs as a commodity at full disposal of their owners.  
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In the contemporary globalized world, where such technologies, their usage, and their 
consequences cannot be confined within national borders. The people created by these 
technologies move to other countries and jurisdictions and take the concerns on their 
identity with themselves; human embryos also can be transferred across the national 
border; and people who are in desperate need to treatments provided by such research, 
also, can move across national borders to find allowing jurisdictions and willing 
providers.368 Each ethical or legal approach to this subject potentially had global 
consequences. Therefore, research on PIHE is also a subject for Global Governance for 
Health Research. 
This part of this chapter is composed of three main parts. The first part provides a 
brief review of scientific facts about research on PIHE. This is necessary to introduce the 
subject of this ethical analysis, show its importance, and portray the areas of ethical 
concerns. Then, the second part provides a portrait of ethical perspectives and concerns 
of three main ethical schools of thoughts regarding this subject. This part shows that there 
are some significant, well justifies, and almost globally consensual concerns and ethical 
principles/norms regarding research on early human embryo that can be used as the basis 
of the ethical framework for Global Governance for Health Research on early human 
embryo. The third part examines this subject and its ethical controversies in the global 
scale and on the global scene.  This part shows that there are unaddressed ethical 
concerns and gaps in this regard that need global attention in terms of legislation and 
enforcement. In other words, research on PIHE needs a global ethical framework. This 
global ethical framework should be developed, adopted, and implemented by Global 
Governance for Health Research. 
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At the end, this part of this chapter argues that: (1) there seems to be a global 
consensus on the principle of respect for human embryonic life. Therefore, some 
implications of this principle such as refraining of producing human embryo just for 
research purposes can be considered as globally accepted standards of practice. These 
standards can be delineated and enforced as parts of global governance for research on 
PIHE, and (2) for preventing the noteworthy harmful consequences of unleashed and 
uncontrolled exploitation of human embryos, the existing soft international laws are not 
sufficient and there is a need to hard laws that protect early human life from destruction 
and exploitation. 
Genetic Research on PIHE: As explained above, the reason behind arising the 
furious debates and controversies on the ethical status of PIHE in the previous decades 
has been the scientific and technological advances that made it possible for scientists to 
produce in vitro embryos and use them for research purposes. Among these research 
purposes, the most notable ones have been stem cell research and cloning.  
Human reproductive cloning has never been attempted or ethically approved, at least 
to the public and available knowledge.369 Research/therapeutic cloning has not been 
successful on providing real treatments yet, however, is a promising field of research.370 
Stem cell research, however, with use of embryonic cells that destroys PIHEs has been 
developed, and has raised many promises and hopes for finding cure for some serious and 
untreated health problems.  
In this part of this chapter, a concise description is provided on the scientific aspects 
of these technologies, their status quo, and their foreseeable future or futurology. This 
scientific review is useful to grasp a broad perspective of the realities in the field. This 
 168 
perspective/knowledge is necessary for discussing the ethical importance, implications, 
and controversies in this field.  
A Scientific Review: Stem Cell Research and Cloning: Stem cell research is a 
promising and expanding field of research in genetics and medicine that has opened 
doors to new hopes for finding treatments for a group of currently incurable diseases such 
as Parkinson’s disease or Degenerative Heart Failure.371  
There are two main sources for stem cells: Adult cells and Embryonic Cells. Adult 
stem cells can generate replacements for the cells and tissues that are lost through injury, 
disease or normal wear and tear.  Adult stem cells are also called somatic stem cells. 
Adult stem cells usually develop into the same type of cell as the tissue from which they 
have been extracted.  For instance, Stem cells found in muscle tissue normally give rise 
to new muscle cells. Embryonic stem cells, however, are “starter cells” that can be 
directed into becoming any of the specialized cells of the body. That’s why the 
embryonic stem cells are called “pluripotent.” Embryonic stem cells are derived from 
human embryos that have been created in the laboratory, not in a woman’s body. A new 
achievement in the field, however, is creation of what are called “Induced-pluripotent 
stem cells” that are adult stem cells that have been genetically manipulated to behave like 
embryonic stem cells. At present, they serve a valuable role in research and drug 
testing.372 
Creating and using embryonic stem cells through in vitro fertilization and then 
destroying the PIHEs for retrieving stem cells has been the subject of many controversies 
as it is apparent in the history of banns and then permissions on such research in the past 
decades in the United States.373 The invention of Induced-pluripotent stem cells is a 
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promising stem toward abandoning the use of human embryos for harvesting stem cells. 
However, the potential of Induced-pluripotent stem cells for replacing human embryonic 
stem cells is still a subject of research and uncertainty.374  
In addition to developed countries those have always been pioneers in advanced 
scientific and technological developments, some developing countries have also taken 
noteworthy steps in these fields. For example, Iran has been one of the pioneers in the 
field of stem cell research. This was partly because of flexibility of the religious 
authorities in permitting such research as described below.375 
Futurology: Humane Genetics or a New Brave World: Scientific and 
technological advances in the field of human genetics have always raised concerns on the 
potential endangerment of human life or values by them.  There have always been deep 
concerns about the legitimate and ethical boundaries of human science and technology 
that distinct humane achievements from building a “Brave New World”.376  
As describe above, stem cell research and cloning have been very promising for 
finding cures for a group of most debilitating and fatal human conditions such as 
degenerative and congenital diseases. On the other hand, creating, using, manipulation, 
and destroying PIHEs for this purpose have been subject of furious criticisms, especially 
from the religious and prolife perspectives.377  
Although Induced pluripotent stem cells have created a promising perspective of 
abandoning the use of human embryos for harvesting stem cells, the potential of Induced-
pluripotent stem cells for replacing human embryonic stem cells is still a subject of 
research and uncertainty.378 Therefore, it seems that in the foreseeable future, the 
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scientists will need and keep using the PIHE for research purposes that will be a source of 
ethical controversies about the moral status and inviolability of early human life. 379  
In addition, because of globalization, international and multicenter research projects 
on PIHE are growing in number and quantity.380  This means that in the era of 
globalization, they embryos that are created in one country and jurisdiction can be 
transported and used on other countries or jurisdictions. This makes the governance of 
such research a subject of global governance for biomedical research. These facts 
necessitate the existence of an overarching law to regulate this enterprise and prevent 
violation of human dignity and the sanctity of early human life.381 
Ethical Status and Protection of PIHE in Genetic Research: In this part, a 
perspective is provided toward the current viewpoints on the ethical status of the early 
human embryo. For this purpose, three of the main and most influential ethical 
accounts/schools in the contemporary world that have distinct and leading perspectives 
toward this subject have been selected and discussed. These three schools are: 
Secularism, Catholicism, and Islam. 
Secularism is the basis for legislation in developed countries, also is the basis of 
international and cross-cultural legislations.382 An international consensus or legislation, 
which is needed in global governance, should be based on secular reasoning.383 
Therefore, this is important to shed light on this perspective toward ethical status of 
embryonic human life. 
Catholicism is also a very influential school of thoughts, especially when it comes to 
protecting the dignity and sanctity of early human life. 384 The formal position of the 
Catholic Church toward in vitro fertilization (IVF) and research on PIHE has been very 
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influential and controversial at the same time.385 It seems that Catholicism has adopted 
the most conservative approach in defending the ethical status of PIHE; therefore, this 
perspective should be included in any review of current influential and important 
perspectives toward the ethical status of human embryo. 
Covering at least 10% of all Muslims in the world and making the second largest 
bough of Islam (After the Sunni branch), the Shiite branch of Islam has its own 
theological, jurisprudential and ethical schools. Among the Islamic countries, Iran, Iraq, 
Azerbaijan, Lebanon and Bahrain are Shiite majority ones. In all the aforementioned 
countries, Shiite jurisprudence and ethics have a great influence on life style of large 
groups of people, including their decisions about child bearing, using assisted 
reproduction technologies, or abortion. In Iran, according to the constitution, all the rules 
and regulation should be in accordance with Shiite jurisprudence.386 Therefore, the Shiite 
perspective towards such important issue as the moral status of early human embryo, not 
only is important as a noteworthy part of religious ethics, but also deserves attention 
because of its great impact on some vital aspects of lives of more than 200 million people 
in the world.387 
Considering the above facts and reasons, in this part of this paper, a review is 
provided of the perspectives of these influential schools of thoughts, namely Islam, 
Catholicism, and Secularism, toward the ethical status of PIHE. This critical review is 
necessary for establishing sound theoretical grounds for global governance for research 
on the early human embryo. 
Secular Perspectives: According to the secular perspectives, in ethical assessment of 
using human embryos for stem cell research, two ethical duties come into conflict: (1) 
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The duty to prevent or alleviate suffering and (2) The duty to respect the value of human 
life.388 Both of these duties are cross-cultural and can be considered secular and prima-
facie. Therefore, the main ethical challenges in front of secular bioethics in dealing with 
stem cell research on PIHE is weighing these two duties and compare them in the case of 
PIHE.389 
For providing a sound answer for the above question, secular bioethics has to 
determine the ethical status/value of the PIHE. A wide variety of viewpoints in this 
regard can be defended by secular reasoning, varying from bestowing full ethical status to 
a fertilized egg to postponing ethical status to even after birth. However, when it comes 
to collective –international or domestic – agreements in secular societies, it seems that 
human life in its first 14 days is considered valuable, but not as full human life with 
ethical status. Therefore, they incline to permit use of human embryos for valuable and 
scientifically sound purposes, but restrict this use to surplus embryos remained after In-
Vitro Fertilization (IVF) procedures.390 
The secular perspective to the ethical status of human embryo has also been reflected 
in international soft and hard regulations that have been discussed in a later part of this 
part of this chapter (see below). 
Catholic Perspectives: Catholicism is the largest one, in the size of population, 
among the denominations of Christianity391.  In dealing with bioethical debates and 
issues, Catholicism mostly relies on the discipline of theology392. Therefore, the moral 
debates and deliberations in Catholic bioethics are based on reasoning rather than only 
the Holy Scripture393.  
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Catholic ethics relies on the concept of natural law394. According to the theory of 
natural law, human beings are able to differentiate between right and wrong, morally 
speaking. They do so by appealing to their reason and life experience, either individual or 
collective, because God has created them and the universe in a way that makes it 
possible.395 In its normative meaning, however, the theory of natural law infers that there 
are some acts, which are against nature (contra naturam). Accordingly, these acts are 
intrinsically evil. This concept of being intrinsically evil is an important concept in the 
approach of Catholic bioethics toward practical issues like terminating an early human 
life.396 
According to the Catholic perspective, the human being is created in the image of 
God. This is the very basis of human dignity and sanctity of life in Catholicism. The 
human person ordered to God by grace and alienated from God by sin. However this is 
about their conscious life. The human early life, or the PIHE has not gotten the chance of 
choosing between grace and sin. This person. However, is protected by human dignity 
and sanctity of life because he or she is created in the image of God.397  This is the basis 
of the sometimes controversial positions of the Catholic Church is safeguarding the early 
human life and considering it as eually dignified as other stages of human life.398 
In the Catholic perspective, human embryo is bestowed by ethical status or 
personhood from the very moment of the infusion of soul into its body. However, no 
official Catholic Church document specifies an exact age or developmental phase of 
human embryo as the time of ensoulment. This uncertainty, however, has led to adopting 
a position that covers all the probable times of ensoulment. In the other words, 
considering that from the time of conception, the human embryo, even if pre-implanted 
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and pre-differentiated, constitutes human life and is ready and capable for accepting a 
human soul, therefore, according to the official Catholic Church documents, should be 
treated as if it has ethical status and personhood. 399 
The position of Catholic Church on the ethical status of PIHE is based on church 
doctrine and its interpretation of scientific facts. According to this interpretation, the early 
human embryo is the earliest form of human life and should be protected by dignity and 
sanctity of life. The validity of such interpretation, considering the developing nature of 
current knowledge on human embryo and the existing findings, has also been a subject of 
controversy and criticism.400 
Although there are some alternative perspectives among Catholic scholars and some 
of them argue that the ethical status and personhood starts at the later phases of 
embryonic life, the official position of Catholic Church is still based on bestowing full 
ethical status and personhood to human embryo from the time of conception.401  
Islamic Perspectives:  
Early Human Embryo (Nutfah) in the Holy Qur’an: The term “Nutfah” by which the 
semen and early human embryo have been named in the most Islamic classical texts and 
scriptures, has been repeated 12 times in Holy Qur’an. In some verses, the consecutive 
stages of embryonic and fetal development are described. For example: 
“We created the human from an essence of clay. Then we made him, a drop (Nutfah), 
in a secure receptacle (the womb). Then we created of the drop, a clot (of congealed 
blood) and we created the clot into bite size tissue, then we created the bite size tissue 
into bones, then we clothed the bones with flesh, and then produced it another creation. 
Blessed is Allah, the best of creators”!402   
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And: … and that it is he who created pairs, the male and the female, from an 
ejaculated drop (Nutfah) and that upon him is the second creation.403 
Obviously, the term used for referring to early human embryo in the Holy Qur’an and 
Islamic Holy Scripture is Nutfah. Other terms, like Alghah (the clot) and Muzghah 
(tissue) that represent the subsequent stages of fetal development, are not covered by this 
part of this chapter. 
According to Holy Qur’an, Nutfah is the very first stage of development of an 
embryo. Whether it is attributed to: (a) the sperm (male gamete) which continues to form 
an early embryo in the womb (the traditional understanding of embryonic development); 
Or (b) just to the result of conception which develops in the womb after fertilizing an egg 
by a sperm (the modern understanding of embryonic development), is not very clear in 
the verses themselves. However, the commentators, based on their understanding of 
embryology, have read the text differently.   
In some verses, the former interpretation is more obvious, for example: 
…was he not a drop of fluid which gushed forth?404 
While, the proponents of the latter interpretation, refer to the verses which denote a 
“mixed Nutfah” as the very first stage of embryonic development, for example:  
Indeed, there came upon the human a period of time when he was an unremembered 
thing. We have created the human from a drop (Nutfah), a mixture, testing him; we made 
him to hear and see.405 
As a matter of fact, in describing natural issues – from the human body to astronomic 
facts – Qur’an never obviously contradicts the knowledge of the era in which the Prophet 
lived. Therefore, the commentators of Qur’an, before the modern era, never understood 
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the Qur’anic verses describing the growth and development of fetus in contradiction with 
the Aristotle’s or Galen’s descriptions of early human life. Accordingly they did not 
consider any difference between semen and the early human embryo (before 40th day).  
Even now, some commentators and jurists utilize this word with ambiguity. Some 
others, however, clearly recognize the findings of modern science, which show the very 
difference between sperm (the male gamete) and early embryo (the result of conception 
in which a male and a female gamete are combined to form a zygote and then the zygote 
multiplies to form the embryo).406  
The Importance of Implantation: In their assessment of the tort committed against the 
fetus, jurists have regarded implantation of the Nutfah in the uterus as the beginning point 
of the sacred embryonic life beyond which any infliction of harm to it requires 
compensation (Diah). Before implantation, destroying the Nutfah without any justifiable 
reason is considered as wrong, but, according to the majority of Shiite scholars, no 
monetary compensation has been considered for it. The monetary compensation gets 
higher with growth of the embryo and fetus and reaches its maximum level after 120 days 
which is the very point of ensoulment.407 
Ensoulment and its Implications: As mentioned above, the later phases of fetal 
development, including the one in which ensoulment takes place- is beyond the scope of 
this part of this chapter. However, because of the important implications of this event on 
the ethical and legal status of human fetus, it is worth mentioning, albeit briefly. 
According to Muslim jurists, including the Shiite ones, ensoulment, which is the 
breathing of divine soul into the human body, takes place after 120 days of embryonic 
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life after implantation. It does not mean that this is the exact time of ensoulmant, but it 
means that ensoulment never takes place before 120 days after implantation. 
After the very point of ensoulment, the human fetus is considered as a human person 
entitled to all moral and legal advantages attached to personhood. Before this point, 
however, the human embryo or fetus (including early human embryo) is not considered 
as a human person entitled of all legal and ethical rights. Accordingly, killing the human 
embryo or fetus before ensoulment is forbidden but is permissible under certain 
circumstances. After ensoulment, however, the fetus is considered as an inviolable human 
person.  
Controversies on Withdrawal: It has been claimed that withdrawal (the pull out 
method for contraception) is the oldest contraceptive method used by human being. In 
Shiite jurisprudential scriptures, the legitimacy of this method, which is named Azl, has 
been discussed and different opinions have been expressed. According to the traditional 
understanding of the very meaning of the term Nutfah, this method is a kind of wasting 
Nutfah. Although today we know that during withdrawal it is only semen, not embryo, 
which is wasted, but Muslim scholars, at least until recent scientific discoveries showed 
the difference between semen and embryo, considered the semen as the very beginning 
stage of human development (i.e. Nutfah).  
Reviewing the above- mentioned discussions can shed light on the ethical status of 
early human embryo in Shiite jurisprudence. Some Shiite scholars consider Azl as 
permissible and plausible, provided the consent of wife has been obtained. They refer to 
the Sunnah in which Prophet and Imams considered Azl as permissible. Some of them 
consider it as permissible even without informing the wife. 
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Other scholars, however, consider Azl as forbidden, as they mostly argued that the 
purpose of marriage is child bearing and avoid bringing a baby is unacceptable for a 
Muslim couple. Also they refer to the part of Sunnah whose documentation is less valid 
than the part, which permits Azl. Accordingly, we can conclude that both the proponents 
and opponents of this method did not consider any ethical status for Nutfah before 
entering the womb. 
Pre-Implantation Embryo: Bearing in mind that no monetary compensation (Diah) is 
considered for destroying pre-implantation embryo, it seems that there is no ethical 
relevance and worth for such embryos. Some contraceptive methods like intrauterine 
device (IUD), which prevents implantation thus destroys the early embryo, have been 
approved by religious authorities and used widely in contraception clinics in Iran.  Most 
Shiite scholars, however, consider this stage of embryonic life as respectful which means 
that it should not be wasted or destroyed without having a justifying reason. Medical 
research and health-related interventions such as contraception or infertility treatment are 
among such reasons. 
In 2003, Iran was the first Muslim country that adopted an act on embryo donation, as 
a treatment for infertile couples. The act of embryo donation to infertile couples states 
that the surplus early human embryos, produced by IVF for a legally married couple, can 
be transferred to the womb of the recipient. This legislation paved the way for numerous 
infertility clinics in Iran to use this technology, however, raised major ethical concerns 
that is discussed elsewhere.408 
As a matter of fact, almost all Shiite religious authorities and scholars, accepted in 
vitro fertilization (IVF) as a permissible and legitimate mean for treating infertility. Also, 
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they permitted scientists to conduct stem cell research involving destruction of human 
embryo, with the purpose of finding new treatments for fatal or chronic diseases. 
Regarding human embryonic stem cell research, Shiite authorities issued Fatwas and 
declared it as permitted and legitimate.409  
Moreover, mostly influenced by the guideline developed in the Western world, the 
Iranian National Guideline for Research on Human Gamete and Embryo requires 
researchers to perform research only on surplus embryos remaining after infertility 
treatment and forbids producing human embryos just for research purposes.410 
This chapter is inclined to conclude that according to the dominant reading of Shiite 
jurisprudence, early human embryo, before implantation, does not have any ethical value 
and can be utilized, manipulated or destructed for justified medical purposes. The ethical 
value of human embryo is considered and talked about whenever implantation takes 
place. 
Global Governance and Genetic Research on PIHE: As mentioned in the previous 
chapters of this dissertation, the Global Governance for Health Research has mainly took 
place and been mirrored in the following ways: First, the international declarations, 
codes, and guidelines developed for setting global ethical standards for health-related 
research; second, the national rules and regulations made by the countries that host the 
main funding bodies and institutions on international research; and third, the internal 
regulations, standards, and guidelines of the various sorts of organizations that fund 
international research.411 In the following parts the approach of global heath governance 
toward research on human embryo is discussed. First, as an important and integral part of 
global governance, the related international legislations and guidelines are discussed. 
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Then, the existing ethical problems and gaps are introduced and at the final part, the 
possible and practical ways toward an ethical consensus are depicted. 
International Legislations and Guidelines: The most well-known and influential 
international declaration on biomedical research that can be called as the cornerstone of 
global governance for biomedical research is the World Medical Association's 
Declaration of Helsinki. The principles of the Declaration of Helsinki will apply to all 
clinical research in respect to human embryo, including PIHE, as well as all problems 
that arise out of such clinical research. The World Medical Association recommends that 
physicians refrain from intervening in the reproduction process for the purpose of making 
a choice as to the child’s sex, unless it is to avoid the transmission of serious sex-linked 
disease. Also, the World Medical Association expressly condemns any 
commercialization by which ova, sperm, or embryo is offered for purchase or sale.412 
In 2005, the United Nations (UN) approved a Declaration on Human Cloning that 
urged member states to ban all forms of cloning, including therapeutic cloning.413 In the 
same year, the UNESCO Universal Declaration on Bioethics and Human Rights was 
approved and promulgated by UNESCO.414 The perspectives of George W. Bush 
administration influenced the UN Declaration on Human Cloning, therefore, this 
declaration entailed a total ban on human cloning even for research purposes.415 The 
UNESCO Universal Declaration on Bioethics and Human Rights, however, does not 
explicitly mention early human life, but some of its principles/articles are applicable to 
this subject. These articles are as follow:  
(1) human dignity that includes protecting human embryo regardless of considering it 
as person or not.416 The principle of human dignity is the cornerstone of the theories that 
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support the inviolability of early human life. This concept is very important in both 
secular and religious schools of thoughts.417  
(2) Respect for Human Vulnerability and Personal Integrity that covers early human 
life according to Catholicism.418 The PIHE can be considered among the vulnerable 
entities that need legal support and protection.419  
(3) Protecting Future Generations, in a broader understanding of this principle, is also 
applicable to this debate.420 Early human embryo is the very beginning of the next 
generation. Therefore, protecting the future generations implies protecting and 
safeguarding the early human life and the PIHE.421 
The Existing Problems and Gaps:  From what explained in this part of this chapter, 
one can conclude that despite the great achievements and promises in the field of research 
on PIHE, there are some ethical problems and legislative gaps than need the attention of 
Global Governance for Health Research. These problems and gaps are as follow:  
(1) The need to explicit inclusion of the rights of early human life in the international 
declarations and legislations in the way that the ethical norms on them there is a global 
consensus (such as forbidding production of human embryos for research purposes) be 
included in these instruments. An explicit recognition of the ethical status of early human 
life is a necessity for establishing sound ethical grounds for legislations that will protect 
early human life through the global health governance.422  The international organization 
such as the WMA, WHO, and international treaties can shape the organizational 
backbone and support for these legislations.423 
  (2) The need to protection early human life by enforcing the related regulations 
on the global scene. The organizational backbone of global health governance (see 
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above) should be in charge of enforcing the legislations that protect the early human 
life.424 Enforcing the legislation through the mechanisms and power relations within the 
global heath governance is complicated because in goes beyond and across the authority 
of sovereign states.425  Therefore, there is a real need to establishing global and 
international organizational background to support and enforce the related legislation on 
the global scene.426  
The Way towards an Ethical Consensus: Despite the existing conflicts and 
disagreements among the main schools of ethical thoughts regarding the ethical status of 
PIHE, as described above, there are some norms that can be considered as the area on 
consensus among all these major schools. For example, all of these schools are in favor 
of banning of production of human embryo for research purposes. This common area can 
be used as a common ground and first step for establishing consensus on broader 
concepts, also consents on creation global instruments (soft or hard international law) to 
protect early human life as a function of global health governance. 
  Moving toward legislation and enforcement in this area is one of the main 
functions of global health governance.427 Research enterprise has always been one of the 
concerns of global health governance.428 The areas of consensus among the major schools 
of thoughts have always shaped the bases for developing such soft and hard 
legislations.429 
  For this purpose, interfaith dialogue can be used as a well-designed and 
experienced method in the contemporary world.430 Through interfaith dialogue, different 
schools of thoughts can explore their similarities and differences in order to found a 
consensual basis for developing consensual legislations for global governance.431 
 183 
Therefore, one of the most crucial endeavors that can shape the future of such debates 
and be suggested as a useful mean to achieve consensus on sensitive issues is interfaith 
dialogue.432 
  This can be suggested that the organizations that are involved in global health 
governance develop the specific global guidelines and legislations with reliance on the 
above common and consensual areas and using the well-developed methods such as 
interfaith dialogue as described above.  
Conclusions: This part of this chapter, after a brief review of the scientific facts, 
provided a critical ethical analysis of different significant and influential schools of 
thoughts regarding the ethical status of early human life. Then, concluded that this has to 
be one of the functions of global health governance to provide legislations and safeguard 
the rights of early human life, at least as far as there is a consensus among different major 
schools of thoughts. This is also argued that in face, some areas of consensus exist. As a 
noteworthy example, this part of this chapter presented the currently existing consensus 
on the necessity of placing a legal ban on producing human embryos for research 
purposes.  
As a more detailed summary, this part of this chapter discussed its subject in these 
main parts: (1) the first part provided an overview of scientific and factual realities about 
research on early human embryo. This part showed that for this kind of research, there is 
real need to using and destroying PIHEs and there is a hope that in the future the 
embryonic cells will be replaced by manipulated adult cells, however, this promising 
development has not been able to completely replace the use of embryonic cells yet; (2) 
the second part of this part of this chapter portrayed the ethical perspectives and concerns 
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of three major ethical schools of thoughts regarding this subject. This part showed that 
there are some significant, well justifies, and almost globally consensual concerns and 
ethical principles/norms regarding research on early human embryo that can be used as a 
basis for developing a consensual ethical framework for global governance for research 
on early human embryo; (3) the third part of this part of this chapter examined this 
subject and its ethical controversies in the global scale and on the global scene.  This part 
of this part of this chapter showed that there are unaddressed ethical concerns and gaps in 
this regard that need global attention in terms of legislation and enforcement.   
Based on the above-mentioned parts, this part of this chapter can list its conclusions, 
and then limitations and suggestions, as listed below:  
Conclusive Remarks: (1) there seems to be a global consensus on the principle of 
respect for human embryonic life. Therefore, some implications of this principle such as 
refraining of producing human embryo just for research purposes can be considered as 
globally accepted standards of practice. These standards can be delineated and enforced 
as parts of global governance for research on PIHE; (2) For preventing the noteworthy 
harmful consequences of unleashed and uncontrolled exploitation of human embryos, the 
existing soft international laws are not sufficient and there is a need to hard laws that 
protect early human life from destruction and exploitation. 
Limitations: The limitation of this study is as follow: This study does not include 
other influential schools of thoughts those have their perspectives toward the ethical 
status of early human life, such as Judaism, Buddhism, Zoroastrianism, and others. 
However, the area of consensus that is provided in this part of this chapter does not seem 
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to be violated by examining other schools and religions. However, a more comprehensive 
study can be suggested for the future.  
Suggestions: Further studies can be suggested in this area to further clarify the areas 
of consensus among the major global schools of thought. In addition, further studies are 
needed to explore the best ways in integrating these consensual norms into the 
legislations that shape global governance for health. In addition, this part of this chapter 
suggests more studies on the best and most efficient ways of enforcing the legislations to 
safeguard early human life and at the same time, to protect and facilitate valuable 
research and treatments.  
As the final conclusion, this part of this chapter shows that in the era of globalization, 
this is crucial to establish a comprehensive ethical framework for Global Governance for 
Health Research, so the rights and welfare of the future generations will be protected and 
safeguarded, even in the very first stages of their human life. 
vi. Local and International Alternative Medicines 
At the Intersection of Market, Medicine, and Politics: Using different sorts of 
alternative and complementary medicine have had a growing trend in the USA and in the 
world during the past decades. Many kinds of practices name themselves as alternative 
medicine; therefore, there is a wide range of them from herbal/traditional medicines to 
energy therapy, homeopathy, pressure therapy, and using the ones entail different sorts of 
verbal or material practices. Efforts to revitalize traditional medicine in some developing 
countries have also had political backgrounds and connotations. For example, one of the 
elements of cultural revolution in China at the time of Mao was self-relying and in the 
field of medicine, this was translated into using traditional Chinese medicine to replace 
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Western Medicine.433 In India, establishing new organizations with the mission of 
safeguarding the traditional medical heritage has been considered and effort to fight 
against bio-piracy.  
Two Accounts of Alternative Medicine: The term “alternative medicine” might be 
misleading and confusing, even may lead some patients to abandon their conventional 
therapies and appeal to the unproven methods that present themselves as “alternatives”. 
The cautiousness on using this term, led the NIH to rename its institution from “National 
Center for Complementary and Alternative Medicine” to “National Center for 
Complementary and Integrative Health”.434 Research on local traditional medicine aiming 
at marketing them in the global market has always raised challenging ethical concerns.435 
The existence of real clinical equipoise on some of the clinical trials on alternative 
medicine is questionable.436  
Although the above position seems to be prudent and scientific, in the reality of the 
world of various kinds of alternative and complementary medicines, two different 
accounts exist: The first account believe that the current modern medicine is just one of 
the possible paradigms of medicine and there are alternative and rival paradigms to them 
their respected branch of alternative medicine belongs. Therefore, they are not bound to 
follow the criteria and methods of modern evidence-based medicine for showing the 
efficiency and safety of their products or methods. They can just rely on their traditional 
(and sometimes ancient, mystical, or superstitious) theories to find and prove them. The 
second account, however, regards the alternative medicine as a resource for potentially 
useful hypothetical and potentially useful treatments that have to be examined by well-
designed clinical trials and be added to the current arsenal of medical treatments if their 
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efficacy and safety is adequately proved. Each of these accounts implicate a different 
kind of research. The first account relies on the obsolete –even superstitious -paradigms 
of science and research and can be categorized as pseudoscience. The second account, 
however, is useful if governed properly by local authorities and Global Governance for 
Health Research. Below, a brief analysis of these two accounts and their ethical 
implications for Global Governance for Health Research is provided. 
Alternative Medicine as a Brach of Pseudoscience: Emanuel and Grady in their 
work on the ethical framework for research explain that scientific validity of research (in 
the phase of creating research ideas and deigning research projects) is an important 
ethical necessity.437 In other words, prior to assessing the rights of potential research 
subjects, the review and oversight (i.e. governance) systems have to look at the scientific 
validity of a proposed research. Allowing or conducting a research project that lacks 
scientific validity is unethical.  
Considering scientific validity ad an ethical requirement, the part of alternative 
medicine described as the first account above, raises serious ethical concerns. The only 
valid way available to show the efficacy and safety of medical treatments (medications or 
interventions) is through evidence-based medicine. If a branch of alternative medicine 
systematically flees from scientific evaluation (i.e. clinical trials), or claims that it relies 
on theories beyond the regular understanding of science (the fallacy of different 
paradigms), then there is a serious suspicious that it belongs to the realm of 
pseudoscience and superstitions.438   
Complimentary Medicine as a Useful Resource for Research: All the branches of 
alternative and complementary medicine do not belong to pseudoscience and superstition. 
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In fact, the branches of alternative medicine, especially the local traditional medicines, 
that used various kinds of herbal, natural, and body-mind medications and interventions 
have been practiced for thousands of years and are valuable resources of hypotheses that 
should be evaluated and screened by evidence-based medicine. In this way, the efficient 
and safe medications and interventions can be found and added to the local and even 
global arsenal of medicine. In this way, first it is possible to find more natural, affordable, 
and trustable means of treatment and health promotion for local communities, and 
second, it is possible to market the medications found in the natural resources of local 
communities to the world in a way that they benefit from it. This is a way to prevent and 
counteract the problem of bio-piracy (see above). 
Humoral and Herbal Medicine in Iran and India as a Case Study: Founded and 
developed by ancient Greek and Roman and Medieval Muslim physicians and 
philosophers, humoral medicine is based on theories about human anatomy and 
physiology that nowadays are outdated and obsolete. Founded by Aristotle and 
Hippocrates and expended and optimized by Galen and Avicenna, humoral medicine is 
founded on this belief that human body contains four major bodily fluids or humors 
(yellow bile, black bile, phlegm, and blood) and health is equal to balance among these 
humors. Each of these humors are correspondent with a temperament. For optimum 
health, there should be a balance among different temperaments. Indian ancient medicine, 
Ayurveda, was also founded on a slightly different account of humors and their 
determinant effects on health. The humoral medicine was closely related with the theory 
of four elements, per that, all things are made from four basic elements: fire (presented in 
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yellow bile), water (presented in phlegm), air (presented in blood), and earth (presented 
in black bile).  
Although the humoral theories of medicine are obsolete, some of their methods and 
medications, especially herbal medicine can still be used as a resource for medical 
hypotheses. The traditional Iranian and Indian physicians, who practiced based on 
humoral medicine, often used herbs for creating balance among their patients’ humors 
and temperaments. Some of these herbs can be beneficial, however, their efficacy and 
safety should be proven by evidence based medicine. 
The Case of Pseudoscience: Over the previous decades, a group of Iranian traditional 
physicians (some of them call themselves hakim that is a name for wise physicians in the 
Medieval era) tried to revive the humoral medicine with its traditional theories.439 They 
argue that humoral medicine belongs to a different paradigm from the Western medicine, 
therefore, does not need to be examined by modern standards of evidence-based 
medicine. They appeal to conspiracy theory (modern medicine is West’s plan to destroy 
health and good habits in Muslim societies) and religious beliefs (traditional medicine is 
endorsed by religious figures such as the prophet and holy imams) for promoting their 
practice. This group of traditional practitioners have also got governmental support 
because they seem to promote self-reliance and relying on domestic and Islamic 
resources/knowledge instead of Western ones. The same cause that promoted Chinese 
traditional medicine at the time of Cultural Revolution. They argue that the traditional 
medicine follows a different paradigm of knowledge and is not obliged to follow Western 
standards (i.e. evidence-based medicine). They have taken advantage of the political 
support and established numerous clinics and medical institutions all over the country and 
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attract thousands of patients. In some cases, they provide very misleading and even 
dangerous comments and guidance in the media. The principle of respect for scientific 
validity urges Global Governance for Health Research not to verify these kinds of 
practices and insist on the universal standards of evidence-based medicine and medical 
research that are not Western but are a part of common heritage of mankind. 
The Case of Preventing Bio-piracy: On the other hand, a group of politicians and 
physicians both in Iran and India argue that the herbal medications and regimes of 
traditional medicine should be examined by modern standards to discover the effective 
and safe ones before they are discovered and patented by Western pharmaceutical 
companies (bio-piracy). This is the right and ethical way of using the knowledge of 
traditional medicine and should be supported by Global Governance for Health Research. 
For example, in the Bt Brinjal case, the National Biodiversity Authority of India (NBA) 
sued a US-based transnational company because they had used indigenous varieties of 
brinjal to create a kind of genetically modified food without prior contract or agreement. 
Similar claims have been made about numerous produces such as Curcuma, Neem, and 
Basmati Rice.440 These legal cases showed the legal legitimacy of claims on bio-piracy. 
The best wat to fight bio-piracy, however, is not making lawsuits after it occurred. 
Instead, the best way is trying to conduct research on natural resources and traditional 
knowledge and patent them before being stolen by bio-pirates. Supporting these efforts 
by facilitating scientific research on traditional medicines is part of the ethical duties of 
Global Governance for Health Research. 
Conclusions: Scientific validity as an ethical requirement is the first ethical point 
relevant to the debate on alternative and complementary medicine. Scientific methods for 
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assessment and evaluation of efficiency and safety of new treatments are a well-
established part of medical science all over the world. Therefore, they also can be 
considered as a part of common heritage of mankind. Abidance to the standards of 
scientific validity and protecting the patients/consumers/research subjects from the 
danger of medical pseudoscience and superstitions in an ethical duty for Global 
Governance for Health Research and should be included in any ethical framework 
developed for it.  
On the other hand, alternative and complementary medicine should be considered as a 
valuable resource of hypotheses to be evaluated by scientific methods and presented to 
the communities. In this account, local traditional medicines can be used to find new and 
more natural, culturally acceptable, and cost-effective treatments to be used for treatment 
and health promotion in local communities and to be marketed with benefits to local 
communities so to counteract bio-piracy. 
vii. Conclusions 
The six cases discussed in this chapter reveal different aspects of the issues and 
challenges that Global Governance for Health Research faces and the ethical principles 
that are needed to approach these challenges and issues. A brief depiction of the lessons 
learned and principles that are needed to approach the ethical issues of each cases in 
provided in table 4.1.  
The variety of the factors involved in the challenges of Global Governance for Health 
Research is stunning. A broad range from the problems of exploitation and double 
standard in research in developing countries to the issues of biopolitics and bioeconomics 
in transferring biological and natural samples, to the problems of honesty and integrity in 
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research and publication of the results of research, and to the problems of noteworthy role 
of religious ethics in research on early human embryo. This broadness and variety shows 
that various ethical principles are needed to develop an ethical framework that is capable 
to approach these different issues with efficiency and competency. 
A look at the list of the principles mentioned in table 4.1. show that their number and 
scope is vaster than the traditional set of four principles of biomedical ethics. In other 
words, Global Governance for Health Research needs a broader set of ethical principles 
for approaching its issues and for developing a comprehensive and efficient ethical 
framework. 
 Because of the global nature of this field, only cross-cultural principles can be used and 
relied in developing an efficient ethical framework. Fortunately, three major works have 
already provided a framework and two sets of principles that have proved cross-cultural 
and consensual. The framework developed by Emanuel and Grady,441 the canonical set of 
four principles of biomedical ethics,442 and the principles provided by the UNESCO 
Declaration of Bioethics and Human Rights.443 In the following chapter of this 
dissertation, these theoretical works will be relied upon to develop and ethical framework 
for Global Governance for Health Research. 
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Chapter Five: A Normative Framework 
Adoption of the Universal Declaration of Human Rights by the United Nations 
was actualization of a dream and embodiment of a promise: a global consensus on a 
framework composed of a set of fundamental ethical principles based on the common and 
shared understanding of human dignity among all the cultures and communities and 
inspired by the spirit of cosmopolitanism.444 This historic event showed that reaching 
such a framework is not out of reach of humanity. However, what happened afterwards, 
historically speaking, showed that keeping the promise of human dignity and equity is 
easier said than done.  
When it comes to the realm of global bioethics, the UNESCO Declaration of 
Bioethics and Human Rights, adopted in 2005, is the legitimate and genuine successor of 
the Universal Declaration of Human Rights. Taking a look at the current scene of global 
research, as depicted in the previous chapters of this dissertation, also shows that keeping 
the promise embodied in this declaration is not easy either. However, relying on these 
consensual principles that are an invaluable part of the common heritage of mankind is 
the only legitimate ground for founding an ethical framework for a global enterprise such 
as health research, i.e. an ethical framework for Global Governance for Health Research. 
In this chapter, the main question of this proposal/dissertation is answered. After a 
review of the existing approaches, the suggested ethical framework is provided. This 
ethical framework for Global Governance for Health Research has three main elements: 
First, a background of personal and subjective virtues that are the merging points of the 
traditional masculine and modern feminist accounts of virtue ethics; second, a core of 
principles mainly from the UNESCO Universal Declaration of Bioethics and Human 
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Rights combined with the systematic framework that is named the NIH framework (see 
below), and third, a place for situation ethics embodied in the crucial role of Research 
Ethics Committees (RECs) and Institutional Review Boards (IRBs) composed of well-
trained experts and lay persons from all the involved parties and communities. A brief 
scheme of this framework is depicted in Table 5.2. 
i. A Systematic Framework: 
The necessity of a normative framework for Global Governance for Health 
Research is shown in the previous chapters of this dissertation through depicting and 
discussing the existing ethical challenges and examining the cases that show how these 
challenges affect individuals and communities around the globe (see chapters 3 and 4). 
Research activities involve and entail power relations. For example, power relations 
between researchers and research subjects, researchers and communities that host 
research and research subjects, health policy makers and researchers, corporations and 
researchers and communities, etc. And wherever there is any kind of power relation, there 
is a need to ethics and at the larger scale, an ethical framework. Globalization has brought 
the power relations of research enterprise to a global level. Therefore, it has become a 
subject for global bioethics that assesses and examines the ethical aspects of power 
relations at the global scale. This is the gist of the reason behind the need to an ethical 
framework. The details are provided in the previous chapters. 
The NIH Framework: In this part, the framework developed and introduced by 
Ezekiel J. Emanuel, David Wendler, and Christine Grady is introduced and described. 
This framework helps to tailor the principle-based approach to the special subject of 
research ethics and find the most relevant ethical principles included in other, typically 
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more general, frameworks. Although Emanuel, Wendler, and Grady have not named this 
framework the NIH framework, since all of these authors had been working at the 
Department of Bioethics of the Clinical Center of the NIH, and two of them are still 
working there, and since the current and former heads and the founder of this department 
are among the authors who developed and created this framework, this chapter names this 
framework “the NIH Framework”.  
The NIH framework is the result of the authors’ work on the numerous domestic 
and international research ethics guidelines published during the past 6 decades in 
different countries or by international organizations. They have provided a list of a 
selected group of these guidelines as follow: Nuremberg Code, Declaration of Helsinki 
(WMA), Belmont Report, 45 CFR 46 (Common Rule), International Ethical Guidelines 
for Biomedical Research Involving Human Subject (CIOMS and WHO), Good Clinical 
Practice: Consolidated Guideline (International Conference on Harmonization [ICH] of 
Technical Requirements for Registration of Pharmaceuticals of Human Use), Resolution 
196/96: Rules on Research Involving Human Subjects (National Health Council, Brazil), 
Convention on Human Rights and Biomedicine (Council of Europe), Medical Research 
Council Guidelines for Good Clinical Practice in Clinical Trials (United Kingdom),  
Guidelines for the Conduct of Health Research Involving Human Subjects in Uganda 
(Uganda National Council for Science and Technology), Tri-Council Policy Statement: 
Ethical Conduct for Research Involving Humans (Tri-Council Working Group, Canada), 
National Statement on Ethical Conduct in Research Involving Humans (National Health 
and Medical Research Council, Australia), Ethical Guidelines for Biomedical Research 
on Human Subjects (Indian Council on Medical research), Guidelines on Ethics for 
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Health Research in Tanzania (Tanzania National Health Research Forum), Guidelines on 
Ethics in Medical Research: General Principles (Medical research Council of South 
Africa, Guidelines for Good Clinical Practice in the Conduct of Clinical Trials in Human 
Participants in South Africa (Department of Health, South Africa).445 This list shows that 
they reviewed a variety of influential and pivotal guidelines along with other ones 
representing different geographical areas.  
Emanuel, Wendler, and Grady argue that all these guidelines suffer from a number 
of common problems such as: they have either created and published in response of a 
specific scandal (e.g. Nuremberg code in response to the revelation of the experiments 
done by Nazi researchers and Belmont Report as a reaction to the revelation of the ethical 
flaws in Tuskegee Syphilis Study) or had an specific practical aim rather than taking a 
comprehensive approach (e.g. International Conference for Harmonization was held to 
develop common rules of registration of pharmaceuticals for human use). In addition, to 
some extent because of their reactional nature, they are mistaken in some of their 
guidance’s (e.g. The Nuremburg Code regards taking voluntary consent as an absolute 
requirement that makes beneficial research on incompetent and incapacitated people 
impossible). Therefore, none of these guidelines have created a broad, comprehensive, 
and systematic ethical framework for research on human subject. They also have overlaps 
that should be organized into a consistent whole. 446 
For creating a comprehensive and systematic ethical framework that is free of the 
above-mentioned shortcomings and flaws of previous guidelines and minimizes the 
possibility of exploitation, Emanuel, Wendler, and Grady developed and published a new 
framework for clinical research. This framework consists of eight principles and each 
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principle entails a number of benchmarks that elaborate and explain each principle by 
providing practical interpretation on the requirements that each principle entails. A 
characteristic of the principles of this framework is that they are presented in a sequential 
manner, i.e. orderly from the stage of designing a research project to the stages of 
conducting and oversighting them. The principles on the NIH ethical framework are as 
follow: 
Collaborative Partnership: The role of communities that host research is 
incorporated in this principle. This role starts from the very first stages of research, when 
the research idea and design is shaping and the first drafts of the proposal is being 
prepared. This principle implies the participation of community representatives in all the 
stages of research projects, from designing to the dissemination of results. The 
community representatives as the partners of research team, also hold responsibility in 
safeguarding the ethical principles and regulations. They also help the research team in 
abiding with this benchmark of this principle that the values, norms, and cultures of host 
communities will be respected.447 The limit of this respect will be the principles implied 
by human dignity and fundamental human rights as described in the UNESCO 
Declaration of Bioethics and Human Rights.448 This principle also entails assuring the 
fair benefit of the community from the research. This is corresponding with UNESCO’s 
principle of Sharing the Benefits.449 Tangible benefits such as intellectual property and 
authorship should be considered too. Collaborative partnership is the principle that 
prevents unethical patterns of research behavior such as helicopter research and is helpful 
in preventing others such as having double standards. Therefore, the ethical principle of 
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collaborative partnership is a crucial component of the ethical framework for Global 
Governance for Health Research.450  
Social Value: This is an ethical imperative for health research to be beneficial for 
the society. Otherwise, the resources used for research are wasted and the risk imposed to 
the research subjects is unethical. Assessing the social value of research should be done –
or started- from the first stages of designing and proposal-writing in a prospective way. 
Although there is no principle in the UNESCO Declaration of Bioethics and Human 
Rights that can be considered exactly equivalent to the principle of social value, some 
principles of this declaration are partly consistent with the principle of social value, 
including: Benefit and Harm; Equality, Justice, and Equity; Respect for Cultural 
Diversity and Pluralism; Solidarity and Cooperation; Social Responsibility and Heath; 
Sharing of Benefits and Protecting Future Generations.451 
The benchmarks of the principle of social value entail a number of considerations. 
For example, determining the group (or groups) of person to whom the research is 
valuable. In Global Governance for Health Research, this is important to see if the 
communities from them the research subjects will be recruited is among the potential 
benefactors of the short-term and long-term results of the research. In addition, the 
consistency of the research project with the health priorities and needs of the host country 
is of crucial importance. One of the challenges of Global Governance for Health 
Research is conducting research in LMICs that are designed to cover the health needs of 
HICs. This problem was examined in the case of HIV/AIDS research in the previous 
parts of this dissertation. Another example is Malaria research. Although Malaria is a 
health problem of LMICs, however, when the exact questions of research are assessed in 
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relation with the health needs of the host community, new challenges arise. In the case of 
Malaria, for example, research on medications for preventing Malaria for a short period is 
more useful for tourists who travel to the Malaria-infested regions, while research on 
Malaria vaccine is more compatible with the health needs of local people. In addition, 
provisions for maximizing the social value of research is of ethical importance. Requiring 
data-sharing, as discussed in Chapter 3, is one of the regulations adopted by Global 
Governance for Health Research to fulfil this ethical imperative. Also, the burden of 
research on the healthcare infrastructures of the host community/country is another 
benchmark derived from the principle of social value.452 
Scientific Validity: Observing the scientific and methodological standards is an 
ethical imperative. Any deviation from the generally accepted scientific and 
methodological standards should be justified. In addition, the research should be designed 
and conducted in a way that is useful for solving the problem or answering the question 
for which it was designed and conducted. In other words, to be used for solving the health 
problems of people. Providing essential healthcare services for research subjects and 
preventing them from unnecessary or serious harms is another benchmark of this ethical 
principle.453 This principle is compatible with the following principles in the UNESCO 
Declaration of Bioethics and Human Rights: Benefit and Harm; Equality, Justice, and 
Equity; and Social Responsibility and Health. The value of scientific validity, however, is 
not emphasized in this declaration in the shape of an individual principle.454   
When it comes to Global Governance for Health Research, respect for scientific 
validity shows its importance in challenges such as the one described in the case of 
Alternative and Complementary Medicine (see chapter 4). The lack of scientific validity 
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causes wasting of resources, harming the subjects, and unwanted promoting of 
pseudoscience in research enterprise. Only scientifically valid research is useful for 
promoting health and dealing with health problems in communities. Therefore, Global 
governance for Health Research should emphasize on the importance of scientific 
validity through including it in the soft law and require research funding, oversight, and 
policy-making bodies to consider this important factor in funding, confirming, and 
monitoring research projects.  
Fair Participant Selection: This is the first principle of this framework that mostly 
pertains to the phases of conducting research projects. This principle requires that the 
criteria of recruiting human subjects for clinical research be limited to only the ones that 
necessitate by the research objectives, risks, benefits, and the feasibility of conduction the 
research. No other factors, such as availability and vulnerability of the potential subjects 
is ethically justified. The benchmarks of this principle entail that the research population 
be selected to ensure and maximize the scientific validity and reliability of the data and 
results based on research objectives and methodological considerations, minimizing risk 
for the research subjects, and maximizing the social value of research and the benefit of 
the research project of its individual subjects.455 This principle is more compatible and 
consistent with the following principles of the UNESCO Declaration of Bioethics and 
Human Rights: Human Dignity and Human Rights; Benefit and Harm; Respect for 
Human Vulnerability and Personal Integrity; Equality, Justice, and Equity; Non-
Discrimination and Non-Stigmatization; Solidarity and Cooperation; and Social 
Responsibility and Health.456  
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The importance of this principle for Global Governance for Health Research 
cannot be overemphasized. Some of the major challenges of Global Governance for 
Health Research, as explained in chapters 3 and 4, are related to the fairness in 
recruitment of research subjects. The challenge of double standards entail having unfair 
double standards in recruiting research subjects in developing countries or poor 
communities. The vulnerable populations in marginalized and poor communities are at a 
greater risk of exploitation by research purposes. Other considerations are also important 
and relevant, for example including the imperative of conducting phases I and II of 
clinical trails only in developed countries, with the purpose of protecting potential 
research participants in developing countries, once included in the CIOMS guidelines in 
1993, subsequently was removed because of objections made by the representatives of 
developing countries.457 
Favorable Riske-Benefit Ratio: Clinical research imposes risk on research 
participants to produce beneficial knowledge. The risk of research should be assessed and 
minimized. This is the first benchmark of this important principle. This benchmark 
entails that the assessment and minimizing the risk should be done based on scientific 
evidence. In addition, the research should be conducted by qualified researchers. 
Benefits, on the other hand, should also be assessed, maximized, and enhanced. The 
benefits of research can be categorized into two groups: first, the benefits for the society 
that entails the social value of research. Second, the benefits of research for its individual 
research subjects. The ethically important imperative is that in risk-benefit assessments 
for justifying a research, only the health benefits of research interventions or medications 
should be considered and calculated. In other words, although payment to research 
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subjects for reimbursing their time and efforts is not ethically wrong, and enhancing the 
health benefits and ancillary care for research subjects, especially in communities that 
they cannot receive them outside the research setting, is an ethical standard, these 
secondary gains (e.g. payment or ancillary care) should not be considered as the benefits 
of research in risk-benefit assessment.458 
This principle is clearly consistent – and even identical- with the principle of 
Benefit and Harm in the UNESCO Declaration of Bioethics and Human Rights: Human 
Dignity and Human Rights.459 Also is consistent with the principles of Sharing the 
Benefits, and Social Responsibility and Health.460 
In the perspective of Global Governance for Health; the risk-benefit analysis and 
the imperative of maximizing the benefit to risk ratio; preventing unnecessary and 
unjustified harm; and enhancing health benefits for research subjects, especially for 
vulnerable groups are very relevant to ethical issues in research in developing countries, 
as explained above under the titles of double standards and helicopter research in chapter 
3. The vulnerable populations in developing countries may not be able to assess the risks 
and benefits and make decisions independently. In addition, politicians and political 
representatives of such countries may have conflicts of interests and may not be the fairly 
selected and democratic representatives of local people. Their deals with pharmaceutical 
companies should be under scrutiny of a sort of governance that takes care of the interests 
of local and vulnerable populations in risk/benefit analysis of research. For this purpose, 
having real representatives of local communities and populations in oversight bodies (e.g. 
Research Ethics Committees and Institutional Review boards) is important and should be 
emphasized by Global Governance for Health Research. In addition, empowering local 
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members of Research Ethics Committees and other oversight and policy making bodies 
for performing efficient and accurate risk-benefit analyses is of crucial importance. As an 
example, the programs funded by Fogarty International Center (FIC) of the NIH for 
research ethics education LMICs has been a noteworthy step in this regard. Although 
accused of ethical imperialism, these programs have empowered local experts to take part 
in research oversight and monitoring and tried to keep its funded training programs 
compatible with local cultures and value systems.461 
Independent Review: Over the first decades after WWII, when utilitarianism was 
the predominant paradigm in research ethics and research oversight (mostly in the United 
States as the pioneer in health research and bioethics), it was thought that ethical research 
is dependent on ethical virtues of researchers. In other words, good and virtuous 
researchers and doctors necessarily do ethical research. It was believed that the unethical 
behavior of Nazi doctors in their experiments on human subjects during WWII was 
because of them being wicked and having unethical ideas and purposes. After the 
revelations made by Henry Beecher in 1967 that showed that unethical behavior 
happened in prestigious American universities and institutions and by reputable doctors 
and researchers, the above perspective changed and the importance of independent 
review based on ethical principles was proved.462 Consequently, the importance of 
establishing Institutional Review boards (IRBs) or Research Ethics Committees (RECs) 
and independent review as an institution in the governance of research enterprise was 
emphasized and entered the soft and hard law of research oversight and Global 
Governance for Health Research. 
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Independent review is aimed at protecting all parties involved in research, 
especially the more powerless and vulnerable ones, against the possible conflicts of 
interests and ensuring “public accountability”. The benchmarks of this principle include: 
establishing regulations for independent research review and oversight by law and 
regulations and making sure that they are properly followed; ensuring the independence 
and competency of the IRBs (or RECs); and the decisions of review and oversight bodies 
being transparent, legitimate, and ethically informed.463 
The UNESCO Declaration of Bioethics and Human Rights, also puts emphasis on 
the importance of independent review. In article 19, this declaration states that: 
“independent, multidisciplinary, and pluralistic ethics committees should be established, 
promoted, and supported at the appropriate level.” This imperative is consistent with 
principles such as: Benefit and Harms; Respect for Human Vulnerability and Personal 
Integrity; Equality, Justice, and Equity; Respect for Cultural Diversity and Pluralism; 
Sharing of Benefits; and Protecting Future Generations.464 
In this part of this ethical framework, again, the importance of empowering local 
experts and individuals for taking part in independent ethical review of internationally 
funded research is obvious. In other words, fulfilment of this important part of ethical 
framework for research and its benchmarks is dependent on having enough expertise and 
research ethics knowledge to take the role of independent review and represent local 
people and their interests in reviewing research projects. In sum, this principle has two 
major implications for Global Governance for Health Research: first, including the 
necessity and obligation of independent review in the related laws and regulations, and 
second, empowering MLICs and vulnerable communities/populations to take part in 
 205 
independent review via their informed, trained, and qualified representatives. The latter 
implication, again, raises the issues of research ethics training, the duty of HICs to 
provide this training, the concerns on ethical imperialism and colonialism, and the respect 
for local cultures and value systems as discussed above under the title of Favorable Risk-
Benefit Ratio.465 
Informed Consent: One of the characteristics of the NIH framework is its 
accordance with the sequences of research projects. It starts with the considerations 
mainly relevant to the phase of developing research idea and proposal and continues with 
the obligations of the phase of subject recruitment and afterwards deals with the ethical 
concerns that are related with the rights of the people who are selected to be invited to 
join the research as research subjects, the most important among them being informed 
consent. Informed consent has been the most discussed topic in research ethics. In other 
research frameworks, usually informed consent takes the first place in order. Although 
Beauchamp and Childress assert that their framework of principles does not connote any 
order or ranking among the four principles, however, in Western culture the principle of 
respect for autonomy has always taken the utmost priority. In other guidelines and 
frameworks, such as The Belmont Report, the principle that entails the obligation of 
taking informed and voluntary consent (respect for person in Belmont Report) is placed 
at the top.466 In the UNESCO Declaration of Bioethics and Human Rights consent is the 
fourth in the order of principles, however, human dignity and human rights, as the 
theoretical background of consent, is the first principle of this declaration.467 
The benchmarks of this principle entail attention to the sufficiency and adequacy 
of information provided for the participants in a way that they are nor ambiguous and 
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inadequate nor too detailed and overwhelming. In addition, considering the surrogate 
decision making if the subject does not have capacity and taking additional informed 
consent from local authorities if demanded by local norm and the consistency of the 
informed consent with the cultural and political contexts in which the subjects are 
recruited. 468 
The UNESCO Declaration of Bioethics and Human Rights incorporates Consent as 
an individual principle. In addition, the following principles are also in relevance with 
consent: Human Dignity and Human Rights, Autonomy and Individual Responsibility, 
Persons without the Capacity to Consent, Respect for Human Vulnerability and Personal 
Integrity, Non-Discrimination and Non-Stigmatization, and Respect for Cultural 
Diversity and Pluralism.469 
Informed consent is one of the most crucial and discussed topics in Global 
Governance for Health Research. All the competent participants of research, regardless of 
the contextual factors such as the country of residence or the socioeconomic status, 
deserve to be respected by obtaining voluntary and informed consent. The contextual 
factors, such as the cultural issues cannot override this fundamental right. In addition, the 
content of the informed consent should be compatible with cultural context and 
conditions, for example, the information should be provided in a language that is 
understandable for the research participant. In the cases that local authorities demand to 
be asked for permission for research, their permission can be added to the individualized 
informed consents but cannot replace them. For example, if a research project needs to 
recruit subjects from a tribe, the researchers can obtain a consent from the head of tribe 
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but does not exempt them from the obligation of taking informed consent from each 
individual research participant from that tribe. 
Respect for Participants: The ethical duties of researchers to the participants is not 
limited to informed consent, but they start with it. The ethical responsibility of 
researchers toward the participants start when they approach the participants to invite 
them to join the research project and continues even after the end of the project. The 
researchers are responsible to continuously do their best to minimize the risk and harm 
for the participants. The researchers should monitor the health and well-being of the 
participants all over the study and as long as the effects of the experimental study might 
persist. Other rights of the participants, including privacy and confidentiality, should be 
strictly observed. This is also applicable to the data that are kept for a period of time after 
the research, such as the data that may be shared (see data-sharing in chapter 3) and the 
samples kept in biobank and big data.470  
The other benchmark of this principle is the right of the participants to withdraw 
themselves from the research project without any penalty or adverse effect on their 
healthcare. During and after the end f trial, the researchers should pay attention to the 
healthcare of patient. This may include providing ancillary care during the trial and 
referring to local healthcare providers at the end of research project. Also, paying proper 
attention to the accidental findings during the research and informing the third parties of 
their health interest is at stake.471 
This principle is consistent with the following principles of the UNESCO 
Declaration of Bioethics and Human Rights: Human Dignity and Human Rights; Benefit 
and Harm; Autonomy and Individual Responsibility; Consent; Persons without Capacity 
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to Consent; Respect for Human Vulnerability and Personal Integrity; Privacy and 
Confidentiality; Non-Discrimination and Non-Stigmatization; Respect for Cultural 
Diversity and Pluralism; Solidarity and Cooperation; Social Responsibility and Health; 
and Sharing of Benefits.472 
This principle and its consistent principles in the UNESCO declaration have 
numerous implications for Global Governance for Health Research. The challenges of 
double standards, exploitation and helicopter research, and data sharing and big data are 
in close relevance with this principle. The researchers should take care of both 
fundamental rights and health needs of their research subjects and their communities and 
abide to this ethical responsibility with considering the cultural contexts (to provide the 
best care in a culturally friendly and consistent way) and socioeconomic contexts (to pay 
attention to the health needs of the participants that cannot be met outside of research) in 
which the research is being hosted and the participants live and will continue living after 
the end of the research projects.  
The Missing Parts of the NIH Framework: The most notable missing parts of the 
NIH framework are the principles that would govern research integrity, conflict of 
interest, and publication ethics. The NIH framework is created to govern clinical research 
and is focused on the practical/clinical aspects of research and their ethical issues and 
concerns. This characteristic makes this framework even more relevant to Global 
Governance for Health Research. A review of the challenges and case studies presented 
in chapters 3 and 4 of this dissertation shows that the most prominent ethical concerns of 
global health research are in relation with clinical research. Epidemiological research 
creates less ethical issues. Research integrity and intellectual property and patenting are 
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among the prominent ethical issues in global health research and are covered by 
principles provided by the UNESCO Declaration of Bioethics and Human Rights that is 
appealed in developing an ethical framework for Global Governance for Health Research 
in this chapter (see below). 
ii. Principle-based Approach: Pros and Cons 
In this part, the principle-based approach will be analyzed. The pros and cons of 
this approach will be reviewed trying to answer this question that whether the principle-
based approach provides an effective and comprehensive ethical framework for Global 
Governance for Health Research or not? As described below, the most consistent and 
comprehensive framework of principles available to be used in formulation and ethical 
framework for Global Governance for Health Research, is the framework adopted by 
UNESCO in 2005. As described above and depicted in Table 5.1., Each principle of the 
systematic framework of the NIH is consistent with a certain number of principles of the 
UNESCO Declaration on Bioethics and Human Right. In this part of this chapter, after a 
review of the existing sources of ethical principles for Global Governance for Health 
Research, the comprehensiveness of the UNESCO model is shown and its principles are 
adopted to be combined with the research-specific and systematic approach of the NIH 
framework to shape the main element of the ethical framework that this chapter suggests 
for Global Governance for Health Research. 
The Existing Resources of Principles: One of the fundamental ethical principles in 
research ethics is the principle of non-exploitation.473 This principle was discussed in 
detail in chapter 3 of this dissertation. The framework suggested by this chapter for 
Global Governance for Health Research adopts this principle as one of its fundamental 
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components along with two other principled, Human Dignity and Human Rights. Other 
major sources of principles for health research (that are also the main sources of 
principle-based approach in global bioethics) are the four principles theory of Beauchamp 
and Childress474 and the UNESCO Declaration on Bioethics and Human Right.475 In 
addition, as described above, an ethical framework for health research in developed and 
another one for developing countries is developed and presented by Emanuel and 
Grady476.  
The Principle of Non-Exploitation: As explained above, this principle in not among 
the principles of UNESCO Declaration of Bioethics and Human rights, however it has 
been argued that the most fundamental concern in research ethics, especially when it 
comes to clinical research, is avoiding exploitation. It has been argued that non-
exploitation is an overarching principle for all the principles and regulations in the field 
of research ethics, including the most general ones such as respect for person and 
beneficence.477 A detailed conceptual analysis of this principle is provided in chapter 3 
under the title of Exploitation and Helicopter Research. The accounts provided by 
Wertheimer, Kant, and Marx are discussed there (see chapter 3).  
In clinical research, human subjects are “used” to generate health knowledge, 
therefore, they are at the risk of exploitation. The same is true about the host communities 
and countries (see Exploitation and Helicopter Research, above in chapter 3). This risk of 
exploitation is compatible with both classic Kantian account (using individuals merely as 
a mean and not simultaneously as an end) and the more recent account presented by 
Wertheimer (unfair distribution of the benefits and burdens of an interaction) and 
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explained above in chapter 3. Minimizing exploitation is the fundamental ethical purpose 
behind the ethical framework of Emanuel, Wendler, and Grady (see above).478 
The Canonical Set of Four Principles: A set of principles for biomedical ethics 
had previously been presented at time of drafting the UNESCO Universal Declaration on 
Bioethics and Human Rights. This set of principles presented by Beauchamp and 
Childress is called the four principles approach (or the Georgetown approach) to 
biomedical ethics. A version of these principles had previously been developed and 
published in the Belmont report. Those set of principles includes: (1) Respect for 
autonomy: This principle demands the healthcare providers to respect the informed 
decisions made by their patients or their legal representatives. This principle is part of the 
wider one entitled “respect for person” in Belmont report. (2) Beneficence: This principle 
denotes that the main purpose of health care should be maximizing good results and 
outcomes for the patients. This principle in addition to Non-maleficence (the next one) is 
entitled “beneficence” in Belmont report. (3) Non-maleficence: This principle implies the 
old motto that says: “first, do not harm” and implies the obligation of health care 
providers to minimize harms for their patients. (4) Justice: This principle with the same 
name exists in the Belmont report. This principle can be discussed in different levels 
from the bedside to the entire heath system of country or even global heath 
governance.479 
The above principles are crucial and fundamental. They are relevant to every level 
and scale of health-related research, from the small projects in local institutions to the 
large multicenter and internationally collaborative ones. Global governance for 
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biomedical research, however, needs more principles for dealing with its specific ethical 
challenges as described above. 
The UNESCO Universal Declaration on Bioethics and Human Rights: For 
portraying the most multilateral and inclusive ethical frameworks for a branch of global 
governance, as discussed above in this chapter, one should rely on the most consensual 
sets of such principles/norms. The UNESCO developed this consensual set of principles 
of global healthcare after long discussions and deliberations of the delegates of almost all 
of live and large cultural traditions in the world. 
The UNESCO Universal Declaration on Bioethics and Human Rights has been 
compiled and finally adopted by acclamation by the General Conference of the United 
Nation’s Educational, Scientific and Cultural Organization (UNESCO) in October 2005. 
It is noteworthy that many of the principles presented by this instrument are the ones that 
were proposed by delegates of developing countries to the previously existed classical 
sets of principles, which had been developed and introduced by Western bioethicists.480 
In the UNESCO Universal Declaration on Bioethics and Human Rights, all the 
above principles do exist, but other ones are added which are more relevant to global 
health governance. Therefore, in discussing this very issue in seems that the UNESCO 
deceleration provides the best available – and internationally agreed upon – framework of 
values and norms in the form of a set of principles. 
 As described above in this chapter and depicted in Table 5.1., among the 
principles presented by this international instrument, some of them are the most relevant 
ones to the realm of health research ethics and consequently to the Global Governance for 
Biomedical Research. These principles that shape a crucial part of the ethical framework 
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suggested by this dissertation. The list of these principles can be found in Table 5.2. A 
certain number of the most repeated (see Table 5.1) and referred ones are listed and 
briefly described below:  
human dignity and human rights: This principle, along with non-exploitation that 
has been called the “fundamental ethical purpose” of the NIH ethical framework for 
health research,481 shapes the fundamental/basic layer of principles of the principle-based 
element of the ethical framework for Global Governance for Health Research. The 
concept of human dignity, although not fully and exclusively defined yet, and despite the 
large amount of theoretical debates and controversies that exist on its bases, limits, and 
implications, is the conceptual basis of fundamental human rights and freedoms as 
asserted in the UN Universal Declaration of Human Rights.482   
The concept of human dignity and its implications formulated as the fundamental 
human rights and freedoms are a part of common heritage of mankind and shape the 
limits and red lines for various interpretations of other principles. In other words, no 
interpretation or understanding of other principles, including the principle of Respect for 
Cultural Diversity and Pluralism, is ethically allowed to violate and restrict the principle 
of Human Dignity and Human Rights.483 These are the reason behind placing this 
principle among the ones in the more basic/fundamental layer/level of principles in the 
suggested framework for Global Governance for Health Research (see Table 5.2). 
Respect for Human Vulnerability and Personal Integrity: Vulnerability can be 
defined as special fragility and susceptibility to confronting with risks and harms. In a 
broad sense, all human beings are vulnerable. Therefore, research ethics considers this 
general vulnerability and safeguards different parties of research interactions from 
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exploitation. However, some groups of people have specific traits and characteristics that 
make them more vulnerable. In health research, vulnerable groups included infants and 
children, captive populations, unborn humans, people with mental or physical 
impairments and disabilities, people who live in poverty, the elderly, among other social 
and demographic groups. These groups deserve special attention and consideration in all 
the phases of research. The relevant ethical guidelines should be observed. And the RECs 
and IRBs should pay attention to safeguarding the rights and safety of these groups of 
potential research subjects.484 
Equality, Justice, and Equity: The fundamental equity of all human beings is rooted 
in the concepts of human dignity and human rights. All human beings, regardless of the 
sources and sorts of dignity that may acquire or lose throughout their lives, are bestowed 
with fundamental human dignity that guaranties their fundamental human rights and 
freedoms. In addition to this basic equity, the concepts of justice, fairness, and equality 
are crucially relevant to Global Governance for Health Research. Seriously considering 
the shares and benefit of research participants and the host communities/countries is 
among the implications of this ethical principle. In all phases of research, from 
formulating research idea and proposal (considering the social value and avoiding to 
waste common resources by scientifically invalid designs) to the phase of recruiting the 
research participants and the phase of distributing the results of research and taking 
advantage of them (e.g. patents, affordability for people of host communities), the 
principles of justice and equality are relevant. Therefore, this principle of the UNESCO 
declaration is included among the principles of the suggested framework for Global 
Governance for Health Research.485 
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Respect for Cultural Diversity and Pluralism: This principle has numerous 
implications in global health research. As an instance, the issue of taking consent from 
local authorities has been previously discussed in this chapter. Although this crucial 
principle is the backbone of global collaboration and solving the problems such as ethical 
imperialism and colonialism, it is limited by distinct red lines, that is the fundamental 
human rights and freedoms. Within the area allowed by these red lines, however, respect 
for cultural diversity and pluralism brings about social capital and mutual respect and 
collaboration that is earnestly needed by the global research enterprise.486 
Solidarity and Cooperation: In a broader perspective than social the ones of social 
responsibility and sharing of benefits, the concepts of solidarity and cooperation are in 
consistence with the virtues of empathy, compassion, and care. Human beings ultimately 
belong to a specie with shared origin, inhabitant, and destiny. Well-being and prosperity 
for some is meaningless when is accompanied with misery and poor health for others, 
even in far distances. The historic scandals of global ethics enterprise as described in 
chapters 3 and 4 have been rooted in the lack or deficit in the sense of solidarity.487 
Virtues such as solidarity and cooperation are antidotes of unethical global trends such as 
the ones promoted and desired by neoliberalism (see chapter 6). 
 Social Responsibility and Health: Access to healthcare is among the human rights 
that guarantee equal opportunities. Health research is not free of responsibility of 
providing healthcare for the society, either through the results of research activities that 
should be of social value, or through providing healthcare for research subjects and host 
communities and considering both the short and long-term benefits of the communities 
from hosting research projects. In this direction, the duty of research is dealing with the 
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real and serious health needs of the society. In addition, researchers should not be 
ignorant to the health needs of their research participants and host communities. 
Especially about the ancillary and follow-up cares that otherwise they won’t afford or 
have access to them.488 
Sharing of Benefits: When it comes to Global Governance for Health Research, one 
of the most cited and appealed ethical principles is sharing of benefits. Research has 
short-term and long-term benefits. Being of social value is a precondition for health 
research to be approved and conducted (see above). These benefits, however, are not 
always distributed fairly. As described through various challenges and cases in chapters 3 
and 4, different kinds of exploitation violate the principle of fair benefit sharing.  In 
Global research interactions, this concern has always been raised that the less powerful 
parties, i.e. research subjects and the poor host communities and countries receive an 
unfair share of the benefits of research. The challenge of helicopter research and the case 
of HIV research in Africa are among the examples of the situations that have raised this 
concern. This principle asserts that the short and long-term benefits of research should be 
shared in a fair manner.489 This principle covers multi-central and international research 
in developing countries and the share of the host communities of the benefits of research 
(e.g. affordable access to the resulted medications and vaccines) and even the issue of big 
data and data sharing in the sense that the benefit obtained from imposing risk to research 
subjects should be shared in the best possible wat through data sharing and fair access to 
biobanks and big data.490 The debates on bio-piracy and exploitation of local natural and 
knowledge resources of developing countries by pharmaceutical companies (see chapter 
4) is another example of ethical issues that necessitates the inclusion of the principle of 
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sharing of benefits in any suggested ethical framework for Global Governance for Health 
Research.491 
Protecting Future Generations: Protecting future generations is mostly relevant to 
the genetic research and research on human gamete, embryo, and fetus (see chapter 4). 
Although included among the vulnerable groups and covered by the principle of respect 
for vulnerability (see above) the importance of protecting human gametes and embryos 
from unethical research interventions (e.g. mass production of human embryos only for 
research purposes) necessitates another principle to be included in the ethical framework 
to establish a globally accepted, adopted, and enforced protection of the future 
generations. Other issues such as inducing and producing permanent genomic changes in 
germlines and research on human enhancement are among other ethical concerns covered 
by this principle both in domestic and global research enterprise.492 
Protection of the Environment: This principle is titled as “Protection of the 
environment, the Biosphere, and Biodiversity”, however, is shortened to “Protection of 
the Environment” because the other two components were in in the same direct and 
crucial relation to the ethical issues of Global Governance for Health Research.    
 All the above principles, including cultural diversity should be accepted and 
respected within the limits of human rights and fundamental freedoms. This important 
point is explicitly made in the declaration to prevent any kind of abuse under the name of 
cultural diversity.493  
Principles and Ethical Framework: In this part of this chapter, the UNESCO 
Universal Declaration on Bioethics and Human Rights is used to shape the principle-
based element of the ethical framework of the Global Governance for Health Research. 
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The UNESCO framework incorporates other major relevant ethical frameworks such as 
the ones included in the Universal Declaration of Human Rights and the four-principle 
framework of Beauchamp and Childress. 
These principles and principlistic approach form one of the three major elements of 
the ethical framework suggested in this chapter. This element is divided into two layers: 
the more basic/fundamental layer that is consisted of more fundamental principles, 
including human dignity, human rights, and non-exploitation. The second layer is 
consisted of other principles that are of crucial importance in the ethical framework for 
Global Governance for Health research (see Table 5.2). 
iii. Particularistic Approach: Pros and Cons 
Particularistic approaches that sometimes are called “situation ethics” claim that 
ethical principles are not useful in determining moral goodness or badness in the real 
world. Instead, one should rely on the specific context and specifics of each act/situation 
for moral judgment/decision-making about it This is why this approach to ethics has also 
been named “situation ethics”.494 
In the fields of global/international health research and Global Governance for Health 
Research, each situation or problem has its own specifics and characteristics, including 
the context in which that situation or problem takes place. Situation ethics claims that the 
principles outlined in the previous part of this proposal are not able to lead the ethicists, 
researchers, policy makers, or other decision makers toward the ethical 
solutions/answers. Instead, in each case, those specifics and characteristics compromise 
the ethically relevant features that should be examined, analyses, and balanced on a case-
by-case basis to find the most ethically acceptable/suggestible solutions, answers, or 
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approached. Situation ethics does not reject the ethical principles as morally acceptable 
and enlightening thoughts and accepts their role in teaching ethics for students. However, 
claims that in approaching the real, complex, multifaceted, and complicated ethical cases, 
these principles are not helpful as described above.495 
As an example pertaining to the realm of Global Governance for Health Research, the 
challenge of bio-piracy as explained in chapter 3 is one of the major challenges related to 
health research. The principles of sharing of benefits led the global community to act. 
The result was the Nagoya Convention (see above). However, the production of Influenza 
Vaccine has been adversely affected and delayed because of the obligations made by this 
principle and the resulted convention (see chapters 3 and 4). Therefore, a generally good 
and acceptable principle may cause irregularities and adverse implications in its practical 
application.  
Another example is the problem of risk-benefit analysis. In non-therapeutic health 
research, it has been argued that the risk imposed to the participants (who obviously 
won’t benefit from their participation) should be limited to the standard of “zero risk” 
that means the risk of normal activities of life. However, considering this double-track 
assessment (i.e. dividing health research projects into two major groups: therapeutic and 
non-therapeutic ones and conducting their risk-benefit analyses in two separated tracks) 
brings about some serious practical problems. For example, the phases I and II of many 
of clinical trials would be banned if the standard of zero risk was followed. Therefore, 
instead of adopting the double-track process, the risk-benefit analysis should be done for 
both therapeutic and non-therapeutic research projects because in some, of course well-
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considered and analyzed – cases, the great social benefits can justify some levels of risk 
for research subjects even in non-therapeutic research. 
RECs and IRBs for Situation-Based Practical Approach: The above argument 
(asserted by the proponents of situation ethics) and examples, show that having a 
framework of principles is not enough but is just the beginning of the sophisticated 
process of ethical oversight and governance for research, either domestic or global. The 
ethical analysis, considering all the ethically relevant items and characteristics and details 
of each case, should be done by a group of well-trained and ethically and culturally-
informed people. This lesson of situation ethics has been the basis of establishment of 
Research Ethics Committees (RECs) and Institutional Review Boards (IRBs). The RECs 
and IRBs consider the principles provided by the framework, however, they also examine 
and analyze each case with specific attention to all its ethically relevant details. 
For ethical review and oversight of international research, the RECs and IRBs of the 
host countries should be involved, because they are well-informed on the cultural 
specifics of the host community and can safeguard the benefits and interests of research 
subjects and their communities and countries. Therefore, as described above, one of the 
ethical imperatives for Global Governance for Health Research is training people in host 
communities to take part in research monitoring and oversight through RECs and IRBs. 
In addition, sharing the experiences and ethical wisdom of all people who take part in 
research monitoring and oversight (i.e. governance) all over the world through shaping 
and strengthening networks among RECs and IRBs is another ethical imperative for 
Global Governance for Health Research. 
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Therefore, in the ethical framework for Global Governance for Health Research 
provided in this chapter, one of the three major elements is the situation ethics and its 
practical implication that is assessment and analysis of each research project and research 
governance system by a network of RECs and IRBs (see Table 5.2). 
iv. Virtues as the Subjective Backgrounds 
 Principles are crucial in shaping a framework and solid knowledge on ethics. 
However, genuine abidance to the principles and normative frameworks is dependent on 
personal (internal or subjective) virtues of professionals. In the realm of research ethics 
and Global Governance for Health, only virtuous researchers genuinely follow the ethical 
principles and normative frameworks. Otherwise, the abundance of principles, laws, and 
regulations can never actually minimize the unethical research behaviors, abusive power 
relations, and exploitation. This part of this chapter belongs to depicting a set of virtues 
that (1) are grounded in both classical/traditional masculine virtues and feminist virtues, 
and (2) are crucial in forming a solid subjective/personal background for health 
researchers. These virtues are empathy, compassion, and care that shape the 
internal/subjective solid backgrounds of the ethical framework for Global Governance for 
Health Research. It has been argued that these virtues are the “desired moral attitudes of 
physicians”.496 
Compassion has been called “the emotional and virtuous core of the desired 
professional attitude” in medicine.497 The Ethics Committee of the American Society of 
Academic Emergency Medicine (SAEM) considers compassion “a part of professional 
competence” which is “perhaps as important as technical competence.”498  These 
emphasizes on the central role of compassion in the shaping of the professional character 
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of healthcare providers shows the central importance of this concept in medicine and 
medical ethics as well as in research ethics at its domestic and global levels. 
Compassion is internal/subjective reaction to the suffering of other sentient being(s) 
and is conjoined with recognition of the suffering, detesting and disapproving that 
suffering, feeling personal responsibility and engagement with the experience, and 
tendency to relief the suffering with good intentions toward the sufferer(s).499 Therefore, 
one can argue that compassion is always a good trait and there is not such a thing as a 
“bad compassion” (see below). 
From the ancient times, the utmost obligation of physicians has been to alleviate or 
eliminate human suffering.500 Daniel Callahan calls this very obligation “a foundation 
stone of the practice of medicine.”501 Patients’ suffering is not limited to pain or other 
symptoms of their diseases; it also encompasses their mental and social discomfort. This 
suffering originates from all different sources including their disease, the treatment, their 
realistic or unrealistic fears and anxieties, their financial and social distresses and all 
other sorts of discomfort they experience through the courses of their disease, treatment, 
and recovery.502  
The broadness and existential importance of the concept of suffering and its 
importance in the life of a patient, shows how crucial the virtue of compassion is in the 
practice of medicine and in the pursuit of its goals. Suffering elicits the “impulse of 
compassion” in almost every normal human being,503 but it should develop into a virtue 
in physicians to make them more similar to the ideal ones. 
This part of this chapter analyzes the notion of compassion as a common virtue 
between the traditional/masculine and care/feminine sets of virtues and shows that 
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compassion as a reunion and merging point of the both sets of human virtues has a crucial 
role in the pursuing the goals of medicine and healthcare and medical research. This role 
can be actualized by development and promotion of compassion as an important part of 
the character of an ideal physician/healthcare provider/health researcher. In addition, this 
part argues that the notions of empathy, compassion, and care can shed light on some 
important debates in the contemporary debates on healthcare provider-patient and health 
researcher-research subject relationships. 
Empathy, Compassion, and Care as Virtues: According to Alasdair MacIntyre, a 
virtue is a developed trait of a human’s character that tends to qualify him/here to realize 
the goals of a certain practice (in our case, medicine and health care) with excellence.504 
Traditionally, according to the Aristotelian understanding of the virtues and virtue ethics, 
the human virtues have been considered related to masculinity.505 In recent decades, 
however, the founders and advocates of the ethics of care described and introduced a set 
of virtues with feminine nature (see below). This part of this chapter portrays empathy, 
compassion, and care as the common virtues between these two sets of universal virtues. 
Both the traditional and feminist theories of virtue ethics emphasize on the importance of 
these virtues when it comes to healthcare ethics, healthcare provider-patient relationship, 
and health research ethics. At the end of this part, one can conclude that empathy, 
compassion, and care as a set of virtues are the merging points of the masculine and 
feminine virtues in the realm of medicine and health research and are of crucial 
importance in shaping the character of a virtuous physician/researcher. 
Masculine Virtues: Virtue Ethics: Andre Comte-Sponville argues that contrary to 
sympathy, compassion is a virtue.506 Other scholars have also noticed the difference 
 224 
between concepts like sympathy, empathy, and pity with the concept of compassion.507 
This differentiation as described briefly below shows how one can consider compassion 
as a virtue, not a feeling that can be morally good or bad. 
Comte-Sponville differentiates sympathy and compassion in this way: Sympathy, 
which means “fellow feeling”, is not a virtue by itself. Its goodness or badness depends 
on the “feeling” which is being shared between fellows. Having sympathy to malice 
intents is not good, therefore, sympathy, by itself, can never be a virtue.508 Compassion, 
however, is sympathy in suffering and every form of suffering, even the ones originated 
from wrong causes such as wrongful jealousy or rivalry, deserves sympathy.509 In 
addition, compassion encompasses other specifics such as benevolence and inclination to 
relief the suffering.510 
Comte-Sponville brings Christ’s compassion for his executioners as an example of 
the goodness of compassion even for evil people who suffer because of their evil and 
malice acts, intents, and characters.511 Andre Comte-Sponville argues that compassion, as 
the same time, is a feeling and a virtue because we can feel it as a feeling and we can 
want and gain the capacity of being compassionate.512 In this sense, compassion is similar 
to love. In the Buddhism, compassion is regarded a great virtue. In Christianity, charity 
has the same status. However, charity is not identical with compassion. As a matter of 
fact, the feeling and capacity of empathy, compassion, and care can lead to and resemble 
charity.513 
As a set of virtue in its traditional/masculine sense, empathy, compassion, and care 
are in close relation with biomedical and health research ethics. As mentioned above, 
alleviation of suffering is a core obligation/goal in medicine and healthcare. The virtue, 
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which targets suffering, is compassion. Therefore, the pursuit and realizing this main goal 
of medicine depends on the establishment of this very virtue in healthcare 
providers/physicians. 
Feminine Virtues: Ethics of Care: The ethics of care is among the most recently 
emerged moral theories and attracted a large deal of attention in the recent decades.514 Its 
new and innovative approach and viewpoint in dealing with ethical issues has shed light 
to some formerly dark and overlooked parts of human beings’ moral obligations and 
duties. As a moral theory, ethics of care has its implications and influences on biomedical 
ethics. Healthcare is one of the most prominent manifestations of care and caring relation 
in the world of humanity.515 Therefore, it is obvious that ethics of care has much to say 
when it comes to health, healthcare, health research and the goals of medicine. 
The ethics of care as a distinct moral theory was born inside the feminist ethics. The 
founders of this theory were feminist philosophers who found the caring nature of 
femininity of enormous ethical value.516 As described above, traditionally, in moral 
theories and even in moral psychology it was considered for granted that ethical virtues 
are stronger in males.517  It was because ethical norms and virtues like justice and 
impartiality were consistent with the role of males as hunters and breadwinners. The role 
of females, as cares had always been underestimated, morally speaking. According to the 
founders of the ethics of care, however, this caring nature of female role is of utmost 
moral superiority and importance and can be considered as a basis for a self-sufficient 
moral theory. Although some of them believe that the ethics of care is not a sort of virtue 
ethics, but still it is obvious that this moral theory is founded based on considering care 
and compassion as unambiguous virtues.  
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One of the main themes of the ethics of care is considering partiality as a virtue. In 
the traditional/masculine virtue ethics, justice and impartiality have always been 
indubitable virtues. However, in the ethics of care, special caring relations come along 
with obligation of special care and partiality. This is very true in the case of physician-
patient and health research-research subject relationships. Medical ethics and research 
ethics ask physicians and health researchers to always give priority to the health and 
health needs of their own patients. This priority comes from a relationship: the 
physician/doctor/healthcare provider-patient relationship. It seems that the typical model 
of the ethics of care shows itself in this case. Physician should be partial and give priority 
of his/her patients because of the specific relationship established between them. This 
partiality shows itself in the form of care and compassion. This care and compassion is 
aimed to realize the goals of medicine as described below. 
Compassion and the Goals of Healthcare: Daniele Callahan specifies the goals of 
medicine as follow: the prevention of disease and injury and the promotion and 
safeguarding of health, the relief of all kinds of suffering resulted by maladies, the 
treatment of disease and providing care for non-curable ones, and the evasion of a 
premature death and the pursuit of a serene death.518 It seems that the virtues of empathy, 
compassion, and care play crucial roles on realizing all these four goals of 
medicine/healthcare.  
Empathy, Compassion, and Care in Researcher-Research Subject Relationship: 
The root of the word “compassion” is in Latin language where it means “suffering with”, 
equal to the Greek root of the word “sympathy”.519 It is interesting that compassion 
shares its Latin root with the word “patient” meaning sufferer.520 This common root 
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symbolically shows the relation between compassion and caring for parents and relieving 
their suffering as embodies in the healthcare and medicine. Medicine relies on science but 
is not merely a sort of science. It also is an art: art of establishing a healing and trustful 
relationship with the patients. This art depends on certain virtues in physicians, among 
which is the very crucial one of compassion. 
Recent developments in medical technologies along with reliance on science have 
transformed doctor-patient relationship in the post WWII era.521 However, these changes 
and evolutions have not led to elimination of humanistic aspects of doctor-patient 
relationship and transforming it to a mechanical/machine like relationship. Therefore, still 
the therapeutic relation depends largely on development of trust and rapport between 
physician and patient. This trust and rapport take place when patient realize that his/her 
doctor recognizes his/her suffering and feels for his/him and is intended to alleviate or 
eliminate his/her suffering. And this is the very definition of compassion as described 
above in this paper. Therefore, it seems that despite all the evolutions and transformations 
in the modern medicine, the cornerstone of doctor-patient relationship is still personal 
virtues and among them, the very important one of compassion. 
Taking a look at the history of debates in the contemporary biomedical research 
ethics clearly shows that no single moral theory has a monopoly on the realm of truth in 
biomedical research ethics. Instead, in each situation and in analyzing each specific issue 
of searching for each specific ethical solution, one or more of ethical theories show to be 
helpful and reliable. In this part, the viewpoint of the virtue ethics has been used and 
analyzed to shed light on some aspects of biomedical research ethics and to show that 
empathy, compassion, and care as a set of virtues play a vital role in the pursuit of the 
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goals of healthcare and medicine in the realm of research, at both the domestic and global 
levels. 
Healthcare, in practice and research activities, involves a great deal of interpersonal 
involvements and interactions. Therefore, the character of physician/healthcare provider 
is of crucial importance. This importance paves the way for virtue ethics to play a 
considerable role in analyzing and problem solving in healthcare provider-patient issues. 
In this context, compassion, as a virtue, is of extreme importance in pursuing the goals of 
medicine/healthcare as described above. 
Empathy, compassion, and care are common virtues between the 
traditional/masculine and feminist/feminine theories of virtue ethics and according to the 
both of them are crucial virtues in biomedical ethics and medical professionalism. The 
traditional/masculine sense of the virtue of compassion can strengthen the relationship 
between physician and patient (in this case, researcher and subject) with trust and mutual 
understanding. In addition, the partiality resulted from this relationship shows itself in the 
form of giving priority to the one’s own patients and is compatible with the feminine 
account of virtues such as compassion and care. The main goal of medicine is to alleviate 
or eliminate suffering. Therefore, compassion, along with empathy and care, are the most 
crucial virtues in pursuing the goals of healthcare and medicine both in practice of 
medicine and in health research. 
Despite the recent technological and scientific transformations in medicine, still the 
interpersonal relationship between healthcare providers and patients (and researchers and 
research subjects) play a vital role in pursuing the goals of healthcare and health research. 
For establishing effective and trustful physician-patient and researcher-subject 
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relationships, the virtues of empathy, compassion, and care play central roles. These 
central roles show themselves in ethical issues such as ancillary care and following 
ethical principles such as sharing of benefits (and in general, the most fundamental 
ethical principle of Global Governance for Health Research, that is non-exploitation). 
Making the best decisions in the situations that raise such concerts, depends largely on 
the trust and rapport which are achievable by virtue of empathy, compassion, and care in 
the researchers and recognizing this compassion by the patient/subjects and the host 
communities. 
In sum, empathy, compassion, and care can be called the merging and reunion points 
of the feminine and masculine virtues in pursuing the goals of healthcare and medicine 
both in practice and in research. Therefore, they shape the virtuous grounds of the ethical 
framework for Global Governance for Health Research. 
v. Global Norms and Cultural Diversity 
This part deals with the debate about the potential conflicts between universal norms 
and cultural/local values. Respect for cultural diversity and the priority of fundamental 
human rights and freedoms over local ethical variations are discussed above. However, 
the importance of this subject in global bioethics, especially its relevance to the ethics of 
health research, demand and necessitate a specific attention to this subject at this part of 
this dissertation. One of the most famous cases on this kind of conflicts in international 
health research is the debate over who has to give an informed consent in specific 
communities, such as tribes in some developing countries, where the traditional 
authorities overrule the personal right of individuals to give voluntary informed 
consent.522 
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Since asking for informed consent is one of the fundamental rights of every 
competent human subject, appealing to cultural diversity is not enough to compromise 
this basic right and ask for collective consent from the local authorities. Instead, a 
possible solution would be insisting on obtaining individual informed voluntary consent 
in addition to the permission of those authorities. 
The above case is just an example of cases in which the local cultural norms and 
traditions come into conflict with universal ethical standards and how the researchers and 
ethicists can manage to find creative ways to keep adherent to global ethical standards 
and respectful to cultural diversity and local traditions at the same time. 
In sum, this part of this chapter argues that the principles adopted in the Universal 
Declaration of Human Rights and UNESCO Universal Declaration of Bioethics and 
Human Rights are parts of common heritage of mankind and do not belong and are not 
limited to a specific culture or geographic area. In addition, the principle of respect for 
cultural diversity, as discussed above, cannot be interpreted in a way that comes with 
conflict with human dignity and fundamental rights and freedoms. Therefore, the 
principles that consist the principle-based element of the framework suggested in this 
chapter are of universal and cross-cultural nature and although they include the important 
principle of respect for cultural diversity, they are not limited to any culture or nation or 
geographic region. The limitations of this universal and cosmopolitan approach will be 
discussed further in chapter 6. 
vi. The Global Framework for a Global Network 
This part of the dissertation, suggests an ethical framework for global governance for 
research. This framework is developed to encompasses all the strengths of both principle-
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based and particularistic moral approaches. In the light of the above discussions about the 
existing problems and their ethical nature (chapter 3), and the discussed cases (chapter 4), 
and the discussions on the theoretical backgrounds provided above in this chapter, this 
part of this chapter provides a framework that looks to be both comprehensive and 
systematic. 
In addition, the existence of different and sometimes conflicting schools or morality 
that in some cases are embodied in the various ways of life, is another important point in 
developing an ethical framework at the global level. The final framework has to show 
respect for cultural diversity and adherence to global ethical mandates (fundamental 
human rights and freedoms) at the same time. For this purpose, considering the global 
norms as the common heritage of humanity (rather than the impositions of ethical 
colonialism) can be illuminating and helpful.523 
As described above, the power imbalances among the different parties involved in the 
global research enterprise raise serious concerns about safeguarding the rights and 
benefits of the vulnerable people or communities as an ethical mandate. Each ethical 
framework has to be attentive to this important imbalance in power and its resulted 
ethical concerns and problems and this truth that one of the most crucial goals of such an 
ethical framework is dealing with this power imbalance in a way to maximize the benefit 
and minimize the harm for the most vulnerable parties. In sum, this part of this chapter 
provides a systematic, comprehensive, and appropriate ethical framework for Global 
Governance for Health Research. 
The Criteria of Appropriateness: The aim of this chapter is providing the “most 
appropriate” ethical framework for global governance for health research. For this 
 232 
purpose, this study needs to delineate a set of criteria for appropriateness. The following 
points are among the ones that should be taken into consideration as the “criteria of 
appropriateness” for the proposed framework: 
1. The suggested framework should be based on and justified by the universal moral 
values and principles that can be considered part of the common intellectual heritage of 
mankind. In other words, this framework should observe and include fundamental 
human rights and freedoms and other cross-cultural norms and values as formulated in 
international and universal declarations. At the same time, this framework should be 
cultural sensitive. This means that this framework should make room for respect for 
pluralism and cultural diversity. One of the main challenges in formulation this network 
is finding the most appropriate framework for fulfilling both functions (observe 
universal norms and respect for cultural diversity) without any conflicts or 
contradictions. 
2. This framework is to promote the substitution of governance/globalization from 
above with the governance from below.524 The sustainability of global governance and 
the international research enterprise depends on the extent of its success in this 
substitution as an ethical mandate or priority. 
3. Although no specific government is in charge of global governance, this field is 
not free of leadership. The ethical framework has to take this important component into 
consideration. For this purpose, this ethical framework has to promote the network 
model of leadership and formulate its ethical mandates such as transparency, 
accountability, representation, and participation.525 
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4. The ethical framework has to cover all the broad range of role-players in the 
global governance for research. Only a broad and all-encompassing model can solve the 
complex and complicated problems of global health research. Being inclusive is one of 
the most important features of an effective model. 
5. For refraining unilateral interventions, and providing the best possible cost-utility 
justification for global heath interventions – including the ones related to heath research 
– this is suggestible to strengthen the role of WHO as the leader of global heath 
governance.  
6. Human health is inseparable from the health of animals and the ecosystem. The 
recent experiences of zoonotic pandemics clearly showed that global heath governance 
for people is in close relation with and dependence on the global health governance for 
animals, and the nature at all. Global warming and its disastrous impacts on global 
health is another revealing example. Therefore, having an integrated perspective toward 
the health of human beings, animals, and the nature as a whole, is crucial for an effective 
governance for every aspect of health, including health research, in the future.  
The framework provided below for Global Governance for Health Research has three 
main components: (1) the normative cornerstones that appeal to the central concept of 
human rights as a part of common intellectual heritage of mankind. (2) The 
systematic approach that appeals to the NIH Framework to implement the principles 
of universal declarations to the global research enterprise. (3) The situation-based 
practical approach that incorporates situation ethics into the framework by describing 
the crucial role of the existing networks especially Research Ethics Committees 
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consisted of well-trained, culturally informed, and ethically aware members from the 
participating and hosting communities. 
The Normative Cornerstones: Inspired by the Nuremburg Code, the Universal 
Declaration of Human Rights was adopted by the United Nations in 1948. This 
declaration later shaper the foundation of various ethical and legal declarations, 
guidelines, conventions, and treaties. Embodied in almost all consensual international 
and global agreements in the past seven decades, the Universal Declaration of Human 
Rights is a noteworthy and radiant part of the common intellectual heritage of mankind. 
According to Henk ten Have, this declaration owes this status to its universality and 
emancipatory force.526  
Because of the fundamental and globally consensual nature of the articles of 
Universal Declaration of Human Rights the ethical framework for Global Governance 
for Health Research should adopt them as its normative and moral cornerstone. This 
declaration has been embodied in the field of global ethics by the UNESCO Universal 
Declaration on Bioethics and Human Rights. he UNESCO declaration provides an 
unbiased and globally consensual interpretation and expansion of the Universal 
Declaration of Human Rights in the field of global bioethics. Therefore, is applicable 
and relevant in shaping an ethical framework for Global Governance for Health 
Research. Therefore, the second step of the normative cornerstone of the ethical 
framework for Global Governance for Health Research is the UNESCO Universal 
Declaration on Bioethics and Human Rights. 
The ethical principle of Non-Exploitation and the ethical virtue of Compassion are 
also the cornerstones of the ethical framework for Global Governance for Health 
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Research. The most fundamental ethical concern in health research activities is 
exploitation. In addition, although relying on the personal virtues of researchers has been 
supplemented and complemented with other reassuring provisions such as independent 
review, it does not mean that there is no place for virtues in ethical frameworks. On the 
contrary, still the most important fundament of ethical behavior is personal commitment 
of people, especially the ones who are at the more powerful sides of relations and 
transactions. Therefore, compassion as a personal virtue relevant to the golds of 
healthcare and health research is one of the cornerstones of Global Governance for 
Health Research. 
Table 5.1. The principles of the NIH framework with their corresponding principles in 
the UNESCO declaration of Bioethics and Human Rights and their implications on the 
Ethical Framework for Global Governance for Health Research (GGHR). 
 
The NIH Framework The UNESCO 
Principles 
Ethical Framework for 
GGHR 
Collaborative Partnership  Human Dignity and 
Human Rights 
 Benefit and Harm 
 Respect for Human 
Vulnerability and 
Personal Integrity 




 Respect for Cultural 
Diversity and Pluralism 
 Solidarity and 
Cooperation 
 Social Responsibility 
and Health 
 Sharing of Benefits 
 Protecting Future 
Generations 
 Respect for the Role and 
Participation of Host 
Communities; Only Limited 
by Human Dignity and 
Human Rights 
 Prevents unethical 
behaviors such as helicopter 
research and double 
standards 
 Assures the fair benefits of 
hosting communities 
Social Value  Benefit and Harm 
 Equality, Justice, 
and Equity 
 Consistency between 
research questions/aims and 
the health needs of host 
societies 
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 Respect for Cultural 
Diversity and Pluralism 
 Solidarity and 
Cooperation 
 Social Responsibility 
and Heath 
 Sharing of Benefits 
 Protecting Future 
Generations 
 Data sharing 
 Considering the burden of 
research on health 
infrastructures of host 
communities/countries 
Scientific Validity  Benefit and Harm 
 Equality, Justice, 
and Equity 
 Social Responsibility 
and Health 
 The importance of 
inclusion of scientific validity 
as a principle in the soft law 
 Avoiding unwanted 
promoting pseudoscience 
and superstitions through 
invalid and poorly designed 
research 
 
Fair Participant Selection  Human Dignity and 
Human Rights 
 Benefit and Harm 
 Respect for Human 
Vulnerability and Personal 
Integrity 
 Equality, Justice, and 
Equity 
 Non-Discrimination and 
Non-Stigmatization 
 Solidarity and 
Cooperation 
 Social Responsibility 
and Health 
 Preventing double 
standards in international and 
multi-central research 
projects 
 Considering the potential 




 Risk and Benefit 
 Sharing of Benefits 
 Social Responsibility 
and Health 
 Protecting the 
Environment 
 Considering the importance 
of fair and systematic risk-
benefit ratios in developing 
countries and populations 
that lack the expertise or 
democratically selected 
representatives to do so. 
 The importance of training 
local experts for risk-benefit 
analysis 
 The issue of ethical 
imperialism and colonialism 
in research ethics training 
and the importance of 
considering local culture and 
value systems 
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Independent Review  Benefit and Harms 
 Respect for Human 
Vulnerability and 
Personal Integrity 
 Equality, Justice, and 
Equity 
 Respect for Cultural 
Diversity and Pluralism 
 Sharing of Benefits 
 Protecting Future 
Generations 
 The importance of inclusion 
of independent research 
review in the laws and 
regulations 
 The importance of providing 
research oversight training for 
LMICs 
 The issues of ethical 
imperialism and respect for 
cultural diversity 
Informed Consent  Human Dignity and 
Human Rights 
 Consent 
 Autonomy and 
Individual Responsibility 
 Persons without the 
Capacity to Consent 
 Respect for Human 
Vulnerability and Personal 
Integrity 
 Non-Discrimination and 
Non-Stigmatization 
 Respect for Cultural 
Diversity and Pluralism 
 Informed and voluntary 
consent as a right of each 
competent research 
participant 
 Consistency of informed 
consent with the cultural and 
political contexts 
 The need to additional 
informed consent from the 
local authorities does not 
override the obligation of 
taking consent from each 
individual research participant 
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Respect for Participants  Human Dignity and 
Human Rights 
 Benefit and Harm 
 Autonomy and 
Individual Responsibility 
 Consent 
 Persons without 
Capacity to Consent 
 Respect for Human 
Vulnerability and Personal 
Integrity 
 Privacy and 
Confidentiality 
 Non-Discrimination and 
Non-Stigmatization 
 Respect for Cultural 
Diversity and Pluralism 
 Solidarity and 
Cooperation 
 Social Responsibility 
and Health 




The ethical framework suggested by this chapter is an interactive combination of 
three main elements (see Table 5.2):  
The first element that shapes the subjective and personal background and support of 
this framework is adopted from virtue ethics. The merging point of two accounts of 
virtue ethics: the classic, Aristotelian virtue ethics relying on a set of Masculine ethics 
and the modern feminist account of virtue ethics adopted by the Ethics of Care. This 
chapter holds that this merging point in the realm of medicine and health research is 
embodied in empathy, compassion and care. These virtues (or ethical 
attitudes/Attributes) are the basis and background of abidance to this – and any other- 
ethical framework by physicians, healthcare providers, and health researchers. 
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The second element is consisted of a certain group of principles originated in the 
concepts of human dignity, human rights, and non-exploitation (as the deeper and 
fundamental level of principles). These principles are formulated (in the form of an 
expanded and detailed framework) and adopted by UNESCO through the UNESCO 
Declaration of Bioethics and Human Rights. These principles, because of their 
consensual, universal, and cultural-sensitive nature can be considered a part of common 
heritage of mankind. For ensuring their best compatibility with the realm of health 
research, they are combined with a set of principles provided through the NIH 
framework in a systematic manner for research, especially for global research. 
The third element of this framework is inspired and informed by the schools of 
situation ethics. The virtues and principles should be applied and implemented into 
specific situations with innumerable details and characteristics that cannot be 
summarized or categorized under specific virtues or principles. A group of ethically 
trained and culturally informed and aware persons are needed to deliberate on each case 
and appeal and infer to various virtues and principles to formulate the best and most 
ethical and culturally acceptable way to apply and implement those abstract notions to 
practical situations. This is the share of situation ethics. This mission is being done by 
RECs and IRBs all over the world. Without competent and independent IRBs and 
RECs, no ethical framework can be useful and applicable to solve the challenges, 
issues, and cases ahead of Global Governance for Health Research. 
This framework is not free of limitations. In addition, the current trends in politics 
show that numerous challenges threaten the integrity of Global Governance for Health 
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Research. A brief discussion of these challenges is provided in the next chapter of this 
dissertation. 
Table 5.2. A scheme of the elements of the ethical framework for Global Governance 





The global network of Research Ethics Committees (RECs) and 




Collaborative Partnership, Social Value, 
Scientific Validity, Fair Participant Selection, 
Favorable Risk-/Benefit Ration, Independent 
Review, Informed Consent, Respect for 
Participants 
Expanded Level 
Benefit and Harm; Autonomy and Individual 
Responsibility; Consent and Persons Without 
Capacity of Consent; Respect for Human 
Vulnerability and Personal Integrity; Privacy and 
Confidentiality; Equality, Equity, and Justice; 
Non-Discrimination and Non-Stigmatization; 
Respect for Cultural Diversity and Pluralism; 
Solidarity and Cooperation; Social 
Responsibility and Health; Sharing of Benefits; 
Protecting Future Generations; Protection of the 
Environment 
Basic Level 
Human Dignity, Human Rights, Non-
Exploitation 












Chapter Six: Futurology and Conclusions 
In this final chapter, a conclusive picture/analysis of the suggested ethical framework 
for Global Governance for Health Research is provided and its trends and possible 
developments in the future along with the existing and potential threats and promises are 
examined and predicted. In addition, some practical and research recommendations are 
suggested for the future. 
Global Governance for Health Research and its ethical norms, principles, and 
challenges have not been examined sufficiently in the current scholarly literature. 
Although both the research ethics and the Global Health Governance have been subjects 
of amazing scholarly works, the interface of these two fields, that is the ethics and ethical 
framework of Global Governance for Health Research has not been explored by an 
enough number of scholarly works in the past decades. This study has been an attempt to 
fill this gap in the current literature.  
This part of this chapter, after providing a summary of the content of the previous 
chapters and some conclusive remarks, tries to depict the predictable future trends of 
Global Governance for Health Research, provide a number of practical recommendations, 
and finally, suggest further studies that can be the next scholarly steps in exploring and 
analyzing this relatively new field of study and research. 
i. A Brief Summary and Conclusive Remarks 
As described in chapters 1 and 2, Global Governance is composed of sophisticated 
and crowded networks of role players that govern various affairs of human social life at 
the global scale. Global Health Governance is a branch of Global Governance that 
governs the health-related affairs. Although numerous scholarly works have been 
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published concerning Global Health Governance, an important branch of this gigantic 
complex of networks has not been analyzed sufficiently yet. This insufficiently examined 
and analyzed part is global health research enterprise. Global health research, although it 
is a part of global health affairs, has its own characteristics and situations that bring about 
its specific issues and challenges at the global scale. Therefore, Global Governance for 
Health Research, although is generally a part of Global Health Governance, has major 
differences (along with similarities and overlaps) with it is different aspect, including the 
major role-players, and main issues and challenges.  
The major role-players of Global Health Governance are the WHO, the World Bank, 
and UNESCO, along with numerous other ones such as UNAIDS and the private and 
civil society role-players. The WHO and the World Bank, although important in the 
realm of global research, have not been the most influential role-payers in Global 
Governance for Health Research. Since the Global Governance for Health Research has 
mainly been materialized through internationally recognized frameworks and guidelines, 
the organizations that created, adopted, and promulgated these instruments have been the 
most influential role-players in the realm of Global Governance for Health Research, 
among them being the UNESCO, WMA, and CIOMS. 
Global Governance for Health Research has its own challenges that are discussed in 
chapter 3 and studied through cases in chapter 4 of this dissertation. Challenges such as 
exploitation and helicopter research, double standards, bilateralism, and the impact of 
bio-politics. The framework of gaps introduced by Weiss is also relevant to this field and 
the knowledge, normative, policy, institutional, and compliance gaps show themselves in 
Global Governance for Health Research. The analysis of the challenges in chapter 3 
 243 
along with detailed case studies in chapter 4 revealed the ethical nature of the existing 
challenges and shortcomings of this field and the need to a comprehensive and systematic 
ethical framework. This framework is developed and presented in chapter 5.  
The suggested framework for Global Governance for Health Research is composed of 
three elements. A virtue-based element/layer that encompasses the most basic moral 
attributes of physicians/health researchers and underlie their ethical behavior and their 
compliance to the principles. A two-layered principle-based element that encompasses a 
layer of fundamental principles, i.e. Human Dignity, Human Rights, and Non-
Exploitation and a layer of more specific or practical principles that mostly adopted from 
the UNESCO Declaration of Bioethics and Human Rights to have a comprehensive and 
universal approach and from the NIH framework to have a research-oriented systematic 
approach. And the last element of the suggested framework is inspired by particularism 
or situation ethics that demands establishing, empowering, and strengthening networks of 
oversight and review committees/boards to guarantee the continual and comprehensive 
case-by-case ethical review and oversight and monitoring all over the gigantic networks 
involved in global health research enterprise. 
Despite the challenges partly explained below in this chapter, it seems that the 
suggested framework can be helpful in shedding ethical light on the challenges of Global 
Governance for Health Research and in filling its various gaps. This study is a small step 
in filling the knowledge gap. The suggested framework can fill part of the normative gap, 
this framework can be an ethical basis for policies that may fill the policy gap, the 
situation-ethics element of the framework is concerning the necessity and the ethical way 
for filling the institutional gap and finally, removing or alleviating the moral barriers is 
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one of the ways for filling the compliance gap. By the way, this should be reminded that 
filling these gaps is not a one-time mission, instead, the process of developing and filling 
these gaps is continuous and will continue as long as the Global Governance for Health 
research is a reality on the global scene.  
ii. The future of Global Governance and International Research 
This part of this chapter consists of two segments. First, the current trends in the 
realm of politics and economics is discussed. Some threats for implementation and an 
ethical framework for Global Governance for Health Research are discussed. In 
developed countries, the trends of neoliberalism and the recent rise of the wave of 
isolationism and protectionism and in developing countries, the local cultures and 
authorities that resist against the universality of values such as human rights are discussed 
as the existing threats against ethical frameworks for global governance, including Global 
Governance for Health Research. 
In the next segment of this part, it is explained and predicted that with implementing 
the suggested ethical frameworks, what changes would occur in the future of 
international research and its global governance. Among the items that are discussed in 
this part are strengthening the role of WHO as the leading organization in global heath 
governance and adopting an integrated approach to health that include humans, animals, 
and nature (ecosystems, climate, etc.) and take into consideration the social and political 
determinants of health, e.g. in setting research priorities. 
The challenge of neoliberalism, Populistic Isolationism, and Protectionism in 
Developed Countries: Donald J. Trump, although is not a classical neoliberalist, is a sort 
of embodiment of the figure of ground-breaking and rebellious millionaire that was 
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praised and admired by the prophetic figure of neoliberalism, Friedrich Hayek (1899-
1992).527 His winning the 2016 US presidential election, along with the vote to Brexit 
(UK’s leaving the European Union) in the UK in the same year, and the rise of popularity 
of populist politicians in the other powerful European countries that have always acted as 
the engines of globalization, are warning signs for ethical governance of global affairs in 
all areas, including the global research enterprise. 
  Neoliberalism: Neoliberalism is a political and economic theory that centers around 
promoting – or creating – free markets in all areas of human affairs, from ordinary goods 
and services to the ones that ordinarily are not covered by free market such as healthcare, 
basic research, and education. This theory regards individual-centered competition as the 
most ethically (fairly) reliable force for governing human social affairs at both domestic 
and global levels.528 Neoliberal attitudes and practices have caused most of challenges for 
Global Governance for Health Research discussed in chapters 3 and 4 of this dissertation. 
Focusing on maximizing the material benefit and minimizing the costs even at the 
expense of harming the community and humanity (the attitude that Donald Trump 
claimed that makes him ‘smart’ in one of the US presidential election debates in 2016529) 
has been the direct cause of various kinds of exploitation occurred in the arena of global 
research, from the exploitation and helicopter research in the cases of HIV/AIDS research 
in Africa, to having double standards, bilateralism, undue and adverse influence of bio-
politics, the problem of bio-piracy, and countless other ethical challenges and cases and 
scandals.   
All the elements of the suggested ethical framework for Global Governance for 
Health Research imply that the health sector and health research cannot be left in the 
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hidden hands of free market. The personal virtues that shape the basic layer of this ethical 
framework implies that the health professionals and health researchers need to put the 
interests of their patients/subjects/communities ahead of their own interests. Compassion 
implies sensitivity toward humans’ suffering. This sensitivity, when becomes actualized 
in practice, may limit unleashed greed to maximize the material benefits. Furthermore, 
the principal-based element of framework encompasses principles such as social 
responsibility, solidarity, and collaborative partnership that are also in contrast with 
seeking maximized benefits as might be exemplified by the practice of some 
pharmaceutical companies. Finally, the situation ethics-based layer/element of the 
framework insets in empowering local communities in establishing review and oversight 
bodies that protect the interests of local research participants and their communities. This 
element also limits profit-seeking in favor of humanity and morality. This is not what can 
be considered or called “smart” by President Trump or any other greedy entrepreneur in 
the world.  
In his inauguration address, President Trump repeated his slogan: “America First!”530 
This slogan is the gist of the isolationist and protectionist and xenophobic spirit the flies 
over the Western world and has already embodied in Trump’s presidency, the Brexit, and 
popularity of the National Front in France and Freedom Party in the Netherlands. 
Isolationism through closed borders and reduced moral and human rights related 
interventions in the world along with protectionism through putting higher taxes on 
imported goods and tougher immigration regulations will act as the reverse engines for 
globalization. Their adverse effect in the realm of Global Governance for Health 
Research will be (1) less contribution of the Western powers in establishing and 
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strengthening the ethical frameworks through contribution in setting standards and 
founding and empowering oversight bodies in developing countries; (2) dominance of 
neoliberal approach to market and considering health and health research as a part of this 
wild global market left in the hands of greedy companies and  selfish authorities; (3) rise 
of new globally influential powers such as China and India to use their economic power 
as a leverage to fill the vacuum of power and governance in the global affairs including 
healthcare and health research. Some of these rising powers, especially China, have has a 
history of ambiguous and controversial approach to the fundamental principles of the 
ethical framework of Global Governance for Health Research, such and human dignity 
and human rights and even non-exploitation (considering the exploitative nature of some 
parts of labor market in China and the history of exploitation on other areas such ad organ 
transplantation). Therefore, the effect of their leadership in global affairs (along with the 
relative absence of Western powers) on the ethical aspects of global health research 
enterprise should be expected and monitored cautiously.  
The Problem of Universality of Human Right in Developing Countries: It has 
been claimed that a certain group of concepts are consensual and universal in nature and 
belong to the common heritage of mankind. These concepts include respect for human 
dignity and human rights and fundamental freedoms. This universal and consensual 
nature as asserted in some universal declarations has been one of the theoretical bases of 
the framework suggested in the previous chapter of this dissertation for Global 
Governance for Health Research. This universality, however, has not been realized in the 
real world. Some local cultures do not believe in human rights as they are presented in 
the Universal Declaration of Human Rights. In contrary, they argue that their believed 
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schools of thoughts (or religions) provide them with different systems and interpretations 
of human dignity and human rights that is different and sometimes in contrast with the 
concepts presented in the declarations adopted by the UN or UNESCO. They claim that 
the concepts of human rights adopted by these international organizations are not 
universal, but they are rooted in the Western secular and Judo-Christian cultural 
traditions. 
It can be argued that although the values of human dignity and human rights are not 
absolutely consensual, they are enough consensual to shape the value-based fundaments 
of ethical frameworks for Global Governance for health Research. When it comes to the 
health research sector, these values become more agreeable by all the parties. Even 
countries that have some reservations in adopting conventions on children’s right and 
other sensitive topics, have readily adopted the principles of human dignity and human 
rights through the declarations on health and health research. Iran, as an example, 
regardless of domestic controversies and criticized behaviors in the areas of women’s 
rights and freedom of speech, has adopted a series of domestic guidelines for research 
ethics that are in extreme consistence with international ones.531 Some other regional 
authorities that deny human rights, do not have health research sector within their 
territories.  
In sum, it seems that all the countries and jurisdictions that have a sort of health 
research sector within their boundaries have accepted the fundamental principles of the 
principle-based element of the ethical framework suggested in this dissertation. 
Therefore, this dissertation argues that the principles adopted in this framework are 
globally “enough” consensual and universal. 
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An Ethical Framework and a Realistic Place for Optimism: Some practical 
recommendations provided in the following part of this chapter can be helpful in 
promoting ethical governance in the realm of global health research, including supporting 
the key and central role of international organizations as the leading institutions in Global 
Governance for Health Research; embracing integrated approaches to health that not only 
include humans without any discrimination,  but also encompass animals, and the mother 
nature; and the last but not the least, taking this fact into consideration that social and 
political determinants of health are important determinants of the health all over the 
world and they should be included among the global research priorities. 
In sum, despite the irregularities, the global trend in the past decades has been toward 
establishing more ethical and cross-cultural global governance for health research. There 
have been numerous great achievements, partly described in chapter 2 of this dissertation, 
including the international declarations and guidelines, consensual adoption of universal 
values as parts of common heritage of mankind, establishment of international and cross-
cultural organizations along with the unprecedented role-playing in the civil society, and 
the ethics training programs that have empowered local communities to take part in 
ethical review and oversight for research. The above-mentioned trend and achievements 
are promising for a future of continual ethical improvements in Global Governance for 
Health Research. 
iii. Practical and Ethical Recommendations 
The ethical framework suggested in chapter 5 for Global Governance for Health 
Research encompasses the normative guidance of three major philosophical approaches 
to normativity: the virtue-based approach encompassing both classic/masculine and 
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feminine virtues, the principle-based approach that includes a layer of more fundamental 
and a layer of more detailed principles, and the particularistic or situation ethics 
approach. This dissertation argues that implementing this comprehensive model will 
solve the existing challenges and problems of Global Governance for Health Research 
(described in chapters 3 and 4 of this dissertation) in a multilateral and comprehensive 
way. Each virtue and principle included in this framework has its own practical 
implications. Explaining the practical implications of each component of this framework 
is beyond the scope of this chapter. However, some general recommendations are 
provided below to depict how this ethical framework actualize itself in the realm of 
Global Governance for Health Research:  
1- Establishing a governance system from below (instead of the current top-down 
governance) is one of the most fundamental recommendations concluded from the 
suggested framework. The appearance of the term of global governance in the political 
sciences discourse was due to the newly emerged abundance or non-state rope-players in 
the previous decades that take part in governance of global affairs (see chapter 2). The 
states, although sovereign and powerful, are limited and sometimes overwhelmed by the 
political interests of powerful parties and role-players. Therefore, they may not act 
optimally in dealing with challenges of global governance and protecting the interests of 
the powerless. The non-state actors are to be the “voice of the voiceless”. As described in 
chapter 2, many non-state and civil-society role payers act influentially on the sense of 
Global Governance for Health Research. A major part of the existing body of related soft 
law (as the main way through which Global Governance for Health Research is embodied 
and actualized) is created and adopted and promulgated by international civil society role 
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players, the most prominent example being the Declaration of Helsinki adopted by the 
WMA. For implementing the suggested ethical framework for Global Governance for 
Health Research, empowering and encouraging the governance from below by grass root 
institutions and civil society role players seems to be an imperative of utmost importance. 
For this purpose, in addition of strengthening civil society, establishing training courses 
for local people is a major step. Because the ethically knowledgeable and aware people 
are the only ones who can take the lead in establishing and promoting “from below” 
governance. 
2- Promoting respect for cultural diversity and fundamental human rights as the 
common heritage of mankind. Actualization of the principle of “Respect for Cultural 
Diversity” is the best practical way to make disappear ethical Imperialism and 
Colonialism, and bilateralism. This recommendation combined with establishing a 
governance system from below will protect the global research enterprise from some 
major challenges such as helicopter research, exploiting poor countries/communities, 
double standards, bio-piracy, undue influence of bio-politics at the global scale, and 
ethical colonialism. The principle of respect for cultural diversity, as explained in chapter 
5, is limited with the principles of “Human Dignity and Human Rights”. Respect for 
cultural diversity should be observed to protect the benefits and interests of all the parties 
involved in or influenced by research, however should not be appealed to justify any 
violation to the fundamental human rights and freedoms by local authorities. 
3- Strengthening the role of the leading organizations in Global Governance for 
Health Research. The challenge of bilateralism is discussed in chapter 3. The only way 
for implementing the ethical framework for Global Governance for Health Research is 
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strengthening multilateralism. This means that international organizations, such as WHO 
and UNESCO should take the lead in promoting and implementing an ethical framework. 
Some organizations cannot play this role because of their belonging to just one party of 
interactions. For example, the WMA, although created the most influential international 
ethical guideline for research, the Declaration of Helsinki, mostly belongs to physicians. 
Therefore, it seems that the WHO or UNESCO are the best suited organizations to take 
this role because of their inclusiveness and their relations with states that have the power 
and authority needed for implementation and enforcement of ethical guidelines at the 
domestic and global levels. For instance, the UNESCO Declaration of Bioethics and 
Human Rights mainly addresses the member states of UNESCO.532 
4- Adopting an integrated approach to health that includes humans, animals, and 
nature (ecosystems, climate, etc.). This element is actualized when a comprehensive 
approach is taken and the local role-players are empowered and involved. The planet 
Earth is the common habitat of all living organisms. Imposing imbalance and pollution 
will have backlashes for the health of human beings. Sustainability is a crucial 
precondition of each governance system. Sustainability that safeguards the harmonic and 
balanced cohabitation of all the creatures, including the human being. Otherwise, no 
governance system or developing program will be lasting and sustainable. The Global 
governance for Health Research is no exception for this rule. 
5- Taking into consideration the social and political determinants of health, e.g. in 
setting research priorities. In every global health crisis (such as the HIV/AIDS pandemic) 
this question pops up that what the best way for dealing with the health problems is. Is 
this only a technical and biomedical health problem or other factors such as social and 
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political structures should also be considered and repaired to achieve satisfactory 
results?533 Implementing the ethical framework suggested in chapter 5 necessitates a 
comprehensive model. In the realm of research ethics, having independent oversight, 
review, and monitoring bodies is a crucial ethical imperative. Having independent 
oversight bodies is not possible in the absence of a well-established civil society. The 
oversight bodies in the absence of civil society will be dominated by powerful 
authorities.534 Therefore, implementing this framework is only possible when all aspects 
of collective human life are considered as relevant to health, including the political power 
relations and the strength of civil society. 
iv. Suggestions for Future Research 
Studying Global Governance for Health Research and its ethical challenges and 
frameworks is just at its beginning steps and has a long road ahead. Both 
theoretical/normative and empirical studies are needed to fill the knowledge, normative, 
and policy gaps in this field (see chapter 3). The current threatening and promising trends 
that are discussed in this chapter also need to be more clarified via further studies. The 
institutional and compliance gaps also necessitate more research and studies to find the 
best ways to fill them. The dynamic nature of this field and its gaps continually creates 
new gaps and new knowledge to fill them. 
In the near future, the following topics need to be studied to shed light on the next 
steps of Global Governance for Health Research and its challenges and ethical 
frameworks: 
1- The current trend of populism along with isolationism and protectionism in the 
Western countries is a demanding subject of studies. Is this a real and long-lasting trend 
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with continuous impacts on different aspect of globalization and Global Governance, 
including Global Governance for Health Research? Or it is just a reactionary period that 
will end soon and won’t have lasting impacts on global affairs? If the former prediction 
proves right, will there be rising powers among other countries, such as China or India, 
which try to replace the US and Western countries as the leading powers in Global 
Governance? What will be the impacts of more involvement of these rising powers in 
global health research? These questions are to be answered by new studies and research 
in the coming years and their answer will have definite impacts on the ethical frameworks 
that Global Governance for Health Research will adopt and comply with in the real world 
and in practice. 
2- The principle-based element of the ethical framework for Global Governance for 
Health Research will also be a subject of further theoretical studies and debates. What 
principles can be added to or excluded from the existing sets? Are the principles included 
in the suggested ethical framework of real universal and consensual nature? Which one of 
them has been influenced by ethical colonialism and imperialism? What new principles 
can be added to the framework and considered as a part of common intellectual 
framework of mankind? The historical course of creation and development of the sets of 
principles for global research, from the three principles of the Belmont Report to the four 
principles of biomedical ethics formulated by Beauchamp and Childress, to the UNESCO 
Universal Declaration of Bioethics and Human Rights, and the NIH Framework, show 
that over the past decades, many new principles have been added to the existing 
frameworks. The suggested framework in this dissertation have tried to be a 
comprehensive one and encompass the previous ones. However, this does not mean that a 
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final framework is achieved or is achievable. The process of development and evolution 
of ethical frameworks for Global Governance for Health Research is a never-ending and 
continuous process fed by incessant chains of studies and research projects on the 
previous and new principles. 
3- As explained above, the framework of gaps in Global Governance and Global 
Governance for Health Research (see chapter 3) is a dynamic framework. It means that 
the new gaps continuously appear and are filled with new knowledge and practice that are 
rooted in research. Evidence based knowledge created by research is the most 
fundamental need when it comes to filling the gaps in Global Governance. Filling the 
knowledge gap obviously needs new knowledge. The normative gap demands new 
normative and ethical research. The policy gap needs evidence-based knowledge to 
support new policies. The institutional gap needs new research on the situation and 
weaknesses and strengths of the existing institutions, and compliance gap also needs 
research-based information and awareness to be filled. Therefore, as a conclusive remark 
on future research, this chapter holds that the next research projects in this area are 
needed and should be directed to create evidence-based and normative knowledge to fill 
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